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Table 0.1: Abbreviations used in this thesis.
Abbreviation Denotation
(v/v) volume/volume
(w/v) weight/volume
A Ampere
AEC 3-amino-9-ethylcarbazole
BL6 immunocompetent mouse strain, C57BL/6JOlaHsd
BrdU Bromodeoxyuridine (5-bromo-2’-deoxyuridine)
CT Cycle Threshold
C3H immunocompetent mouse strain, C3H/HeNHsd
CatchUp immunocompetent transgenic mouse strain,
C57BL/6-Ly6gtm2621(Cre-tdTomato)Arte
CatchUpIVM-red C57BL/6-Ly6gtm2621(Cre-tdTomato)Arte
x B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J
CD Cluster of Differentiation
cDNA complementary DNA
CFSE Carboxyfluorescein succinimidyl ester
CXCR CXC chemokine receptor
DAMP Danger associated molecular patterns
DC Dendritic cell
DMSO Dimethylsulfoxid
DNA Desoxyribonucleic Acid
DTT Dithiothreitol
ECM Extracellular matrix
EDTA Ethylenediaminetetraacetic Acid
eGFP enhanced Green Fluorescent Protein
ELISA Enzyme linked immunosorbent assay
et al. lat.: ET ALTERI
FACS Fluorecense-Activated Cell Sorting
FC Flow cytometry
FCS Fetal Calf Serum
FSC Forward Scatter
G Gauge
G-CSF Granulocyte colony stimulating factor
HMEC Human Microvascular Endothelial Cells
HPV Human papillomavirus
HRP Horse radish peroxidase
HRPO horseradish peroxidase
HSPC Hematopoietic stem and progenitor cells
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Abbreviation Denotation
HyD-RLD Hybrid reflected light detectors
IF Immunofluorescence
Ig Immunoglobulin
IHC Immunohistochemistry
IMCES Imaging Center Essen
IP Intraperitoneal
ISO-1 4,5-Dihydro-3-(4-hydroxyphenyl)-5-isoxazoleacetic acid methyl ester
IVC Individually ventilated cages
kDA kilo-Dalton
LAD Leukocyte adhesion deficiencies
LTR Long terminal repeat
MACS Magnetic activated cell sorting
MDSC Myeloid derived suppressor cells
MFI Mean fluorescence intensity
MIF Macrophage Migration Inhibitory Factor
MMP Matrix metalloprotease
MOPC Murine OroPharynx Carcinoma cell line
mRNA messenger RNA
NaCl Sodium Chloride
nu/nu athymic nude mice NMRI-Foxn1nu/Foxn1nu
PAGE Polyacrylamide gelelectrophoresis
PAMP Pathogen associated molecular patterns
PBS Phosphate Buffered Saline
PE Phycoerythrin
PI Propidium Iodide
PMT Photomultiplier tube
PMT Photomultiplier tube
PVDF Polyvinylidene Difluoride
qRT-PCR Quantitative Real Time - Polymerase Chain Reaction
RNA Ribonucleic Acid
ROI Region of interest
RT Room Temperature
RT Reverse transcriptase
SCN Severe congenital neutropenia
SDS Sodium-Dodecyl-Sulfate
SN Supernatant
SPF Specific pathogen free animal housing
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SV40 Simian Virus 40
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Table 0.1: (continued)
Abbreviation Denotation
TAM Tumor associated macrophages
TAN Tumor associated neutrophils
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TEMED N,N,N’,N’-Tetramethylethylendiamin
TMB 3,3’,5,5’-Tetramethylbenzidine
Treg regulatory T cell
Tris Tris-hydroxymethyl-aminomethan
Tween Polyoxyethylensorbitanmonolaurat
V Voltage
VEGF Vascular endothelial growth factor
WB Western blot
WHO World Health Organisation
x g multiple of acceleration of gravity (g = 9.80665 ms2 )
ZMB Centre for Medical Biotechnology of the University Duisburg Essen
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1 Introduction
1.1 The life cycle of neutrophil granulocytes
Polymorphonuclear neutrophil granulocytes were named after their staining characteristics in hema-
toxylin and eosin staining and their nuclear morphology. In contrast to the dark blue basophilic and
bright red eosinophilic granulocytes, neutrophils stain neutral pink. As the most abundant white
blood cell, they account for up to 70 % of human peripheral blood leukocytes. Neutrophils belong to
the most rapidly responding cells of the innate immune system making them the essential first line
defense against invading pathogens. This critical role for combating bacterial and fungal infections
becomes apparent when an organism is affected by genetic neutrophil defects as for example in se-
vere congenital neutropenia (SCN) or leukocyte adhesion deficiencies (LADs) in which neutrophils
are unable to enter infected tissues[209, 74]. Accordingly, these patients suffer from augmented sus-
ceptibility to infections.
1.1.1 Granulopoiesis in the bone marrow and release to the periphery
When released to the peripheral circulation, neutrophils account for the most short-lived immune
cells. Depending on the way of estimation in the respective studies, live time measurements range
between a few hours and several days[152]. Therefore, essential constant production of neutrophils is
carried out in the bone marrow resulting in the release of about 1011 cells per day. At this site, dif-
ferentiation is talking place from multipotent hematopoietic stem cells via pluripotent progenitors,
proliferating and lineage-committed myeloblasts, promyelocytes and myelocytes, further proceed-
ing past metamyelocytes and band cells to mature segmented neutrophils. Development and lineage
commitment is thereby strongly regulated by the transcription factors PU.1 and CCAAT/enhancer-
binding protein α (C/EBPα) among others[166]. Most importantly, all phases of a neutrophils’ life
cycle are dominantly regulated by granulocyte colony stimulating factor (G-CSF). This role becomes
apparent in G-CSF knockout mice, which develop chronic neutropenia[114]. Mechanistic evidence for
an implication of G-CSF in lineage commitment was further provided by a study using G-CSF recep-
tor knockout mice in a competitive repopulation assay[164]. While a low production of neutrophils
was still found in those mice, the resulting mature neutrophils showed increased susceptibility to
apoptosis indicating an additional role of G-CSF in neutrophil survival[118]. This underscores the cen-
tral role of G-CSF for homeostasis of neutrophil while additional factors seem to be able to support
granulopoiesis upon loss of G-CSF. Partial compensation, especially in situations called “emergency”
granulopoiesis, can be mediated by granulocyte macrophage colony stimulating factor (GM-CSF), IL-
6 and IL-3[129, 130, 154]. Neutrophil production is further regulated by a feedback mechanism from the
phagocytes which remove apoptotic neutrophils from the circulation. This feedback involves IL-23
and subsequent IL-17 production[188]. Finally, freshly produced neutrophils have to be released to the
periphery. This process is tightly regulated by the antagonistic receptors CXCR2 and CXCR4 and their
respective ligands as well as G-CSF[42, 127, 210]. Thereby, stromal cell derived factor 1 alpha (SDF1α)
attenuates neutrophil mobilization via CXCR4 activation[127]. CXCR2-binding ELR+ (glutamic acid –
leucine – arginine) chemokines further mediate mobilization via CXCR2[42] which is remarkably en-
hanced in the presence of G-CSF disrupting SDF1α mediated retention[210].
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1.1.2 Peripheral challenges: Migration towards infection sites
As mentioned above, a high number of neutrophils is present in the peripheral circulation. However,
migration to the site of infection is mandatory to exert their functions as first line defense against
invading pathogens. Extravasation is initiated upon sensing of chemoattractants including formyl
peptides (such as fMLP), leukotriene B(4) (LTB4), chemokines (such as IL-8) and cytokines like IL-6
and TNFα[115]. These are further derived from tissue resident cells like macrophages, dendritic cells
(DCs) or fibroblasts sensing pathogen invasion[196]. Cytokine activated endothelial cells (EC) further
present adhesion molecules as well as immobilized chemokines to mediate neutrophil attraction.
First interaction is characterized by neutrophil tethering and rolling on the endothelial cell layer and
is mediated by interaction of selectins[128]. Binding via selectins further activates cell surface integrins
(LFA-1)[224] mediating slower rolling which is associated with sensing of presented chemokines[167].
These signals induce cytoskeletal rearrangements and activation of integrins (LFA-1, MAC-1, VLA4)
resulting in firm adhesion to the endothelium[77]. Additionally, MAC-1 (macrophage-1 antigen, con-
sisting of the integrins CD11b and CD18) dependent crawling is initiated which is necessary for local-
ization to optimal extravasation sites[151]. Transendothelial migration (TEM), which can occur para-
or trans-cellularly[214], and subsequent passing through pericytes and the basal membrane[9] finally
results in neutrophil localization in the infected tissue. Further exposure to activating factors such as
foreign pathogen associated molecular patterns (PAMPs) and endogenous damage associated molec-
ular patterns (DAMPs) results in complete activation of neutrophil functions. Consequences of acti-
vation and associated functions will be described in the next section.
1.1.3 Effector functions: Shimpu¯ Tokko¯tai of the immune system
The Shimpu¯ Tokko¯tai were Japanese Special Forces which committed suicide attacks mainly against
the US in the last years of World War II. Their activity is until now better known as kamikaze tac-
tics. This terminology is further perfectly fitting for the actions of neutrophils as they are packed
with deadly weapons and are always ready to die for the defense of the body. Neutrophil granules
contain densely packed antimicrobial proteins and can be divided by content into three subtypes
(primary, secondary and tertiary granules) according to the chronological order of their formation
during differentiation[49].
Neutrophils sense pathogens and tissue damage associated with PAMP and DAMP release via a broad
repertoire of innate immune receptors, primarily toll like receptors (TLR), resulting in activation and
prolonged survival of the responding cell[62]. Thereby, exocytosis is one of the obvious responses
to activation. Notably, exocytosis is more likely for granules that are formed later during develop-
ment. This especially holds true for gelatinase (tertiary) granules and defensin-rich over defensin-
poor azurophil (primary) granules[50]. Degranulation and release of secretory vesicles containing
inflammatory modulators such as cytokines therefore induces first antimicrobial effects and attracts
further immune cells. Main cytokines released by neutrophils are TNF-α, IL-1β, IL-8, macrophage in-
flammatory protein 1α (MIP-1α), and MIP-1β[110], which act primarily on neutrophils themselves as
well as on monocytes, macrophages and endothelial cells. Further cytokine dependent interactions
between neutrophils and DCs, B cells, NK and Th17 cells occur under specific circumstances[135].
A detailed overview of neutrophil derived cytokines and chemokines is provided by reference [124]
implicating further interactions with additional T cell subsets. Neutrophil degranulation further in-
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creases availability of cell surface receptors and integrins, which are also stored in the granula, result-
ing in a higher probability of additional activation and transmigration[49]. In the process of migration
outside of the blood stream, neutrophils make use of specific proteins to modulate extracellular ma-
trix (ECM) structure. Such proteins are matrix metalloproteinases (MMPs) which are also contained
in tertiary granules[136]. By degradation of ECM structures, MMPs allow for tissue remodeling and
simultaneously release further ECM bound molecules such as cytokines further promoting immune
activation[148].
Importantly, Fcγ receptors which bind Fc fragments of antibodies, C-type lectins and complement
receptors are transported to the cell surface during the process of degranulation and their activation
induces phagocytosis of pathogens. Killing in the phagocytic vacuole is a multistep process. Initially,
electrons enter the vacuole via NADPH oxidase producing superoxide radicals (O2-) resulting in an
alkaline pH and a discharged membrane. O2- dismutates by the help of specific enzymes to hydrogen
peroxide (H2O2) further increasing pH by H+ consumption and leading to the accumulation of an-
timicrobial concentrations of these reactive oxygen species (ROS). Additionally, granular contents get
incorporated by fusion of primary and secondary granules with the vacuole within 20 seconds after
pathogen engulfment and high vacuolar pH buffers the acidic pH in these granules. The resulting
pH is perfect for neutral proteases. K+ further enters the vacuole to compensate charge separation
by NADPH oxidase mediated electron transport and further activates neutral proteases which then
potently kill engulfed pathogens[174]. As proteases are inactive in granules and do not meet accord-
ing environments when released from the cell, these adjustment mechanisms are critical for killing
activity in the vacuole as well as a matter of protection of the surrounding tissue when neutrophils
undergo necrosis. Additionally, extracellular active proteases are inhibited by endogenous serine pro-
tease inhibitors (serpins)[100] which can in turn be inhibited by neutrophil derived MMP9[148]. In the
phagocytic vacuole, influx of chloride further results in the formation of antimicrobial hypochlorous
acid from H2O2 by granular myeloperoxidase (MPO)[98]. In total, killing is mediated by the vast body
of microbicidal contents of the fused granules which become active by the adjusted environment in
the vacuole and are supported by the production of ROS and oxidized halides. As these processes are
highly toxic, phagocytosing neutrophils soon die in accordance with the Shimpu¯ Tokko¯tai analogy.
As an additional way of neutrophil mediated antimicrobial function, NETosis was described in the
year 2004[17]. Formation of neutrophil extracellular traps (NETs) is associated with translocation of
elastase from primary granules to the nucleus, where it cleaves specific histones and leads to chro-
matin decondensation[147]. Furthermore, ROS are indispensable for NET formation[57]. The resulting
effector molecule-covered DNA net is then spit into the environment resembling a sticky and deadly
trap for extracellular pathogens.
Further modulator functions of neutrophils are just arising to be recognized in the field and com-
prise interactions with the adaptive immune system. Therefore, neutrophil functions can not only
be found during infections and autoimmunity, when the described mechanisms result in accelerated
tissue damage, but also in the context of malignant diseases.
1.2 Cancer Immunology
Malignant disease is based on an accumulation of multiple independent alterations in the genome of
one single cell which is in fact a very rare event. These changes can be attributed to external or genetic
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factors and result in aberrant cell growth, proliferation and apoptosis by deregulation of signaling
pathways. Thereby, the cells gain cancerous characteristics like self-sufficiency in growth signals,
insensitivity to anti-growth signals, the ability to evade apoptosis, capability for tissue invasion and
metastasis, a limitless replicative potential and sustained angiogenesis as summarized by Hanahan
and Weinberg in 2000[70]. More recently, additional characteristics have been added to these core
hallmarks which are not less of importance for malignant progression: deregulation of metabolic
energy pathways and evasion of immune attack as well as genomic instability and tumor promoting
inflammation were emerging in the last 15 years[71].
1.2.1 Immunosurveillance and Immunoediting
The immune system patrols the body continuously and is well trained by self tolerance mechanisms
to not accidentally recognize and damage host tissue. According to this, a malignant tumor cell which
arises in a host would not be detected. That this assumption does not hold true has been postulated
by Burnet in 1957 suggesting the existence of tumor associated antigens resulting in continuous con-
trol of arising transformed cells by the immune system[21]. This process was named immunosurveil-
lance of cancer. Therefore, a malignant cell has to evade the immune system as the result of a process
that is called immunoediting which is a three-step process from elimination via an equilibrium phase
resulting in tumor immune escape. The elimination phase contributes to immunosurveillance and
is characterized by innate immune cell mediated recognition and killing of tumor cells, dendritic cell
mediated cross priming of T cells and finally generation of tumor antigen specific T cells which home
to the tumor origin resulting in an effective antitumor response[97]. By this process, most of the aris-
ing transformed cells get killed without further notice. Nevertheless, eradication of transformed cells
puts a selection pressure on the malignant cells resulting in less immunogenic cell clones. This rep-
resents the second step, the equilibrium phase, which can take years before resulting in manifested
tumor progression[97]. To finally escape immune control, additional adjustments take place in the
tumor cells themselves as well as in the microenvironment. To this end, reduced tumor recognition
is mediated by reduced antigen presentation via major histocompatibility complex class I molecules
(MHC-I)[95]. According to the missing self hypothesis, cells with low MHC-I expression are eliminated
by NK cells but tumors evade this regulation for example by additionally decreased expression of NK
activating NKG2D (natural-killer group 2, member D) ligands[26]. Further immune ignorance has
been postulated to take place by restriction of availability of tumor antigens[144]. Finally and proba-
bly most importantly, microenvironmental changes result in the formation of an immune privileged
site. Local immunosuppression is thereby mediated by the presence of mainly tumor derived factors
including vascular endothelial growth factor (VEGF), IL-10, Transforming growth factor beta (TGF-
β), prostaglandin E2, soluble phosphatidylserine, Fas, FasL and MHC class I polypeptide-related se-
quence A (MICA)[97].
In the battle of immune evasion by the tumor, tumor cells do not act alone but also recruit and re-
educate immune cells to promote tumor progression and immunosuppression. A central role in this
context is subscribed to macrophages. Those can be alternatively activated resulting in a so called
M2 phenotype which is characterized by secretion of anti-inflammatory molecules like IL-10, TGF-β
and arginase1. Furthermore, general promotion of tumor angiogenesis, growth, metastasis, and im-
munosuppression has been described for M2 tumor associated macrophages (TAM)[73]. In addition,
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tumoral factors are potent modulators of dendritic cell differentiation and it was demonstrated that
immature DCs in tumor hosts mediate TGF-β dependent regulatory T cell (Treg) expansion thereby
promoting tumor progression via immunosuppression[63]. Tregs are classically characterized by ex-
pression of cell surface CD25 and FoxP3 transcription factor activity and were associated with malig-
nant disease very early on[58]. Their central role for tumor progression was demonstrated by antibody
dependent depletion of the cell population expressing CD25 which resulted in complete block of tu-
mor growth in leukemia, myeloma and sarcoma models[146] as well as melanoma[179]. The response
to this treatment was mediated by induction of an antitumor cytotoxic T and NK cell activity[179].
Thus, a vast array of immune cells was indicated to be associated with tumor progression. In con-
trast, an involvement of neutrophils only started to be addressed by research and this advance further
shapes the complexity of tumor associated inflammation.
1.2.2 Role of neutrophilic cells in human cancer
An association between high peripheral neutrophil counts and tumor progression as well as poor
survival has been found for a variety of malignant diseases[201] and was generally identified as a sign
of systemic inflammation. Additionally, more specific functional alterations in neutrophils became
apparent in the last years. In head and neck cancer (HNC) patients, recent studies in our group
demonstrated increased peripheral blood neutrophils and enhanced inflammatory activity[203]. Fur-
thermore, neutrophils in HNC patients were characterized by lower inducible ROS production, re-
duced spontaneous apoptosis and by an increased number of immature cells[204]. Immature neu-
trophils were also found in the blood of terminal lung, breast and gastrointestinal cancer patients
where they associated with poor prognosis[28]. In this line, reduced ROS by neutrophils was also
demonstrated in acute lymphoblastic leukemia[198] and hepatocellular carcinoma[205]. A whole set
of studies concentrated on the identification of the secretory patterns of neutrophils in oral cavity
cancer patients. Thereby, they showed increased IL-1β and IL-1Ra release[88], higher VEGF and lower
IL-18 secretion[89], a reduction in soluble tumor necrosis factor related apoptosis inducing ligand
(TRAIL)[87] as well as an increase in the abundance of IL-17A and IL-17E in neutrophils in the tumor
bearing hosts[61]. These findings implicate a functional involvement of tumor-modulated neutrophils
in human tumor development and progression.
Among the neutrophil induced processes, promotion of angiogenesis is apparent by VEGF produc-
tion which was also shown in a set of additional metastatic malignancies[108]. VEGF can directly act
on endothelial cells promoting blood supply of the tumor. Further induction of angiogenesis was also
described for MMP9 derived from peritumoral neutrophils in hepatocellular carcinoma[102]. Again,
neutrophils exerted profound MMP9 expression in HNC patients as well[38]. The main mechanism
by which MMP9 can directly influence angiogenesis is degradation of ECM and thereby release of
ECM bound VEGF. ECM degradation furthermore enables mobility of cells and MMP9 can therefore
also influence invasiveness of tumor cells. A direct link between neutrophils and tumor cell invasion
was further suggested by our group showing that tumor infiltrating neutrophils induce invasion and
migration promoting cortactin expression in tumor cells in orohypopharynx carcinoma[37]. Further
association of neutrophils with metastasis was presented in hepatocellular and gastric cancers which
was shown to depend on cell-cell contacts between tumor cells and neutrophils[217]. Finally, tumor
associated neutrophils were also implicated in suppressing antitumor responses primarily by the re-
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lease of arginase1 in non-small cell lung cancer[168] as well as glioblastoma multiforme patients[184].
Neutrophil derived arginase1 can profoundly suppress T cell responses by depletion of L-arginine.
These findings draw a wide scaled picture of the multilayered functional consequences of neutrophil
accumulation and infiltration in cancer patients. Murine models and advanced in vitro studies pro-
vide further insight into the mechanisms underlying these functions and will be described in the next
chapter.
Additional complexity arises from the identification of distinct immunosuppressive neutrophil-rela-
ted subsets which can be found in cancer patients. The so called granulocytic myeloid derived sup-
pressor cells (MDSC) were first identified in mice and subsequently also emerged to be present in can-
cer patients. Even though identification is challenged in humans by the lack of Gr-1 antigen, which is
present in mice, we recently suggested a phenotyping strategy specifically identifying human MDSC
subsets[41]. In HNC patients, these cells comprised immunosuppressive immature neutrophilic cells
with low density in gradient centrifugation and impaired chemotactic responses[15]. As immunosup-
pressive functions were also described for neutrophils, their implications in cancer progression are
most probably overlapping. Furthermore, exact relations of both cell types are not yet well defined
and are frequently discussed in the field[14].
1.2.3 Immune status in HNC
Head and neck tumors, which are most frequently resembling squamous cell carcinomas histolog-
ically, are mainly induced by two independent causative agents: human papillomavirus (HPV) in-
fections and toxic nicotine abuse in combination with alcohol resulting in accumulation of genetic
alterations[64, 6]. Both immunogenic viral antigens and nicotine and alcohol induce inflammatory
processes which can likely result in malignant transformation[16, 56]. In case of HPV infections, ex-
pression of viral oncogenes further promotes carcinogenesis[226]. The resulting chronic inflammation
often results in T cell exhaustion and inefficient tumor clearance.
Absolute numbers of CD3+, CD4+, and CD8+ T lymphocytes were decreased in patients with HNC[107].
Furthermore, expansion of CD8+CD45RO-CD27- T cells was described, which are T cell receptor zeta
chain negative and sensitive to apoptosis[106]. Thus, this cell type is rather unresponsive. Increased
spontaneous apoptosis was also described for peripheral blood mononuclear cells (PBMC) as well
as tumor infiltrating lymphocytes (TIL) of HNC patients[160] most likely contributing to decreased
total T cell numbers. Furthermore, spontaneous apoptosis correlated with FasL expression in the
tumor[160] potently removing tumor infiltrating T cells. Additional suppression of T cells in HNC pa-
tients is mediated by expansion of Tregs[190, 211] which show increased responsiveness to TLR stim-
ulation and gain additional suppressive activities by the tumor derived DAMP high-mobility group
protein B1 (HMGB1)[211, 212]. Next to the T cell compartment, tumor associated macrophages were
also described to correlate with tumor progression as measured by metastasis and tumor stage[125].
On top of that, our group revealed expansion of immunosuppressive MDSC in HNC patients and
further characterized central alterations in neutrophil granulocytes in this tumor entity as described
above.
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1.3 Models of tumor-neutrophil and neutrophil-tumor interaction
While patient material is only able to give insight into the current status of an individual state of dis-
ease, mechanistic knowledge can be obtained by further experimental models. Complex context can
therefore be simplified and mimicked in in vitro setups. To this end, many cancer cell lines have been
established and can be utilized to study responses of immune cells to tumoral factors. Furthermore,
direct effects of isolated immune cells on tumor cells are investigated. Thereby, single cell interactions
can be dissected. Transplantable as well as chemically or genetically induced tumors in mice resem-
ble a unique opportunity for the investigation of tumor immune interactions in the living organism.
As the murine and human immune systems are closely related, such mouse models are often used
to mechanistically study disease progression. Neutrophils have been investigated in both models as
described in this chapter.
1.3.1 Neutrophil-tumor crosstalk in vitro
For the analysis of functional properties, human neutrophils can be isolated from the peripheral
blood. Only their short life span limits the in vitro applicability of these cells. Nonetheless, important
findings have been made which help to understand the complex interaction between tumor cells
and neutrophils. Using supernatants from tumor cell lines, survival promoting effects of tumoral
factors as well as chemotactic properties on neutrophils were demonstrated[39, 203, 217, 215]. Further-
more, functional links to tumor promoting properties have been made. For example, angiogenesis
promoting functions of neutrophil derived tissue inhibitor of metalloproteinase (TIMP)-free MMP9
have been identified in chorio-allantoic membrane (CAM) assays and by analysis of HUVEC (human
umbilical vein endothelial cell) spheroid sprouting[8, 10]. Additional studies demonstrated that MMP9
release by neutrophils can be induced by tumor derived factors, which lead to an activation of the p38
mitogen-activated protein kinase (MAPK)[38]. Furthermore, immunosuppressive activity was identi-
fied to be mediated not only by arginase1 in response to IL-8[168] but also by oxidative stress. H2O2
was herein identified to induce T cell dysfunction in vitro which was mediated by impaired T cell
actin dynamics[173, 99].
Next to that, additional studies concentrated on the direct feedback effects of neutrophils on cancer
cells. A study from our group indicated neutrophil release of factors like MMP9 in response to HNC
tumor supernatants which in turn resulted in increased tumor cell invasion and ECM adhesion[39].
Another study convincingly demonstrated a similar feedback effect especially on hepatocellular car-
cinoma cells by induction and release of HGF from neutrophils[86]. Further invasion promoting ca-
pacities on fibrosarcoma cells have been suggested for neutrophil derived serine proteases, namely
elastase, cathepsin G and proteinase-3, which were shown to activate proMMP-2[178]. In a breast can-
cer model, direct interaction of neutrophils and cancer cells was assessed. Thereby it was found that
these cell-cell interactions induced oncostatin M release from neutrophils which promoted an inva-
sive phenotype of the breast cancer cells[157]. It was further demonstrated in a similar setting that
interaction via ICAM-1 on tumor cells and β2 integrins on neutrophils (e.g. CD11b) was mandatory
to enhance migratory capacities of breast tumor cells[191]. As invasiveness is also closely linked to
metastasis, several studies also addressed neutrophil aided tumor cell extravasation in sophisticated
in vitro settings. Neutrophil induced tumor cell transendothelial migration was herein first shown in a
HUVEC migration assay and was also dependent on ICAM-1–MAC-1 (CD11b/CD18) interaction[215].
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Further evidence for this mechanism was provided in an extravasation assay which included blood
flow conditions where melanoma cell derived IL-8 induced MAC-1 increase on neutrophils and re-
sulted in enhanced melanoma cell extravasation[83].
The described findings indicate that a complex functional interplay between neutrophils and tumor
cells was identified by in vitro studies. These studies were ultimately required for our current under-
standing of in vivo processes. Nevertheless, culture systems always harbor one major disadvantage
which is the lack of cell components that cannot be mimicked due to tissue complexity. In vitro
studies therefore need to be verified by additional approaches to ensure the in vivo validity of the
identified mechanisms.
1.3.2 Neutrophils in murine tumor models
In the murine system, mechanistic analysis can be realized by diverse interventions ranging from
chemical inhibitors to genetic modifications. These possibilities result in a vast array of studies on
tumor-immune interaction in mice. Murine neutrophils are identified by the expression of the mye-
loid integrin CD11b and the neutrophil specific marker Ly-6G. As Ly-6G can be detected by Gr-1 spe-
cific antibodies, which also bind to the monocytic Ly-6C antigen, one has to closely examine results
from studies using Gr-1 for identification of neutrophils (and also monocytes). Additionally, differen-
tiation between neutrophils and MDSC is impossible in murine hosts as MDSC have been described
as CD11b+Gr-1+ cells in tumor bearing mice[175] which accounts for all neutrophils. To prevent mis-
understandings, this study prefers to stick to the phenotypic identification by CD11b and Ly-6G. Nev-
ertheless, accumulation of these cells in the tumor bearing host is a central characteristic in most
studies. Tumor induced changes in CD11b+Ly-6G+ cell differentiation and function thereby include
modulation of granulopoiesis in the bone marrow[111, 126] and extramedullary sites like the spleen
have also been suggested as a reservoir of CD11b+Ly-6G+ cells in some tumor models[30]. The tu-
mor microenvironment is furthermore capable of attracting and functionally activating CD11b+Ly-
6G+ cells for example by the presence of the inflammatory chemokines CXCL1[138] and CXCL5[225].
Based on their important roles in inflammatory and homeostatic neutrophil trafficking the respective
receptors CXCR2 and CXCR4[42] were suggested early on to be involved in recruitment of CD11b+Ly-
6G+ cells to the tumor[171]. Consequently, CXCR2 blockade and knockout experiments resulted in
diminished CD11b+Ly-6G+ cell infiltration into the tumor and decreased CD11b+Ly-6G+ cell associ-
ated tumor promoting angiogenesis[91], metastasis[219] and immunosuppression[79]. Mechanistically,
murine studies provided and verified many functional connections between neutrophils and tumors
which could also be applied to the human system as described below.
According to the human studies, MMP9 and VEGF mediated tumor angiogenesis was also supported
in several murine tumor models[218, 103]. The role of MMP9 was further strengthened in knockout
mice for either the MMP inhibitor TIMP2 or MMP9 itself in which neutrophil induced angiogenesis
was either enhanced or reduced, respectively[68, 11]. Mechanistically, increased signal transducer and
activator of transcription 3 (STAT3) activity was demonstrated to be associated with promotion of
angiogenesis[90, 103]. On top of these findings, also a MAC-1 / ICAM1 dependent metastasis promo-
tion could be verified in vivo. This has been demonstrated by β2 integrin knockout experiments[200]
as well as by novel intravital imaging techniques[185].
As indicated by the term myeloid derived suppressor cells, immunosuppression by CD11b+Ly-6G+-
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cells has been extensively studied in murine cancer models. The identified mechanisms include
T cell suppression by Treg expansion[176, 29], arginase 1 and inducible nitric oxide synthase (iNOS)
activity[194, 85, 19], block of T cell homing mechanisms[137, 72], Th17 polarization[27], TCRζ chain down-
regulation[131] and cysteine sequestration[186]. Knockout studies further demonstrated the central
role of the MyD88 innate immune receptor adapter molecule for suppressive functions of CD11b+-
Ly-6G+ cells on T cells[81]. Additionally, suppression of NK cells was indicated by cell-cell contact
dependent inhibition of STAT5 activation[117] and direct NKG2D downregulation[45] by membrane
bound TGFβ in spleen and liver of tumor bearing mice[113]. These variant mechanisms for CD11b+-
Ly-6G+ cell mediated immunosuppression demonstrate the key role of these cells once induced by
a tumor and further imply that specific tumor derived factors decide about the mode of action of
CD11b+Ly-6G+ cells.
On top of various protumoral functions of CD11b+Ly-6G+ cells, recent studies provided evidence for a
critical role of CD11b+Ly-6G+ cell localization in different organs within the tumor host on their func-
tional properties. For example, Fridlender and coworkers[55] demonstrated that CD11b+Ly-6G+ cells
from the spleen and tumor obtained protumoral gene expression changes compared to resting neu-
trophils. This was supported by a second study comparing resting and mobilized neutrophils from
naive mice to MDSC from tumor bearing mice[221]. Furthermore, tumor infiltrating cells showed
a pronounced upregulation of immunomodulatory cytokines and protumoral factors compared to
spleen derived CD11b+Ly-6G+ cells from tumor bearing hosts[55]. Similarly, in a murine prostate can-
cer model, Gr-1+ cells isolated directly from the tumor site, but not those from the spleen, showed
high suppressive activity without need for additional ex vivo activation[76]. These studies conclusively
demonstrate the necessity of neutrophil activation by tumoral factors in the tissue for the exertion of
their complete protumoral repertoire.
Noteworthy, protumoral functions do not resemble the complete portrait of CD11b+Ly-6G+ cell tu-
mor interactions. Mostly associated with therapeutic interventions, CD11b+Ly-6G+ cell activation
was shown to be associated with potent antitumoral effector functions[13]. Probably the most cited
example for this dichotomy is a study from Fridlender et al. in 2009[54]. They could show differ-
ential phenotypes associated with distinct gene expression patterns of tumor infiltrating CD11b+Ly-
6G+ cells upon TGFβ blockade compared to untreated tumor bearing mice resulting in what they call
a N1 rather than the “usually” occurring N2 tumor associated neutrophil (TAN). This terminology
was chosen in analogy with proinflammatory and antitumoral M1 and protumoral M2 TAM. Another
example is Bacillus Calmette-Guérin (BCG) induced immunotherapy of bladder cancer which is only
effective upon the presence of neutrophils mediating the key antitumoral response[193]. Additionally,
also intrinsic antitumoral properties of G-CSF stimulated neutrophils have been described with the
inhibition of lung metastasis formation in murine breast cancer models[66]. This process involved the
production of H2O2 which was further supported by a recent study to promote tumor cell killing after
c-Met activation in CD11b+Ly-6G+ cells[52]. Taken together, these studies demonstrate the complex
interaction between CD11b+Ly-6G+ cells and the tumor which is highly dependent on respective tu-
moral factors and therefore depends on detailed characterization of the model and the cancer entity
in patients. Notably, a detailed analysis of CD11b+Ly-6G+ cells in murine HNC models is missing and
would be beneficial for further investigation of neutrophil-HNC interactions.
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1.3.3 Antibody mediated depletion as major technique for investigation of neutrophil
functions
To address the in vivo relevance of CD11b+Ly-6G+ cells, many studies make use of antibody mediated
depletion. For this purpose, researchers use antibodies directed against either Gr-1 (clone RB6-8C5),
which is binding to Ly-6G as well as Ly-6C even though with lower affinity, or Ly-6G specific mon-
oclonal antibodies (mAb)[32]. Efficient depletion of CD11b+Ly-6G+ cells is rapidly induced upon in-
jections of αGr-1 mAb and provided important insight into short term models of infection[33, 24]. In
contrast to depletion in infectious disease models, multiple and continuous injection of antibodies
has to be applied for most tumor models to obtain longer depletion of neutrophils. Questions about
the technique arose with a recent study by Ribechini et al. demonstrating that bone marrow derived
CD11b+Ly-6G+ cells seemed to be resistant to antibody mediated depletion due to anti-apoptotic
MCL-1 expression[163] which might additionally interfere with longer depletion periods. Limitations
of the technology were also highlighted in a report suggesting that hepatic CD11b+Ly-6G+ cells are
not depleted by Gr-1 mAb in tumor bearing mice[123]. In spite of that, many studies showed impor-
tant mechanistic relationships between neutrophils and tumor progression using this technique.
Significant contribution to the understanding of neutrophil mediated tumor progression was made
by studies with intermediate depletion periods of about one to two weeks. In such a setting, angio-
genesis promoting functions of CD11b+Ly-6G+ cells was verified in a melanoma model[90]. A number
of studies could further show the essential contribution of CD11b+Ly-6G+ cells to tumor cell metasta-
sis. In this regard, CD11b+Ly-6G+cells were shown to be critical for lung colonization by fibrosarcoma
cells[200] and by a lung cancer cell line[187]. In the 4T1 breast cancer model, a functional link has been
described for CD11b+Ly-6G+ cell abundance and metastasis to lung[182] as well as liver[195]. Addition-
ally, depletion of CD11b+Ly-6G+ cells was implied to induce immune response activation in a genetic
glioma model[59] as well as by the lung cancer study of Srivastava et al.[187] who were the only ones so
far reporting more than one mechanism of CD11b+Ly-6G+ cell protumor function in one study. These
studies indicated that effects of neutrophils on tumor progression can occur rapidly and are therefore
measurable within one to two weeks. Nevertheless, many studies also went for longer depletion peri-
ods of three weeks and longer which is essentially also required for genetic and toxin induced tumor
models due to the slow onset of disease. These studies include the first description of tumor growth
delay by granulocyte depletion in a nude mouse model in 1995[150]. Essentially, these studies ver-
ified CD11b+Ly-6G+ cell effects on tumor growth in different tumor models[84, 4, 197, 113, 139, 67, 92, 117]
which was mainly contributed to an activation of antitumor immune responses during Gr-1 or Ly-6G
depletion[84, 113, 54]. Thus, functional implications of CD11b+Ly-6G+ cells in tumor progression were
observed in murine models using both intermediate and long-term depletion.
It has to be noted that depletion schemata highly vary between studies. The applied treatment reg-
imens range from low abundance (100 µg twice per week)[54] to high availability of antibody (500
µg three times per week)[92]. Furthermore, the point of time of initiation of depletion may also differ
and direct comparison of effects on tumor establishment and advanced progression are rarely men-
tioned. A recent study of Mishalian et al. indicated a late over early activity of CD11b+Ly-6G+ cells in
lung carcinoma and mesentheloima models in which a CD11b+Ly-6G+ cell priming switch only oc-
curred with tumor progression[133]. Additionally, also the choice of antibody has to be considered, as
αGr-1 mAb potentially also depleted other cell subsets which might interfere with interpretation of
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results[24, 32].
Regardless of varying treatments and limitations of the technique, all of these studies highlight the
power of antibody mediated depletion to unravel important aspects of neutrophil biology. Neverthe-
less, limitations and variables also arise from the differences between tumor models. Surprisingly,
a detailed and longitudinal analysis of the efficacy and functional consequences of antibody medi-
ated depletion of CD11b+Ly-6G+ cells in the various compartments of tumor bearing mice is missing.
Furthermore, it is largely unknown how the appearance of a tumor and thereby induced CD11b+Ly-
6G+ cell modulation in the host may affect the process of neutrophil depletion.
Aim of the study
As described in the previous chapter, significant progress has been made in the understanding of neu-
trophil induced tumor progression in mouse models, which also reflect functional relationships to
human malignant diseases. In head and neck cancer (HNC) patients, recent studies from our group
indicated the importance of neutrophil granulocytes and identified further modulatory activity of
HNC cells on human neutrophils in vitro[15, 203, 39]. Accordingly, analysis of these interactions in a
murine model would provide a desirable tool for investigation of neutrophil functions in the tumor-
immune crosstalk, which was not yet described in a HNC model. Studies in other tumor models
reported a number of protumoral functions of neutrophils and it was suggested that infiltration into
the tumor is a critical process for the activation of protumoral functions of neutrophils[55]. Contrary,
accumulation of immunosuppressive neutrophils1 in spleen and blood was also described as a key
characteristic of many tumor models suggesting that these cells are also affected by the tumor in the
periphery. Furthermore, it is not clear yet, whether protumoral neutrophils are specifically promoted
to exert one single function or whether they are able to affect tumor progression by several means
being for example angiogenesis and immunosuppression at the same time. A major tool to address
these questions is provided by antibody mediated Ly-6G+ cell depletion, which is often used in ex-
perimental tumor models. As neutrophils are highly modulated in the same tumor models and this
modulation affects activation as well as differentiation of these cells[30, 223, 111], an interference be-
tween proceeding tumors and CD11b+Ly-6G+ cell depletion might occur. Nevertheless, the actual
efficacy of neutrophil depletion is often not monitored and detailed analysis in long-term depletion
experiments are lacking. Additional interest should be put into the function of the Ly-6G protein as
such, which is targeted by these depletion regimens. Albeit no specific role was yet found for this
molecule, antibody mediated ligation could either activate unknown pathways or interfere with its
potential functions. A role for Ly-6G in CD11b+Ly-6G+ cell trafficking has been proposed[208] but was
not confirmed in different experimental settings[75] and therefore remains elusive. The presented
study will address several questions arising from the above stated proceedings in the field of neu-
trophil oncology as outlined below.
1. In the first part of this thesis, CD11b+Ly-6G+ cell frequencies as well as functional activation will
be investigated in a HNC model. A main point of interest in this part of the study is the tissue
specific localization of CD11b+Ly-6G+ cells and their organ dependent functions in the tumor
bearing host during advanced disease progression.
1also called granulocytic myeloid-derived suppressor cells (MDSC)
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2. Next, this study will focus on the impact of neutrophils on HNC progression and tumor growth.
Using antibody mediated depletion of Ly-6G+ cells, the role of neutrophils during the stages of
tumor establishment and advanced disease progression will be assessed. Further analyses will
address potential simultaneous functions by which CD11b+Ly-6G+ cells mediate tumor pro-
gression in the specific stage.
3. A major part of this study concentrates on the evaluation of neutrophil depletion efficacy in
the tumor bearing host. To this end, this study will longitudinally analyze the effects of neu-
trophil depletion on frequency and function of these cells in different tissue compartments of
the tumor bearing host.
4. In the final part of this thesis, a pilot study is presented aiming at the identification of Ly-6G me-
diated and tumor related functions in knockout mice. In a small experimental setup using the
CatchUp mice[75] in the HNC tumor model, tumor associated trafficking and immune effector
interactions will be analyzed.
Taken together, this study will serve new and until know unrepresented insights into HNC-neutrophil
and neutrophil-HNC interactions by establishment and functional analysis of a HNC mouse model.
Furthermore, detailed and longitudinal analysis of external neutrophil modulation in experimental
tumors will be provided for the first time.
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2 Material
2.1 Biological material
The table lists cell lines used for this work and their origin. For description of culture media see table
2.11.
Table 2.1: Cell lines and respective culture conditions.
Cell line Origin Reference
B16F10 murine melanoma selected for for-
mation of lung metastasis, BL6
Filder 1975[51]
EL4 murine T cell lymphoma known to in-
duce high MDSC accumulation, BL6
Youn et al.2012[221]
FaDu human pharynx squamous cell carci-
noma
Rangan 1972[159]
HEK293T human embryonic kidney, constitu-
tively expressing simian virus40 (SV-
40) large T antigen
DuBridge et al.[35]
HMEC human microvascular endothel, im-
mortalized
Ades et al.[3]
MOPC- murine oropharyngeal carcinoma,
tonsil-derived, BL6
kindly provided by John Lee[213]
MOPC-eGFP derived from MOPC- cells by lentivi-
ral transduction
established in this work
MOPC+ murine oropharyngeal carcinoma,
tonsil-derived, HPV E6/E7+, BL6
see MOPC-
UM22b human HNSCC provided by Thomas Hoffmann[80]
SCCVII spontaneously arising squamous cell
carcinoma of C3H mice
kindly provided by Reinhard Zeidler
[145]
2.2 Animals
Common names of animals used in this work are listed in the following table including the official
names according to the standardized international nomenclature.
Table 2.2: Animals and respective breeders.
Mouse strain
(general
name)
Official name Breeder
athymic nude
mice (nu/nu)
NMRI-Foxn1nu/Foxn1nu animal facility, University Hospital
Essen
BL6 C57BL/6JOlaHsd animal facility of the University
Hospital Essen or Harlan Winkel-
mann GmbH (Borchen, Germany)
C3H C3H/HeNHsd see BL6
PhD Thesis - PMN in HNC mouse models Katrin Moses
Material 25
Table 2.2: continued
Mouse strain
(general
name)
Official name Breeder
CatchUp C57BL/6-Ly6gtm2621(Cre-tdTomato)Arte animal facility of the Centre for
Medical Biotechnology of the Uni-
versity Duisburg Essen
CatchUpIVM-red C57BL/6-Ly6gtm2621(Cre-tdTomato)Arte
x B6.Cg-Gt(ROSA)-
26Sortm9(CAG-tdTomato)Hze/J
animal facility of the Centre for
Medical Biotechnology of the Uni-
versity Duisburg Essen
2.3 Consumable supplies
Table 2.3: Consumables used in this work.
Consumable Manufacturer
0.45 µm filters Corning, New York USA
12 well cell culture multiwell plate Greiner bio-one, Frickenhausen Germany
23 G needle BD Biosciences, Heidelberg Germany
24 well Millicell Cell Culture Insert Merck Millipore, Darmstadt Germany
96 well cell culture plate flat bottom Greiner bio-one, Frickenhausen Germany
96 well cell culture plate round bottom Greiner bio-one, Frickenhausen Germany
BD Falcon transwell 3 µm BD Falcon, Heidelberg Germany
BD Microlance 3 25G (orange) BD Biosciences, Heidelberg Germany
BD Microlance 3 27G (grey) BD Biosciences, Heidelberg Germany
BD Microlance 3 23G (blue) BD Biosciences, Heidelberg Germany
BD Microlance 3 20G (yellow) BD Biosciences, Heidelberg Germany
BD Microtainer tubes SST with separation gel BD Biosciences, Heidelberg, Germany
Biosphere®pipette tips 10 µL Sarstedt, Nümbrecht Germany
Biosphere®pipette tips 100 µL Sarstedt, Nümbrecht Germany
Biosphere®pipette tips 1000 µL Sarstedt, Nümbrecht Germany
Biosphere®pipette tips 20 µL Sarstedt, Nümbrecht Germany
Biosphere®pipette tips, 200 µL Sarstedt, Nümbrecht Germany
Bottle top filter 500mL GW45 TPP, Trasadingen Switzerland
Casy Cups Roche Innovatis, BIelefeld Germany
CellTrics 100 µmfilters Partec, Münster Germany
CellTrics 50 µmfilters Partec, Münster Germany
Centrifuge tubes, 40 mL Nalgene, Rochester USA
Centrifuge tubes, 50 mL Greiner bio-one, Frickenhausen Germany
Coding plates for CryoPure tubes green Sarstedt, Nümbrecht Germany
Coding plates for CryoPure tubes yellow Sarstedt, Nümbrecht Germany
Combitips®plus 10 mL Eppendorf, Wesseling-Berzdorf Germany
Combitips®plus 5 mL Eppendorf, Wesseling-Berzdorf Germany
Cover slips round 12 mm Carl Roth, Karlsruhe Germany
Cover slip round 18 mm Carl Roth, Karlsruhe Germany
Cryomold®Biopsy 10x10x5 mm Sakura Finetek, Staufen Germany
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Table 2.3: continued
Consumable Manufacturer
Cryomold®Intermediate 15x15x5 mm Sakura Finetek, Staufen Germany
CryoPure 2.0 mL tubes with external thread Sarstedt, Nümbrecht Germany
FEATHER®microtome blades C35 pfm medical, Collone Germany
ImmEdge wax pen Vector, Peterborough UK
Immuno Plates Maxisorp F96 Nunc / VWR, Darmstadt Germany
Immuno Plates Maxisorp F96 Nunc / VWR, Darmstadt Germany
LD Columns Miltenyi, Bergisch Gladbach Germany
LightCycler Capillaries (20 µL) Roche Applied Science, Wiesbaden Ger-
many
LS Columns Miltenyi, Bergisch Gladbach Germany
Health care Respirator FFP3 1873V 3M Medica, Neuss Germany
Microtiter plate, 96 Well, half area UV transpar-
ent
Corning / VWR International, Darmstadt
Germany
Millex-GP Filter Unit Merck Millipore, Darmstadt Germany
Multiply-µStrip pro 4 tubes chain with lid Sarstedt, Nümbrecht Germany
Omnican®100, 30 G needle B.Braun, Melsungen Germany
Pipette tips, clear (300 µL) Sarstedt, Nümbrecht Germany
PP sealing foil Kisker-Biotech, Steinfurt Germany
PPS blood-collecting device, V-cannula blue,
1,5×43mm
MediPac, Rheinbreitbach Germany
PVDF Western Blotting Membranes Roche Applied Science, Wiesbaden Ger-
many
Reaction tubes 0.5 mL, PP Sarstedt, Nümbrecht Germany
Reaction tubes 1.5 mL without cap Sarstedt, Nümbrecht Germany
Reagent and centrifuge tubes 15 mL Sarstedt, Nümbrecht Germany
Rotilabo®-blotting paper 1.5 mm Carl Rot, Karlsruhe Germany
S-Monovette®10 mL 9NC (Citrat) Sarstedt, Nümbrecht Germany
SafeSeal tube 2 mL Sarstedt, Nümbrecht Germany
Superfrost Plus glass slides Carl Rot, Karlsruhe Germany
SuperFrost®microscope slides Langenbrinck, Emmendingen Germany
Syringes (1 mL, 2 mL, 20 mL) Becton Dickision, Heidelberg Germany
Tissue culture dishes Sarstedt, Nümbrecht Germany
Tissue culture flask T175 Sarstedt, Nümbrecht Germany
Tissue culture flask T25 Sarstedt, Nümbrecht Germany
Tissue culture flask T75 Sarstedt, Nümbrecht Germany
Tissue culture plate 24 well Sarstedt, Nümbrecht Germany
Tissue culture plate 6 well Sarstedt, Nümbrecht Germany
Transfer pipette 3.5 mL, sterile Sarstedt, Nümbrecht Germany
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2.4 Equipment
This section refers to general laboratory equipment and specialized analytical machines.
Table 2.4: Equipment used in the laboratory.
Instrument Manufacturer
6-place swinging rotor Hettich Zentrifugen, Tuttlingen Germany
Analytical balance AE260 Mettler-Toledo, Giessen Germany
Avanti J-26XP Beckman Coulter, Krefeld Germany
Autolave VX75 Systec, Linden Germany
BD FACSAria I BD Biosciences, San Jose USA
BD FACSAria III BD Biosciences, Heidelberg Germany
BD FACSCANTO II BD Biosciences, Heidelberg Germany
Bechtop UV Transilluminator UVP, Upland USA
BioDoc-It®M26X UVP, Upland USA
Caliper 100 mm Roeser Medical, Bochum Germany
Carrier for slide carrier Hettich Zentrifugen, Tuttlingen Germany
Casy Cell Counter + Analyser System version TT Roche Innovatis, Bielefeld Germany
ChemiDoc-It®Imager UVP, Upland USA
Centrifuge Mikro 200R Hettich Zentrifugen,Tuttlingen Germany
Centrifuge Universal 320 Hettich Zentrifugen, Tuttlingen Germany
Centrifuge Universal 420R Hettich Zentrifugen, Tuttlingen Germany
CO2Incubator HERAcell 240 und 240i Thermo Scientific, Langenseldbold Ger-
many
Cordless Animal Clipper VET Isis GT420 Aesculap Suhl GmbH, Suhl Germany
Cryomicrotome HM500 Techno-Med, Bielefeld Germany
Dewar - transport container Carl Roth, Karlsruhe Germany
Ear punch device GE30 (mouse earmarks) CHIRMED, Schöneck Germany
ELISA-Washer ELx50 Biotek, Bad Friedrichshall Germany
Eppendorf Research pipette 0.5-10 µL Eppendorf, Wesseling-Berzdorf Germany
Eppendorf Research pipette 20-200 µL Eppendorf, Wesseling-Berzdorf Germany
Glass anti-roll plate 39.5mm Techno-Med, Bielefeld Germany
Heating block Neoblock 1 Neolab, Heidelberg Germany
Ice box 2.5 L Carl Roth, Karlsruhe Germany
InLab Routine Pro pH electorde Mettler-Toledo, Giessen Germany
Incubator & shaker TH30 Edmund Bühler, Hechingen Germany
Inverse microscope CK2-TR Olympus, Hamburg Germany
LC Carousel Centrifuge Roche Applied Science, Wiesbaden Ger-
many
Leica TCS SP8 MP microscope Leica, Mannheim Germany
Laminar flow hood MSC-Advance 1.8 Thermo scientific, Langenseldbold Ger-
many
liquid nitrogen tank LD25 Taylor-Wharton, Husum Germany
LightCycler Roche Applied Science, Wiesbaden Ger-
many
Lock ring for cyto chamber Hettich Zentrifugen, Tuttlingen Germany
MACSQuant®VYB Miltenyi, Bergisch-Gladbach Germany
Variomag Powertherm (magnetic stirrer & heat
plate)
HP Medizintechnik GmbH, Oberschleis-
sheim Germany
Manual HPLC Syringes 20+30 µL Hamilton, Reno USA
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Table 2.4: continued
Instrument Manufacturer
Microcentrifuge Sprout Kisker-Biotech, Steinfurt Germany
Microloop ear curettes, Langenbeck
Microscopy Scissors Carl Roth, Karlsruhe Germany
Microsurgical forceps MK 17 CHIRMED, Schöneck Germany
Minishaker 3D Kisker-Biotech, Steinfurt Germany
MiniVent Type 845 Hugo Sachs Elektronik, March Germany
Multipette stream Eppendorf, Wesseling-Berzdorf Germany
MyCycler PCR maschine BioRad, Munich Germany
MyCycler Thermogr. Upgrade BioRad, Munich Germany
Neubauer counting chamber improved Carl Roth, Karlsruhe Germany
One-funnel chambers Hettich Zentrifugen, Tuttlingen Germany
Panasocis -86◦CUltra deep freezer EWALD Innovationstechnik, Bad Nenndorf
Germany
Pipetman-Pipette P10 Gilson, Limburg-Offheim Germany
Pipetman-Pipette P100 Gilson, Limburg-Offheim Germany
Pipetman-Pipette P1000 Gilson, Limburg-Offheim Germany
Pipetman-Pipette P20 Gilson, Limburg-Offheim Germany
Pipetman-Pipette P200 Gilson, Limburg-Offheim Germany
Pipettus rechargeable battery Hirschmann, Eberstadt Germany
PowerPac Basic BioRad, Munich Germany
Precision analytical balance AZ612 sartorius, Göttingen Germany
QuadroMACSTM Separator Miltenyi, Bergisch Gladbach Germany
Scotsman AF80 ice flaker Scotsman, Vernon Hills USA
Screw Top Bottles, clear 2000 mL Carl Roth, Karlsruhe Germany
Screw Top Bottles, clear 250 mL Carl Roth, Karlsruhe Germany
Screw Top Bottles, clear 500 mL Carl Roth, Karlsruhe Germany
Section extensor for HM500 Techno-Med, Bielefeld Germany
Seven Easy ph-Meter Mettler-Toledo, Giessen Germany
Slide carriers for one chamber Hettich Zentrifugen, Tuttlingen Germany
Spacer Plates 1.0 mm BioRad, Munich Germany
Staining boxes acc. to Schiefferdecker Carl Roth, Karlsruhe Germany
Synergy 2 Multi-Mode Reader BioTek, Bad Friedrichshall Germany
Trans-Blot SD Semi-dry BioRad, Munich Germany
Univentor 400 Anaesthesia Unit Uno, Zvenaar Netherlands
Vortex Mixer VTX-300L Kisker-Biotech,Steinfurt Germany
Watherbath GFL, Burgwedel Germany
2.5 Chemicals
Table 2.5: Chemicals and other substances.
Chemicals and reagents Manufacturer
7AAD Staining Solution BD Bioscience, Heidelberg Germany
Acetic acid Merck Chemicals, Darmstadt Germany
Aceton pure AppliChem, Darmstadt Germany
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Table 2.5: continued
Chemical and reagents Manufacturer
40 % Arylamide/Bis solution, 37.5:1 Bio-Rad, Munich Germany
AEC Solution InvitrogenTM Life technologies, Karlsruhe
Germany
Ammonium persulfate Serva Electrophoresis, Heidelberg Germany
Aqua B. Braun B.Braun, Melsungen Germany
BD Calibrite Beads BD Bioscience, Heidelberg Germany
BD CST Beads BD Bioscience, Heidelberg Germany
BD FACS Flow Sheat Fluid BD Bioscience, Heidelberg Germany
BD FACSRinse Solution BD Bioscience, Heidelberg Germany
BD Shutdown Solution BD Bioscience, Heidelberg Germany
BD MatrigelTM (HC) BD Bioscience, Heidelberg Germany
Cell Proliferation Dye eFluor450 eBioscience, Frankfurt Germany
CellTraceTM CFSE InvitrogenTM Life technologies, Karlsruhe
Germany
Citrate Buffer (pH 6.0), Concentrate, InvitrogenTM Life technologies, Karlsruhe
Germany
CryoSure DMSO Wak Chemie Medical, Bettingen Germany
Dako REAL Peroxidase-Blocking Solution Dako, Hamburg Germany
DAPI BioLegend, Fell Germany
Dihydrorhodamine 123 InvitrogenTM Life technologies, Karlsruhe
Germany
DynaBeads®CD3/CD28, mouse InvitrogenTM Life technologies, Karlsruhe
Germany
Eosin B Carl Roth, Karlsruhe Germany
Ethanol 99,5 %, Ph.Eur., reinst Carl Roth, Karlsruhe Germany
Fibronectin from bovine plasma Sigma-Aldrich, Taufkirchen Germany
Fluoprep BioMerieux, Nürtingen Germany
Forene 100% (Isoflurane) AbbVie, Ludwigshafen Germany
Hydrochloric acid Carl Roth, Kalsruhe Germany
Immersol 518F Carl Zeiss Microscopy, Jena Germany
Kaisers glycerol gelatine Merck Chemicals, Darmstadt Germany
Ketamine 10 % Ceva Tiergesundheit., Düsseldorf Germany
May-Grünwalds Eosin-Methylenblue solution Merck Chemicals, Darmstadt Germany
Methanol pure Ph. Eur. Applichem, Darmstadt Germany
Paraformaldehyde Merck Chemicals, Darmstadt Germany
PEI Sigma-Aldrich, Taufkirchen Germany
PolyFin®, Paraffin Embedding Wax olysciences, Eppelheim Germany
Poly(vinyl alcohol) Sigma-Aldrich, Taufkirchen Germany
2-Propanol reinst Ph. Eur., USP AppliChem, Darmstadt Germany
QTracker 655 Life Technologies, Darmstadt Germany
Roti®-Histokitt II Carl Roth, Kalsruhe Germany
Roti®-Histol Carl Roth, Kalsruhe Germany
Shandon Instant Hematoxylin ThermoScientific, Bonn Germany
Sodium butyrate Merck Chemicals, Darmstadt Germany
sodium citrate tribasic dihydrate Sigma-Aldrich, Taufkirchen Germany
Sodium chloride Carl Roth, Karlsruhe Germany
0.9 % Sodium chloride solution Fresenius Kabi, Bad Homburg Germany
SpectraTM Multicolor Protein Ladder ThermoScientific, Bonn Germany
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Table 2.5: continued
Chemical and reagents Manufacturer
TEMED Bio-Rad, Munich Germany
Tissue Tek®Mounting Media Sakura Finetek, Staufen Germany
Viability Dye eFluor450 eBioscience, Frankfurt Germany
Viability Dye eFluor780 eBioscience, Frankfurt Germany
Xylazine 2 % Ceva Tiergesundheit, Düsseldorf Germany
2.6 Ready to use reaction systems
Table 2.6: Reaction systems and kits.
Description Manufacturer
Annexin V:PE Apoptosis Detection Kit BD Biosciences, Heidelberg Germany
Anti-Ly-6G MicroBead Kit, mouse Miltenyi, Bergisch Gladbach Germany
APO-DIRECTTM Kit BD Biosciences, Heidelberg Germany
BD Cytofix/Cytoperm BD Bioscience, Heidelberg Germany
BD OptEIATM Mouse IFN-γ ELISA Set BD Biosciences, Heidelberg Germany
CD3 MicroBead Kit, mouse Miltenyi, Bergisch Gladbach Germany
CD45R (B220) MicroBeads, mouse Miltenyi, Bergisch Gladbach Germany
CPD Star® Roche Applied Science, Wiesbaden Ger-
many
FITC BrdU Flow Kit BD Biosciences, Heidelberg Germany
human MIF DuoSet®ELISA Kit R&D Systems, Wiesbaden Germany
MaximaTM SYBRTM Green qPCR Master Mix ThermoScientific, Bonn Germany
mouse G-CSF DuoSet®ELISA Kit R&D Systems, Wiesbaden Germany
mouse IL-6 DuoSet®ELISA Kit R&D Systems, Wiesbaden Germany
mouse KC DuoSet®ELISA Kit R&D Systems, Wiesbaden Germany
RNeasy®Micro Kit Quiagen, Hilden Germany
RNeasy®Mini Kit Quiagen, Hilden Germany
SuperScript II RT ThermoScientific, Bonn Germany
VenorGeM Mycoplasma Kit Minerva BioLabs, Berlin Germany
2.7 Plasmids
The following plasmids were used to establish a green fluorescent HNC cell line for intravital mi-
croscopy. This work was performed in kind cooperation with the Institute for Transfusion Medicine
at the University Hospital Essen. The system was established originally in the group of Prof. Dr. Hel-
mut Hanenberg in Düsseldorf[112].
Table 2.7: Three plasmid system for viral particle production.
Plasmid name Description
pCD/NL-BH helping plasmid encoding for structural and regulatory genes
pE01 capsule plasmid encoding modified foamyviral capsule protein
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Table 2.7: continued
Plasmid name Description
pCL6IEGwo lentiviral genome-integrating plasmid, replication incompetent,
encoding eGFP under SSFV promoter
2.8 Recombinant proteins and chemical inhibitors
This section includes recombinant proteins and inhibitors and their respective final concentrations
used in this manuscript.
Table 2.8: Proteins and inhibitors.
Reagent Concentration Manufacturer
G-CSF 100 ng / mL Chugai Pharm, Frankfurt Germany
ISO-1 50 µM Calbiochem, Darmstadt Germany
mIL-2 50 U / mL Roche Applied Science, Wiesbaden Germany
2.9 Antibodies
The following antibodies have been used. The table further indicates final concentrations of anti-
bodies or applied dilutions if stock concentrations were unknown. Antibodies were purchased from
the following manufacturers: R&D Systems, Wiesbaden, Germany; BioLegend, Fell Germany; Acris
Antibodies, Herford Germany; Abcam, Cambridge UK; Miltenyi, Bergisch Gladbach Germany; BD
Biosciences, Heidelberg Germany; eBioscience, Frankfurt Germany; BioXCell, West Lebanon USA;
NEB / Cell Signaling, Frankfurt Germany; Santa cruz Biotechnoligies, Heidelberg Germany; Biozol /
Cederlane, Munich Germany; AbD Serotec, Düsseldorf Germany; Dianova, Hamburg Germany.
Table 2.9: Antibodies used in different applications.
Antigen Isotype Clone Modi-
fication
Manufacturer usage
[µg/mL]
Flow Cytometry
h/m-Arg1 sheep poly APC R&D Systems 0.50
h/m-CXCR7 mouse
IgG2a
8F11-M16 APC BioLegend 5
h/m-NOS2 rabbit IgG1 4E5 none Acris Antibodies 23.75
m-CD11b rat IgG2a 3A33 PE/Cy7 Abcam 2
m-CD3 hamster
IgG1
145-2C11 FITC Miltenyi 0.3
m-CD4 rat IgG2a RM4-5 V450 BD Biosciences 4
m-
CD45R(B220)
rat IgG2a RA3-6B2 APC Miltenyi 0.66
m-CD49b rat IgM DX5 FITC Miltenyi dil: 1:10
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Table 2.9: continued
Antigen Isotype Clone Modi-
fication
Manufacturer usage
[µg/mL]
m-CD49b rat IgM DX5 PE Miltenyi dil: 1:10
m-CD62L rat IgG2a Mel-14 FITC eBioscience 5
m-CD8α rat IgG2a 53-6.7 V500 BD Biosciences 4
m-CXCR2 rat IgG2a 242216 APC R&D Systems 1
m-CXCR4 rat IgG2b 2B11 APC BD Biosciences 20
m-Ly-6C rat IgG2a ER-MP20 PE Acris Antibodies 2
m-Ly-6C rat IgG2a HK1.4 Alexa488 BioLegend 2.5
m-Ly-6G rat IgG2a 1A8 PerCP/-
Cy5.5
BioLegend 2
Depletion
isotype rat IgG2a 2A3 none BioXCell 200 µg
isotype rat IgG2b LTF-2 none BioXCell 100/200
µg
m-CD8 rat IgG2b 2.43 none BioXCell 100 µg
m-Gr-1 rat IgG2b RB6-8C5 none BioXCell 200 µg
m-Ly-6G rat IgG2a 1A8 none BioXCell 200 µg
Immunoblot
h/m-GAPDH rabbit IgG 14C10 none Cell Signaling dil:
1:5000
h/m-MIF rabbit FL-115 none Santa Cruz 0.4
Histology
h/m-MIF rabbit FL-115 none Santa Cruz 2
m-Asialo
GM1
rabbit poly none Cedarlane dil:
1:5000
m-CD11b rat IgG2b M1/70.15.1 none BioSource 0.5
m-CD31 rat IgG2a MEC13.3 none Santa Cruz 0.013
m-CD4 rat IgG2a RM4-5 none BD Bioscience 1
m-CD8α rat IgG2a KT15 none AbD Serotec 2
m-FoxP3 rat IgG2a FJK-16s none eBioschience 2.5
m-Ly-6G rat IgG2a 1A8 PerCP/-
Cy5.5
BioLegend 0.5
m-MCL-1 rabbit Y37 none Abcam 14.27
Secondary Antibodies
rabbit donkey IgG
(H+L)
Alexa488 Dianova IF dil:
1:200
rabbit goat IgG
(H+L)
AP Dianova WB dil:
1:15000
rabbit goat IgG
(H+L)
Cy3 Dianova IF dil:
1:400
rabbit goat IgG
(H+L)
HRPO Dianova IHC dil:
1:50
rabbit goat IgG
(H+L)
PE Dianova FC dil:
1:200
rat donkey IgG
(H+L)
Cy3 Dianova IF dil:
1:400
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Table 2.9: continued
Antigen Isotype Clone Modi-
fication
Manufacturer usage
[µg/mL]
rat goat IgG
(H+L)
Alexa488 Invitrogen IF dil:
1:200
rat rabbit
F(ab)2
HRPO Dianova IHC dil:
1:50
Isotype Antibodies
isotype mouse
IgG2a
G155-178 APC BD Bioscience stock 50
isotype rabbit IgG none Santa Cruz stock 400
isotype rat IgG2a FITC BioLegend stock 500
isotype rat IgG2a 54447 APC R&D Systems stock 25
isotype rat IgG2b A95-1 APC BD Bioscience stock 200
isotype sheep IgG APC R&D Systems stock 10
2.10 Oligonucleotides
The following table lists the primers used for qRT-PCR. The temperature temp x refers to the annealing
temperature in the PCR program which is depicted in table 3.6. All primers were specific to murine
gene sequences. Oligonucleotidec, including Random Primer Hexamer for cDNA Synthesis, were
purchased from InvitrogenTM Life technologies (Karlsruhe, Germany).
Table 2.10: Oligonucleotides for application in qRT-PCR.
Target Direction Sequence Temp x
[◦C]
Amplicon
[bp]
b-actin forward ACCAACTGGGACGACATGGAGAA 60 380
reverse GTGGTGGTGAAGCTGTAGCC
TNFa forward TCGGGGTGATCGGTCCCCAA 65 141
reverse GGTGGTTTGCTACGACGTGGGC
CCL17 forward GGCCGAGAGTGCTGCCTGGA 59 120
reverse GCCCTGGACAGTCAGAAACACGA
VEGF-A forward CTTGTTCAGAGCGGAGAAAGC 55 125
reverse ACATCTGCAAGTACGTTCGTT
CCL2 forward CGGCTGGAGCATCCACGTGTT 65 63
reverse TAGCAGCAGGTGAGTGGGGC
CCL5 forward CCTCACCATATGGCTCGGACACC 66 57
reverse GCGCGAGGGAGAGGTAGGCA
CCL3 forward TGTACCATGACACTCTGCAAC 59 109
reverse CAACGATGAATTGGCGTGGAA
ICAM1 forward ACCCACCCCGCAGGTCCAAT 55 148
reverse CAGCCGAGGACCATACAGCACG
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Table 2.10: continued
Target Direction Sequence Temp x
[◦C]
Amplicon
[bp]
ARG-1 forward GACCACGGGGACCTGGCCTT 55 170
reverse ACTGCCAGACTGTGGTCTCCACC
iNOS forward TGGCAACATCAGGTCGGCCAT 65 110
reverse CGGGCATCTGGTAGCCAGCG
IL-10 forward GCTGGACAACATACTGCTAACC 59 57
reverse CCCAAGTAACCCTTAAAGTCCTG
MMP9 forward GCTGACTACGATAAGGACGGCA 62 136
reverse TAGTGGTGCAGGCAGAGTAGGA
MHCIIH2I/Ab forward GTGTGCAGACACAACTACGAGG 61 133
reverse CTGTCACTGAGCAGACCAGAGT
CCR2 forward GGGAGACAGCAGATCGAGTG 60 71
reverse CAACCCAACCGAGACCTCTT
2.11 Buffers, solutions and media
Table 2.11: Composition of Solutions and Media.
Liquid Recipe and Manufacturer
Accutase®Cell Dissocia-
tion Reagent
InvitrogenTM Life technologies, Karlsruhe Germany
5× AP buffer 100 mM Tris (Carl Roth)
100 mM sodium chloride (Carl Roth)
5 mM magnesium chloride hexahydtrate (Carl Roth)
pH 9.5
10× azidePBS 1.5 M sodium chloride (Carl Roth)
27 mM potassium chloride (AppliChem, Darmstadt Germany)
81 mM twice hydrated disodium phosphate (Carl Roth)
15 mM monopotassium phosphate (Carl Roth)
150 mM sodium azide (AppliChem)
pH 7.4
Biocoll separating solu-
tion
(density 1.077 g / mL, isotone) Biochrom, Berlin Germany
Blocking Buffer 1 % BSA (AppliChem)
R&D ELISA 0.2 M sucrose (AppliChem)
7.7 mM sodium azide (AppliChem)
1× PBS
CASYton Roche Innovatis, Bielefeld Germany
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Table 2.11: continued
Liquid Recipe and Manufacturer
Cell culture medium I RPMI 1640 (InvitrogenTM Life technologies)
(tumor cell lines & 10 % [v/v] heat-inactivated FCS (Biochrom)
primary immune cells) 100 IU / mL penicillin (InvitrogenTM Life technologies)
100 µg / mL streptomycin (InvitrogenTM Life technologies)
Cell culture medium II
(MOPC cells)
DMEM with L-glutamine, glucose, Na-pyruvate (InvitrogenTM Life
technologies)
F-12 Nutrient Mixture (Ham, InvitrogenTM Life technologies)
10 % heat inactivated FCS (Biochrom)
100 IU / mL penicillin (InvitrogenTM Life technologies)
100 µg / mL streptomycin (InvitrogenTM Life technologies)
10 µg / mL EGF (InvitrogenTM Life technologies)
10 mg / mL insulin (Sigma-Aldrich)
25 µg/ mL transferrin (Sigma-Aldrich)
0.25 µg/ mL chorera toxin (Sigma-Aldrich)
25 µg/ mL hydrocortisone (Sigma-Aldrich)
0.2 µg/ mL tri-iodo-thyronine (Sigma-Aldrich)
Cell culture medium III
(HMEC cells)
Microvasular endothelial growth medium (provito, Berlin Ger-
many)
10 % heat inactivated FCS (Biochrom)
Cell culture medium IV DMEM (4.5 g / l Glucose, PAA)
(HEK293T cells) 10 % heat inactivated FCS (Biochrom)
100 IU / mL penicillin (InvitrogenTM Life technologies)
100 µg / mL streptomycin (InvitrogenTM Life technologies)
100 U / mL L-glutamine (Life Technologies)
Cryo medium I 30 % basal medium
(cell lines) 60 % heat inactivated FCS (Biochrom)
10 % DMSO (Wak Chemie Medical)
Cryo Medium II 90 % heat inactivated FCS (Biochrom)
(immune cells) 10 % DMSO (Wak Chemie Medical)
diluted Giemsa solution 30 % 100 mM disodium phosphate (Carl Roth)
(always fresh) 60 % 100 mM monosodium phosphate (Merck Chemicals)
10 % Giemsa solution (Merck Chemicals)
EILSA Diluent Solution eBioscience, Frankfurt Germany
IMEM Lonza, Basel Switzerland
Immunoblot 25 mM Tris (Carl Roth)
transfer buffer 192 mM glycine (AppliChem)
20 % [v/v] methanol (AppliChem)
Laemmli running buffer 247.1 mM Tris (Carl Roth)
1918.2 mM glycine (AppliChem)
34.7 mM SDS (Carl Roth)
MACS buffer 0.5 % BSA (AppliChem)
2 mM EDTA (Serva Electrophoresis)
1× PBS
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Table 2.11: continued
Liquid Recipe and Manufacturer
Mouse Serum Dianova, Hamburg Germany
PBS cell culture grade Life technologies, Darmstadt Germany
10× PBS 1.37 M sodium chloride (Carl Roth)
26.8 mM potassium chloride (AppliChem)
81 mM disodium phosphate (Carl Roth)
14.7 mM monopotassium phosphate (Carl Roth)
pH 7.4
Percoll GE Healthcare, Freiburg Germany
Reagent Diluent 1× PBS
R&D ELISA 1 % BSA (AppliChem)
Red blood cell lysis solu-
tion
Miltenyi, Bergisch Gladbach Germany
SDS lysis buffer 25 mM Hepes (pH 7.3, PAN Biotech)
0.1 % [w/v] SDS (Carl Roth)
1 % [v/v] Triton X-100 (Sigma-Aldrich)
10 mM EDTA (Serva Electrophoresis)
10 mM sodium pyrophsphate (Carl Roth)
10 mM sodium fluoride (Carl Roth)
125 mM sodium chloride (Carl Roth)
freshly add 10 % PhosphoSTOP (Roche Applied Science)
1 % Protease inhibitor cocktail I (Calbiochem / Merck Millipore)
1 % Protease inhibitor cocktail III (Calbiochem / Merck Millipore)
5× SDS sample buffer 180 mM Tris/HCl pH 6.8 (Carl Roth)
2.88 % [w/v] SDS (Carl Roth)
20 % [v/v] glycerol (AppliChem)
8 % [v/v] 2-mercaptoethanol (Merck Chemicals)
0.2 % [w/v] bromophenol sodium salt (Serva Electrophoresis)
Sodium Carbonate 0.1 M sodium carbonate
Buffer (mIFNγ ELISA) pH 9.5
Staining Buffer azide PBS
(intracellular) 1 % heat inactivated FCS (Biochrom)
10× TBS 20 mM Tris (Carl Roth)
1.5 M sodium chloride (Carl Roth)
pH 7.2 - 7.4
TBS-T 1× TBS
0.1 % Tween-20 (AppliChem)
TMB solution 0.48 % [w/v] TMB (Sigma-Aldrich)
10 % [v/v] acetone (AppliChem)
90 % [v/v] ethanol (Carl Roth)
0.6 % [v/v] hydrogen peroxide (Merck Chemicals)
TMB Substrate Buffer 32.8 mM citric acid (Merck Chemicals)
0.02 % [v/v] Kathon (Christ Chemie AG, Reinach Germany)
pH 4.1
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Table 2.11: continued
Liquid Recipe and Manufacturer
Trypsin, 0.25% with
EDTA 4Na
InvitrogenTM Life technologies, Karlsruhe Germany
Wash Buffer 1× PBS
(ELISA) 0.05 % [v/v] Tween-20 (AppliChem)
(ELISA) 0.05 % [v/v] Tween-20 (AppliChem)
2.12 Software
Table 2.12: Software.
Sofware Producer
AxioVision Carl Zeiss, Jena Germany
BD FACSDiva BD Biosciences, Heidelberg Germany
Gen 5 BioTek, Bad Friedrichshall Germany
GIMP 2.6.7 The GIMP Development Team, http://gimp.org
GraphPad Prism V 4.00 GraphPad Software, Inc., La Jolla USA
ImageJ V1.48v Wayne Rasband, National Institutes of Health, Bethesda USA
IMARIS Bitplane, Zurich Switzerland
LAS X Leica Microsystems, Mannheim Germany
LightCycler 3 Roche Applied Science, Wiesbaden Germany
MACS Quantify Miltenyi, Bergisch Gladbach Germany
MikTex 2.9 Christian Schenk, Berlin Germany
ModFit LT Verity Software House, Topsham USA
MS Office 2007 / 2010 Microsoft, Remond USA
Photoshop CS5 Adobe Systems, Munich Germany
R The R foundation, Vienna Austria
VisionWorksLS UVP, Upland USA
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3 Methods
3.1 Cell biology
3.1.1 General cell culture techniques
Adherent tumor and endothelial cell lines were cultivated in 25 – 175 cm2 cell culture flasks at 37◦C
with 5 % CO2 supply in their respective media which are listed in table 2.11. For passaging, cells were
washed with 1×PBS and dislodged with trypsine/EDTA at 80 % confluence twice-weekly. After stop-
ping the reaction with FCS, cells were collected, centrifuged (300 g, 7 minutes, 4◦C) and resuspended
in equal amounts of culture medium. Cell counting was performed in a Casy cell counter in cell line
specific programs via electric conductivity. Cells were seeded according to their growth rate in their
respective cell culture media. Presence of mycoplasma was constantly excluded by a PCR Kit used
with supernatant from confluent cultures (VenorGeM, Minerva BioLabs). For experiments, cells were
dislodged using the more gentle enzyme Accutase® after washing with PBS, counted as described
above and seeded according to the respective protocol.
Cryoconservation
For cryoconservation approximately 5 · 106 cells were pelleted by centrifugation (300 g, 7 minutes,
4◦C) and resuspended in 1 mL cryo medium (medium I was used for cell lines while medium II was
more convenient for primary immune cells, see table 2.11). Cells were immediately put into an iso-
propyl alcohol-containing cryo box for enabling a constant cooling rate of 1◦C per minute to -80◦C.
Long-term storage was performed in liquid nitrogen tanks. After cryoconservation, the cells were
re-transferred to active culture by thawing and washing with the respective medium to immediately
remove DMSO. The cells were then cultivated as described above.
Generation of cell line supernatants
To generate standardized supernatants (SN) from tumor cell lines, cells were dislodged with Accutase
and seeded at a density of 2 · 106 cells / mL of the respective culture medium. After 24 hours, SN were
collected and centrifuged to remove cell debris and dead cells. Cell free SN were frozen at -20◦C until
analysis.
3.1.2 Establishment of a green fluorescent cell line via lentiviral transduction
S2 work was carried out in kind cooperation in the Institute for Transfusion Medicine at the Univer-
sity Medical Center in Essen. The system was established originally in the group of Prof. Dr. Helmut
Hanenberg in Düsseldorf[112] and contains a plasmid encoding for the target protein (plasmid vector)
as well as a helping plasmid and a capsule plasmid (see also table 2.7). The helping plasmid encodes
the structural proteins gag and pol as well as the regulatory proteins vif, vpr, vpu, rev and tat under
the control of the CMV promoter. The third plasmid encodes for CMV promoter driven expression
of a modified foamyviral capsule protein, which is ensuring a broad host and tissue tropism. During
particle formation, the plasmid vector is transported into the viral particles and later transferred into
the transduced cells. It is further capable of integrating into the target cell genome by long terminal
repeats (LTR) and therefore resulting in stably transduced cells. Viral particles are replication incom-
petent by a deletion in the U3 region of the 3‘-LTR of the viral expression cassette. HEK293T cells
PhD Thesis - PMN in HNC mouse models Katrin Moses
Methods 39
enable for the replication of episomal plasmids, which carry a Simian Virus 40 (SV40) origin of repli-
cation, by expression of the SV40 large-tumor antigen [35] and were therefore used for viral particle
production.
Generation and purification of viral particles
Viral particles were produced in HEK293T cells using the plasmids listed in table 2.7 in a 175 cm2
flask. For transfection of the cells, plasmids (0.5 µg / mL pE01, and 3.75 µg / mL NL-BH and pCL6)
were packed in positively charged particles by mixing rigorously with 22.5 µg / mL Polyethylenimine
(PEI) in DMEM and incubation for 30 minutes at room temperature in the dark. 70 - 90 % confluent
cells were supplied with 6 mL PEI-DNA particles and 12 mL DMEM 15 % FCS, 1.5 % penicillin, strep-
tomycin and L-glutamine (PSG) and incubated over night. Particles were taken up by endocytosis
during this time [12]. To induce CMV promoter activity, new medium was supplemented with 10 mM
sodium butyrate and incubated for 6 - 8 hours. This way, viral titers could be boosted to up to 1200 %
[158, 112]. For collecting viral particles, cells were supplied with new medium (culture medium IV) and
virus was produced for 18 - 22 hours before purification. To harvest viral particles, culture medium
was filtered through 0.45 µm pores into a centrifuge tube that is leak proof for aerosols (40 mL, Nal-
gene). Viral particles were sedimented at 25000g for 90 minutes at 4◦C and resuspended in HEPES
buffered IMDM medium with 20 % FCS. Purified viral particles were stored at -80◦C until used.
Stable transduction of target cells
For transduction, target cells (MOPC-) were seeded in 6 well plates in varying densities and were left
to adhere. Viral particles were added in different dilutions for 24 hours. Cells were washed carefully
and observed for stress symptoms by light microscopy. Transduction efficiency was checked by flu-
orescence microscopy and cells with least stress symptoms and highest transduction efficiency were
chosen for further expansion. Expanded mixed cell populations were sorted for eGFP expression us-
ing a BD FACSAria I flow cytometer. The resulting cell line contained >98 % eGFP+ cells among living
cells and is referred to by the name MOPC-eGFP. No differences in growth behavior by MTT assay
in vitro as well as in vivo and morphology have been observed between the modified cells and the
parental cell line MOPC-.
3.1.3 Primary cell isolation
Isolation of human neutrophils
Human neutrophils were isolated via density gradient centrifugation. Due to their specific density
they colocalize with erythrocytes in a gradient with a 1.077 g / mL polysucrose solution and can be
separated from mononuclear cells by this approach. Working fast and at constant room temperature
allows isolation of viable, resting neutrophils.
Venous blood was taken in collection tubes containing 3.2 % trisodium citrate solution (S-Mono-
vette®). After 1:1 dilution with PBS, blood was carefully loaded on the cell separation solution and
subjected to the gradient centrifugation at 300 g for 30 minutes with minimal acceleration and with-
out break. Mononuclear cells were removed and the pellet containing neutrophils and erythrocytes
was collected. Next, erythrocytes were sedimented by applying the same volume 1 % PVA for 20 min-
utes. The neutrophil containing upper phase was collected and pelleted by centrifugation for 5 min-
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utes at 300 g. Remaining erythrocytes were removed by hypotonic lysis in 0.2 % NaCl for 50 seconds
with subsequent readjustment of osmolarity. Cells were maintained in cell culture medium I and
applied to experiments after a 30 minutes resting phase.
Murine immune cell isolation from different tissues
All cell types were cultivated in cell culture medium I.
For the isolation of peripheral blood leukocytes, the mouse was sacrificed by an overdose of inhala-
tion anesthesia (isoflurane). The peritoneum was opened directly and blood was taken from the aorta
using a 25 gauge (G) needle and a 1 mL syringe. Blood was transferred into a tube containing 20 %
[v/v] 3.8 % sodium citrate and mixed gently to prevent clotting. Blood cells were either stained di-
rectly (see whole blood staining in section 3.1.8) or after removal of erythrocytes by hypotonic lysis
using distilled water for 10 seconds followed be readjustment of osmolarity with 2× PBS. After lysis,
cells were washed and applied to further analysis.
Splenocytes were isolated by a mechanical procedure. To this end, the spleen was perforated and
rinsed with PBS using a 23 G needle. Remaining leukocytes were dissociated from the soft tissue by
mechanical pressure using the plugger of a 20 mL syringe. A single cell solution was obtained by
separation of cell clumps using a 23 G needle. Erythrocytes were lysed as described above after cen-
trifugation of the cell suspension. Resulting clumps, which were derived from soft tissue components,
were removed by filtration through 50 µm cell strainers. Cells were counted as described above and
applied to further analysis.
Bone marrow cells were isolated from the femur. Skin and surrounding muscles were removed and
the bone was sterilized in 70 % ethanol prior to opening. Opened bones were rinsed with PBS using
a 23 G needle until the bone turned white. A single cell solution was obtained by separation of cell
clumps using a 23 G needle. Erythrocytes were lysed as described above after centrifugation of the
cell suspension. Resulting clumps were removed using 50 µm cell strainers. Cells were counted as
described above and applied to further analysis.
Lymph nodes were isolated from close proximity to the tumor localization (draining lymph node).
Lymph nodes were cut into pieces and further minced with the plugger of a 20 mL syringe. The sus-
pension was directly filtered using a 50 µm cell strainer and counted as described above.
Leukocytes from the liver were isolated after gentle dissection of the organ. Liver pieces were meshed
using the plugger of a 20 mL syringe and filtered through a 50 µm cell strainer. The cell suspension
was centrifuged at 460 g for 10 minutes and the cell pellet was applied to a Percoll gradient to purify
leukocytes from dead hepatocytes. To this end, cells were resuspended in PBS 5 % FCS and mixed
with isotonic 90 % Percoll solution to a final concentration of 32.5 % Percoll. Gradient centrifugation
was carried out at 850 g for 25 minutes without break. By this procedure, the hepatocytes remain in
the Percoll solution while the leukocytes sediment to the pellet which was gently washed with PBS
5 % FCS afterwards. Erythrocytes were lysed as described above followed by another filtration using
a 50 µm cell strainer. Tumor infiltrating cells were isolated by mechanical dissociation of the tissue
using the plugger of a 20 mL syringe. Erythrocytes were lysed as described above after centrifugation
of the cell suspension. Resulting clumps were removed using 50 µm cell strainers.
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3.1.4 Cell enrichment and purification by magnetic cell separation
Magnetic cell separation or magnetic activated cell sorting (MACS) is based on the characteristic ex-
pression of cell surface proteins on different types of immune cells. Specific antibodies were used to
detect these proteins and coupled to magnetic beads either directly or indirectly by biotin. Sorting
was performed using appropriate MACS columns placed in a MACS Separator, which is a strong per-
manent magnet. Thereby, the MACS Column provides a magnetic field which retains labeled cells.
Columns were equilibrated by addition of 2 - 3 mL MACS buffer and after binding of the cells they
were washed three times with the same amount of MACS buffer if not indicated differentially. Elution
was achieved by removing the column from the magnet and rinsing the column with MACS buffer.
Depletion of B220+ cells from splenocytes
To enhance enrichment of other cell types, B cells were first removed from isolated splenocytes. To
this end, CD45R (B220) Micro Beads (Miltenyi) were used according to manufacturer’s instructions.
Isolated splenocytes were directly labeled using B220 specific micro bead coupled antibody (clone
RA3-6B2, 10 µL / 107 cells) for 15 minutes at 4◦C. After washing, cells were resuspended in MACS
buffer and applied to a LD column as describes above. The cells which passed the column were
collected and further processed as the B220- splenocytes.
T cell enrichment
B220- splenocytes were used for T cell isolation by using the CD3 MicroBead Kit according to the
manufacturer’s protocol. In brief, up to 107 cells were labeled using 10 µL biotin coupled hamster-
anti-mouse CD3 for 10 minutes. After washing with MACS buffer, 20 µL anti-biotin micro beads
were added for the same amount of cells and incubated for 15 minutes. Separation in a LS column was
performed as described above after washing the cells again. The retained T cell-enriched population
was eluted and subjected to proliferation experiments as described below.
Isolation of Ly-6G+ neutrophils
For the isolation of murine neutrophils from isolated BL6 splenocytes, B220 depletion was performed
as described above. Additionally, the Ly-6G MicroBead Kit was applied according to manufacturer’s
instructions. Cells were labeled using biotin coupled rat-anti-mouse Ly-6G antibody (50 µL / 108
cells) for 10 minutes. Anti-biotin micro beads were directly added (100 µL for the same amount of
cells) and incubated for another 15 minutes. Washed cells were applied to a LS column and washed 5
times before purified cells were eluted from the column. Ly-6G+ cells were used for direct analysis or
cultured over night in cell culture medium I to assess survival.
3.1.5 Fluorescence-activated cell sorting
Fluorescence-activated cell sorting (FACS) is a method for isolating cell subsets based on cell surface
expression of antigens by flow cytometry. For this isolation, the cells are detected as described in
section 3.1.8 and after detection the stream is broken into individual droplets containing one cell
each. At this step, an electrical charge is put on the droplet based on the measured properties and
the adjustments by the experimentator. When passing the electrostatic deflection system, charged
droplets are adjusted to get collected in different tubes. For the isolation of different immune cells, a
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BD FACS Aria III was used, which was provided by the Imaging Center Essen (IMCES) in the Institute
for Experimental Immunology and Imaging at the University Hospital Essen.
Isolation of tdTomato+ neutrophils
For the isolation of neutrophils from CatchUp mice, tdTomato expression was used. Expression of the
fluorescent protein is regulated as described in section 3.2.1 in these mice and is restricted to neu-
trophils. Therefore, additional labeling was not necessary leaving the cells as untouched and inactive
as possible. Cells from different organs were prepared as described in section 3.1.3. Cell suspensions
isolated from tumor tissue were further stained for dead cells using viability dye eFluor780 in PBS for
20 minutes. Cell sorting was carried out in cell culture medium I using the gating shown in figure
A.1. The resulting neutrophil population was >98 % pure and was directly applied to cytospins, RNA
isolation or T cell suppression assays.
T cell isolation
Splenocytes were labeled using anti-CD3-FITC antibody to isolate T cells from CatchUp mice. La-
beling was carried out as described in section 3.1.8 using freshly filtered solutions. Cell sorting was
carried out in cell culture medium I using the gating shown in figure A.2. T cells were of >99 % purity
and subsequently used for T cell proliferation assays.
3.1.6 T cell proliferation
Polyclonal activation was used to assess proliferative capacities of T cells as well as suppressive prop-
erties of neutrophils. Cells were purified as described above and labeled using either Carboxyfluo-
rescein succinimidyl ester (CFSE) or Cell Proliferation Dye eFluor450. For CFSE labeling, cells were
pre-warmed at a maximum concentration of 1 · 107 / mL in RPMI, supplied with 5 µM CFSE for 15
minutes and the uptake was stopped by the addition of the same volume FCS. To label cells with
eFluor450, 1 · 107 cells / mL were stained with 10 µM of the dye for 20 minutes at room temperature
and stopped with 4-5× culture medium I for 5 minutes on ice. After washing both T cells could be
supplied to the proliferation assay. The assay was carried out in 96 well round bottom plates in cell
culture medium I supplemented with additional 50 U / mL mIL2 to maintain T cell survival. Prolif-
eration was induced using CD3 and CD28 antibodies coupled to beads (DynaBeads) in a 1:1 T cell to
bead ratio for 3 days. For the suppression of T cell proliferation, purified Ly-6G+ cells were added in
different Ly-6G : T cell ratios.
3.1.7 Transendothelial migration assay
The migration of neutrophils through an endothelium was to be mimicked by this assay. To this end,
a 3 µm cell culture insert transwell system was equipped with an endothel cell monolayer prior to
performing the migration assay.
Three µm cell culture inserts for 24 well plates were coated with 50 µg / mL fibronectin in PBS for 30
minutes and washed twice with PBS afterwards. Endothelial cells (human microvascular endothelial
cells, HMEC) were added at 1 · 105 cells per insert and grown surrounded by cell culture medium III at
37◦C and 5 % CO2 to form a monolayer. Confluence of endothelial cells was assessed by hematoxylin
and eosin staining and microscopic observation as follows. The staining procedure was performed
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using the intact transwell, which was additionally coated and not to be used in the assay. Cells were
fixed in methanol, stained with Shandon Instant Hematoxylin and directly transferred into acidified
0.1 % Eosin solution for 30 seconds each. After rinsing with desalted water, the transwell membrane
was excised using sharp forceps, placed on a glass slide and mounted with Kaiser’s glycerol gelatine.
Confluence was usually achieved after a period of two days.
For performing the transendothelial migration assay, the cell culture insert was placed into a new
well of a 24 well culture plate containing either cell culture medium as a control or tumor super-
natants delivering chemotactic signals. Pretreatment of SN with 50 µM of the MIF inhibitor ISO-
1 (4,5-Dihydro-3-(4-hydroxyphenyl)-5-isoxazoleacetic acid methyl ester inhibiting MIF tautomerase
activity) was performed for 30 minutes prior to the experiment at 37◦C. 5 · 105 isolated neutrophils
were seeded on to the endothelial monolayer and were allowed to migrate for 4 hours at 37◦C and 5 %
CO2. Additionally, the same amount of neutrophils was seeded and incubated in a well without insert
and served as maximum migration control.
After the migration period, cell culture inserts were removed, migrated cell suspensions were mixed
in the well and migrated cell numbers were determined using the Casy cell counter. Percentages of
migrated cells refer to the cell numbers counted in the maximum migration control.
3.1.8 Flow cytometry
Flow cytometry can be utilized to detect, measure and analyze physical and chemical characteristics
of cells or other particles. An advanced application of flow cytometry is fluorescence activated cell
sorting (FACS) as described in section 3.1.5. In general, the cells enter a fluid stream in which they are
led through a laser beam. Detectors are located in line with the laser beam (forward scatter, FSC) and
vertical (side scatter, SSC). FSC represents information on cell size and volume whereas SSC measures
refraction of light by the cells representing granularity and inner complexity. Fluorescence mediated
by transgenic expression of fluorescent proteins or fluorescently coupled antibodies can be measured
by special filters and detectors depending on the instrument settings. Measurements were carried
out on a BD FACSCanto II machine with 3 fixed-wavelength lasers (488, 633 and 405 nm) providing
detection on 8 photomultiplier tubes (PMT).
Cell surface staining
Staining of cell surface epitopes was generally carried out using fluorochrome coupled antibodies in
a 96 well round bottom plate. Cells were washed with PBS prior to staining. Primary antibodies were
diluted in PBS 3 % mouse serum and 10 % FCS, which was supposed to block unspecific binding,
and incubated with the cells for 20 minutes at 4◦C. Next, cells were washed with PBS and dead cells
were stained using viability dyes diluted in PBS. After another wash, cells were resuspended in azide
PBS and directly analyzed in the flow cytometer. Gating always included doublet exclusion and 100 %
cells was set to living cells with a characteristic FSC SSC appearance of leukocytes. Antibodies used
for flow cytometry and applied concentrations are listed in table 2.9.
Whole blood staining
Citrate mixed blood was transferred to a new 1.5 mL reaction tube. Antibodies were added in the
titrated dilutions that were also used for normal surface staining (see table 2.9) and incubated at
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4◦C for 20 minutes. Erythrocytes were lysed directly after staining. For small amounts of blood (up to
10 µL from tail vein blood), lysis was performed using distilled water as described in section 3.1.3. In
all other cases, 1×Red blood cell lysis solution (Miltenyi) was applied for 5 minutes (blood:buffer ratio
1:10). After lysis, cells were sedimented at 460 g for 5 minutes, resuspended in azide PBS and analyzed
in the flow cytometer. Unstained cells were recorded for the correct adjustment of population gates.
Intracellular staining
Many molecules are located inside of cells and cannot be detected on the surface. To stain intracellu-
lar molecules, cells had to be permeabilized to gain access to those epitopes. Cell surface molecules
were stained prior to permeabilization if a combination of both was stained. Cells were washed with
PBS and permeabilization was performed using BD Cytofix / Cytoperm, which is based on PFA, for
20 minutes at 4◦C. Cells were washed, resuspended in antibody containing Perm Wash Buffer and
incubated for 30 minutes at 4◦C. If secondary antibody staining was necessary, it was carried out the
same way. For measurement, which was performed immediately, cells were resuspended in Staining
Buffer.
BrdU staining
For the detection of integrated BrdU, an extended intracellular staining protocol was used accord-
ing to the instructions of the BrdU FITC Flow Kit (BD). Surface staining was performed in advance
and permeabilization was carried out as described above. Permeabilization was stabilized using Cy-
toperm Plus Buffer for 10 minutes. After washing, cells were refixated with Cytofix / Cytoperm for
5 minutes and washed again. A DNase digestion was performed at a concentration of 300 µg / mL
for 1 hour at 37◦C to release the incorporated BrdU. After washing with Perm Wash Buffer, BrdU was
stained using a FITC coupled specific antibody in Perm Wash Buffer for 20 minutes at room temper-
ature. After staining, cells were directly measured in the flow cytometer in Staining Buffer.
Proliferation of T cells
Proliferation experiments were set up as described in section 3.1.6 using CFSE or Cell Proliferation
Dye eFluor450-labeled cells. Upon cell division, the fluorochrome content of the parental cell is
equally distributed to the daughter cells resulting in a reduction of emitted fluorescence intensity by
50 %. Therefore, proliferation was easily assessable by flow cytometry. Additionally, CFSE-labeled
T cell-enriched cultures were stained with α-CD4-V450 and α-CD8-V500 to identify T cells while
eFluor450-labeled pure T cell suppression assays were stained with α-Ly-6G-PerCP/Cy5.5 to exclude
surviving neutrophils prior to measurement as described above. Analysis was carried out using Mod-
Fit software as demonstrated in figure 3.1. The analysis considers the proportion of the mother popu-
lation as well as the number of generations produced and results in the proliferation index (prolifera-
tionindex). For calculation of suppressive capacity, the following equation was used with the relative
modification being either suppression or additional induction of proliferation.
no proliferation: prol i f er ationindex = 1 (1)
inducedindex = prol i f er ationindex −1 (2)
modi f i cation[%]= 100 · inducedindex(modi f ied)
inducedindex(normal )
(3)
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Figure 3.1: Analysis of proliferation assays. Representative plots from ModFit mediated proliferation analysis
are shown. (A) Assay was performed with T cell enriched splenocytes. Proliferation of CD4 and CD8 positive
living cells was analyzed (gate R3). (B+C) Suppression assay was carried out with labeled lymph node (LN) cells.
Gate R3 was set to Proliferation dye positive cells which are negative for Ly-6G. One example for maximum
proliferation (B) and suppression by a 1:1 bone marrow Ly-6G+ cell : LN T cell ratio (C) is given.
Detection of apoptosis
For the determination of apoptosis, cells were stained for the presence of phosphatidylserine on the
cell surface by AnnexinV membrane binding, which resembles an early apoptotic phase, and for 7AAD
incorporation which is taking place upon membrane dysfunction by dead, necrotic and late apoptotic
cells. Treated cells were washed with PBS and resuspended in 1× Annexin binding buffer (provided
by the AnnexinV:PE Kit, BD) containing AnnexinV-PE and 7AAD in a 1:100 dilution each. Staining was
carried out for 15 minutes at 4◦C and was followed by addition of Annexin binding buffer and direct
analysis in the flow cytometer. Surviving cells were identified by being AnnexinV and 7AAD double
negative. To ensure the correct adjustment of gates, unstained cells were measured as a control.
Reactive oxygen species
Reactive oxygen species (ROS) can be detected using Dihydrorhodamine 123. The chemical pene-
trates into the cells and is oxidized by ROS to rhodamine which is not able to leave the cell again but
can be detected by its fluorescence (λex/λem 508/529 nm). Cells were isolated and rested for 60 min-
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utes in culture medium at 37◦C 5 % CO2. Dihydrorhodamine 123 was added to a final concentration
of 2.5 µg / mL and incorporated for 15 minutes under culture conditions. The reaction was stopped by
incubation of ice for 15 minutes and samples were directly measured in the flow cytometer without
washing.
Data analysis
FACSDiva 8 Software was used for the analysis of flow cytometry data except for the analysis of td-
Tomato expression, which was assessed using MACSQuantify software because data was acquired at
a MACSQuant machine. The term ’all cells’ or ’all leukocytes’ always refers to singlet, living cells with
characteristic leukocyte forward and side scatter properties as depicted in figure 3.22. Further gating
for distinct cell populations was carried out with the help of unstained control cells. Expression of
cell surface receptors and intracellular mediators was assessed via median fluorescence intensities
(MFI) with the help of fluorescence minor one (FMO) controls using isotype antibodies in the same
concentrations as specific antibodies for the respective molecule and were calculated as described
below.
∆Median =MF Ispeci f i c −MF IFMO (4)
3.1.9 Enzyme linked immunosorbent assay
Serum preparation
For the analysis of serum cytokine content, mice were euthanized and blood was taken as described in
section 3.1.3. Instead of using sodium citrate, blood was collected in tubes with separation gel. Tubes
were placed to an upright position for 30 minutes to leave blood to coagulate. Cellular components
and serum were separated by centrifugation at 6000 g for 10 minutes. The separation gel localizes
between serum and cellular components in this procedure providing a physical barrier. Serum was
frozen in these tubes at -80◦C until analyzed.
Cytokine determination by ELISA
This assay for the antibody mediated detection of proteins in solutions such as culture supernatants
and sera is performed by enzyme linked immunosorbent assay (ELISA). A sandwich-like approach
was applied here using either Duo Set Kits from R&D or BD OptEIA Set Kits according to manufac-
turer’s instructions. Antibody concentrations as well as highest standard concentrations are listed in
table 3.1. Nunc Maxisorb plates were coated with the provided capture antibody in PBS3 over night at
4◦C. Next, antibody solution was removed and unspecific binding was blocked using Blocking Buffer
(R&D) or Assay Diluent (BD) for 1 hour at room temperature. Plates were also stored at this step for
later usage at 4◦C. After washing, 50 µL of each sample was applied to the plate in triplicates. Dilution
was performed in advance in Reagent Diluent (R&D) / Assay Diluent (BD) if necessary. A standard
dilution in 7 steps and a blank sample without protein were run on each plate in triplicates to enable
2Noteably, all cells were acquired using the same voltages for SSC and FSC photomultiplier tubes
3For mIFNγ, coating was performed in sodium carbonate buffer. Please refer to table 2.11 for buffer composition.
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Figure 3.2: General gating strategy for analysis of flow cytometry. Cells were isolated from different
mouse tissues and applied to flow cytometry. Voltages on photomultiplier tubes were the same for all cell types.
Shown are representative contour plots of the respective analysis. Further analysis will refer to the leukocyte
gate (leuko) as ’all leukocytes’ or ’all cells’. This gate refers to the usual leukocyte SSC and FSC properties but
does not necessarily contain leukocytes only.
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quantification. Serum samples were run in duplicates. Binding by capture antibody occurred dur-
ing a time interval of 2 hours at room temperature or over night at 4◦C. The plate was washed using
Washing Buffer to remove unbound protein and detection antibodies were used to verify binding of
the protein of interest. For BD ELISA, biotinylated detection antibodies were combined with horse
radish peroxidase (HRP) coupled streptavidin and incubated in Assay Diluent for 1 hour before pro-
ceeding with the detection step. For R&D Kits, biotinylated detection antibody was incubated for 2
hours prior to washing and separate incubation with HRP coupled streptavidin was carried out for
45 minutes. Detection was performed using the HRP catalyzed oxidation of 3,3’,5,5’Tetramethylben-
zidine (TMB) to TMB diimine, which is of blue color. After washing the plates, TMB substrate buffer
and TMB solution were freshly mixed in a ratio of 20 : 1 and color reaction was taking place. The reac-
tion was immediately stopped after 20 minutes by addition of half as much 2N sulfuric acid turning
TMB yellow, which was directly measured in a Synergy II plate reader at 450 nm using Gen5 software.
Concentrations were calculated according to the standard curve that derived from the standard dilu-
tions.
Table 3.1: Concentrations of antibodies and standards used in the ELISA technique.
Analyte Capture AB Detection AB Sensitivity Manufacturer
hMIF 5.6 µL / mL 5.6 µL / mL 15.6 – 1000 pg / mL R&D
mKC 5.6 µL / mL 5.6 µL / mL 31.25 – 2000 pg / mL R&D
mG-CSF 5.6 µL / mL 5.6 µL / mL 15.6 – 1000 pg / mL R&D
mIL6 5.6 µL / mL 5.6 µL / mL 15.6 – 1000 pg / mL R&D
mIFNγ 5.6 µL / mL 5.6 µL / mL 15.6 – 1000 pg / mL BD
3.2 Animal experiments
3.2.1 Animals
All animal experiments have been performed in accordance with the animal ethics committee of the
state of North Rhine-Westphalia and the University of Duisburg-Essen and were carried out according
to the German guidelines for experimental animal welfare. Mice were housed under standard specific
pathogen free (SPF) conditions in individually ventilated cage (IVC) racks with a 12-hours circadian
rhythm. Six- to eight-week old BL6, C3H and athymic nude nu/nu mice were used in the experiments.
CatchUpIVM-red were generated by crossing CatchUp with B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J
mice as previously described[75] in kind cooperation with the group of Prof. Matthias Gunzer at the
ZMB in Essen. CatchUp mice carry a transgene which induces the expression of the fluorescence
protein tdTomato under the control of the Ly-6G promoter. tdTomato expression is enhanced in
the CatchUpIVM-red litters because of Ly-6G specific Cre expression, which is activating additional
tdTomato expression at the ROSA26 locus. CatchUp mice were used at any age up to six month. Male
and female mice were used in all experiments.
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3.2.2 Tumor models
To induce tumors, murine tumor cell lines were injected into the respective hosts at different sites. All
tumor injections were carried out under anesthesia by intraperitoneal (IP) application of ketamine
and xylazine dosed at 100 mg / kg and 10 mg / kg body weight respectively and diluted in 0.9 % NaCl
for injection of 10 µL / g body weight. Reasons for anesthesia are given in the following paragraphs.
Subcutaneous tumors
Subcutaneous tumor growth is a frequently used localization of transplantable tumors. The tumor
cells are injected to the subcutaneous space over the dorsal flank of the mouse. This location bears
several advantages and was chosen for those reasons: it causes minimal pain or discomfort through-
out the experiment and it is very well accessible, facilitating a precise tumor volume measurement
(see below).
Mice were anesthetized to enable shaving of the area of injection and thereby decreasing variability
in tumor size estimation. 1 · 106 cells were thoroughly washed in PBS, resuspended in 100 µL PBS
and injected to the dorsal flank using a 27 G needle. Cells were kept on ice to maintain viability. Mice
were carefully observed until they woke up from anesthesia. Tumor size was determined by caliper
measurement in two dimensions (a and b). Experimental end points were defined by a tumor size of
2 cm in one dimension if not stated differently. The following equation was used for calculation of
ellipsoidal tumor volume:
VTumor = a ·b · c · pi
6
(5)
with a < b (6)
c ≈ a (7)
⇒VTumor = a2 ·b · pi
6
(8)
Orthotopic tumors
The term orthotopic describes the implantation of the tumor cells to the organ of origin in this con-
text. This localization is considered more clinically relevant due to the establishment of a more repre-
sentative microenvironment. The orthotopic model was used for HNC cell lines by transplantation of
the cells to the Musculus myohyoideus reflecting a localization that is in close proximity to the origi-
nal tumor site.
Mice were anesthetized to enable the injection procedure which is done through the mouth of the
mouse. 5 · 105 or 1 · 106 cells, MOPC-/+ or SCCVII respectively, were thoroughly washed in PBS, re-
suspended in 30 µL PBS and injected to the floor of the mouth using a 27 G needle. Cells were kept
on ice to maintain viability. Mice were carefully observed until they woke up from anesthesia. Mice
were scaled daily because proceeding tumors of this location were known to cause weight loss due to
reduced food uptake. Experiments were ended upon a weight loss of > 20 %.
Cutaneous ear tumors
The ear was chosen as tumor location for intravital microscopy because it is easily accessible and can
be imaged in a multiphoton microscope without surgical interventions. Tumor cell injection cannot
be performed as standardized as for the other two locations in this case because the final injection
PhD Thesis - PMN in HNC mouse models Katrin Moses
Methods 50
volume may differ. 0.2 · 106 cells were prepared as described above and resuspended in 10 µL PBS per
mouse. Mice were anesthetized and fixed to the working surface with one ear facing upwards. The
ear was additionally fixed to the left index finger and the cell suspension (approximately 10 µL) was
carefully injected using a 30 G needle in a out-to-inwards directionality.
Matrigel-tumor mixtures
Basement membrane matrix (MatrigelTM) was used to give additional stromal support to tumor cells
upon injection. The mixture contains extracellular matrix (ECM) components like growth factors and
matrix proteins. Matrigel-tumors were transplanted to the subcutaneous location. In contrast to the
subcutaneous protocol, cells were first resuspended in 50 µL PBS and mixed with the same volume
MatrigelTM to a final concentration of 5 mg protein / mL solution. Equipment had to be pre-cooled
and placed on ice for the whole procedure because MatrigelTM solidifies at room temperature. Upon
injection to the flank of the mouse, a MatrigelTM ball formed and supported tumor cell seeding. For
this reason, one fifth of the usual cell amount was injected in matrix-supported tumors.
3.2.3 Depletion of Ly-6G+ cells and T cells
For the depletion of different immune cell subsets, an antibody-mediated elimination technique was
applied. Specific monoclonal antibodies were injected via the intraperitoneal route (for treatment
regimens see table 3.2). Injections were performed using a 27 G needle with a total injection volume of
200 µL antibody dilution in 0.9 % NaCl per mouse. In control groups, the respective isotype antibody
was applied the same way. Elimination of cells could be checked by flow cytometry of peripheral
blood. For this reason, blood was taken from the lateral tail veins by tapping with a 27 G needle
and subsequent transfer into tubes prepared with 5 µL 3.8 % sodium chloride solution to prevent
coagulation. Flow cytometric analysis was performed as described in section 3.1.8. Alternatively,
blood could also be transferred to a glass slide and spread thinly and evenly using a rectangular cover
slip. These blood smears were applied to a Pappenheim’s staining for morphological determination
of granulocyte numbers (see section 3.4.3).
Table 3.2: Treatment regimens for depletion of different immune cells.
Target clone isotype AB /mouse
[µg]
treatment in-
terval
CD8 T cells 2.43 rIgG2b, LTF-2 100 weekly
Gr-1 mainly neutrophils RB6-8C5 rIgG2b, LTF-2 200 3 days
Ly-6G neutrophils 1A8 rIgG2a, 2A3 200 3 days
3.2.4 in vivo BrdU assay
Bromodeoxyuridine (5-bromo-2’-deoxyuridine, BrdU) is a analogue of thymidine that can be taken
up by all cells and is incorporated in replicating DNA. For this reason, systemic availability of BrdU
leads to the presence of this nucleoside in all cells that underwent cell division during the presence
of the compound. BrdU+ cells can be detected by specific antibodies after DNA denaturation.
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Mice were injected with 1 mg BrdU in 200 µL PBS IP. After two hours, mice were killed and organs
were either frozen for histology or isolated cells were analyzed via flow cytometry.
3.2.5 Noninvasive intravital microscopy
Intravital imaging is a state of the art technique to investigate cell motility and the effect of differ-
ent kinds of interventions in the living animal. By combining transgenic expression of fluorescent
proteins and transferable targeted or non-targeted fluorescent molecules, a wide array of cells and
processes can be visualized. Multiphoton microscopy is based on an excitation of the electrons of a
fluorophore using long-wavelength photons of which two have to excite one electron simultaneously
to get it to the higher energy level. The red-shifted excitation wavelength enables deeper tissue pen-
etration due to less scattering effects. Furthermore, an additional decrease of background signal is
achieved by two-photon excitation. Due to this technique it is possible to realize noninvasive imag-
ing if the region of interest in close proximity to the skin. An ear tumor model was chosen to enable
intravital noninvasive imaging in the tumor. Ear skin is very thin and tumors were located directly
underneath the keratinocytes. For these experiments, CatchUpIVM-red animals have been used to
visualize Ly-6G+ cells without additional labeling steps. MOPC-eGFP cells were transplanted to iden-
tify tumoral regions by eGFP fluorescence as described in section 3.2.2. 100 µL Qdot non-targeting
nanocrystals (QTracker 655, 1 µM) were injected intravenously (IV) to assess vasculature. Mice were
initially anesthetized by IP injection of ketamine and xylazine dosed at 100 mg / kg and 10 mg / kg
body weight respectively and diluted in 0.9 % NaCl for injection of 10 µL / g body weight. Mainte-
nance of anesthesia for the imaging period was performed by inhalation of a 1.2 % isoflurane oxygen
mixture which was applied via a ventilation unit to the intubated mouse with 250 strokes per minute
at 250 µL volume per stroke. Body temperature was retained using a heating pad adjusted to 37◦C.
The mouse was adjusted on the pad and the ear was shaved and further immobilized on a plastic sy-
ringe to ensure best accessibility with the objective. To this end, a mixture of Vaseline and paraffin in
a ratio of 4:1 [w/w] was used to minimize potential irritations of the ear skin and heated to 50◦C prior
to application. Imaging was performed with a Leica TCS SP8 MP microscope with simultaneous de-
tection via Hybrid reflected light detectors (HyD-RLD) and photomultiplier tubes (PMT) using a HCX
IRAPO L25x/0.95 water objective. Excitation was mediated at 960 nm using a Coherent Chameleon
Vision II Ti:Saph-Laser. Filter settings are depicted in table 3.3.
Table 3.3: Filter settings used for intravital microscopy.
Target struc-
ture
Target fluorophore Filter path Detector
Neutrophils tdTomato transgene BS RSP560 + BS RSP620 +
BP585/40
HyD
Tumor cells eGFP transgene BS RSP560 + BS RSP495 +
BP525/50
PMT
Blood vessels Qdots 655 BS RSP560 + BS RSP620 +
BP660/30
HyD
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Table 3.3: continued
Target struc-
ture
Target fluorophore Filter path Detector
Collagen SHG signal BS RSP560 + BS RSP495 +
BP485/30
PMT
3.3 Protein biochemistry
3.3.1 SDS-PAGE and Immunoblotting
Preparation of cell lysates
A defined number of cells was taken from the cell culture (see 3.1.1) and washed three times with PBS
while handled on ice. For storage, cells were centrifuged at 300 g for 5 minutes at 4◦C, supernatant
was removed and the resulting dry pellet was maintained at -20◦C. To lyse the cell pellets, cells were
thawed on ice and resuspended in 1 mL SDS lysis buffer containing proteases and phosphatases in-
hibitors / 1 · 106 cells and incubated for 5 minutes on ice (for components see table 2.11). Incubation
was followed by 10 minutes centrifugation at 12000 g and 4◦C in a microcool centrifuge to remove cell
debris. Clean protein lysates were transferred to a new tube, mixed with 5× SDS sample buffer (table
2.11) and denatured for 10 minutes at 95◦C. Sample buffer contains β-mercaptoethanol to reduce
disulfide bounds and SDS binding to lipophil protein regions and releasing not covalent boundaries.
Due to the highly negative charge of bound SDS the proteins can be separated by size in the electric
field.
Gel electrophoresis
Proteins were separated according to their molecular weight using a discontinuous sodium dodecyl
sulfate (SDS) polyacrylamide gel electrophoresis as described by Laemmli[109]. The polyacrylamide
gel is made up by a sacking gel and a separation gel differing in polyacrylamide concentration and
pH-value. In the stacking gel, polyacrylamide concentration is low not allowing a separation of the
proteins. Glycine is nearly uncharged at the low pH of 6.8 making it move slowly whereas chloride
ions are highly charged creating a second electric field which is increasing the local field intensity.
Negatively charged proteins move behind the chloride ions and were concentrated on small space
this way. Reaching the separation gel the pH-value changes to 8.8 leading to a negative charge of
glycine which rapidly pushes the proteins into the separation gel.
Table 3.4: Ingredients for SDS PAGE gels. Amounts for two gels are given
Volume Reagent Volume Reagent
separation gel stacking gel
4.5 mL 40 % Acrylamide/Bisacrylamide 630 µL 40 % Acrylamide/Bisacrylamide
5 mL 3 M Tris pH 8.8 210 µL 3 M Tris pH 6.8
5.36 mL distilled water 4.1 mL distilled water
75 µL 20 % SDS 25 µL 20 % SDS
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Table 3.4: continued
Volume Reagent Volume Reagent
30 µL TEMED 20 µL TEMED
30 µL 10 % APS 20 µL 10 % APS
Preparation of the gels was performed by mixing the respective ingredients for the separation or
stacking gel according to table 3.4. Ammonium persulfate (APS) and N, N, N’, N’-tetramethylethyl-
enediamine (TEMED) are added last to start the polymerization process. The separation gel is poly-
merized first while covered with isopropyl alcohol followed by the stacking gel containing the pockets
for protein loading. A Bio-Rad system was set up to run the gel electrophoresis with 2 gels containing
running buffer. Equal sample volumes referring to the same number of lysed cells were loaded using a
1 mL Hamilton syringe. For identification of protein size, one sample pocket was loaded with Spectra
protein ladder. Separation was carried out at 80 V for about 2h.
Immunoblotting
Gel electrophoresis was followed by blotting the separated proteins onto a polyvinylidene difluoride
(PVDF) membrane using a semi dry blotting technique. Gel and membrane were surrounded by 2
piles of Rotilabo®blotting paper without any air bubbles and adjusted at the anode of the blotting
chamber with the membrane being located between gel and anode. Blotting was performed for 60
minutes at 25 V and a maximum current of 300 mA in transfer buffer.
Protein containing membranes were washed in TBS and eventually stored at 4◦C until analysis. Un-
specific binding sites were blocked with TBS-T 5 % BSA for 1 hour at room temperature followed by
incubation with the primary antibody directed against the protein of interest (1 hour, RT) in block-
ing solution. Antibodies and dilutions are listed in table 2.9. Membranes were washed in TBS-T and
stained with alkaline phosphatase-coupled secondary antibody in blocking solution for 1 hour. After
washing, pH was equilibrated using AP buffer and detection was carried out by CPD Star®substrate-
induced, AP-catalyzed chemiluminescent reaction, which was recorded in the ChemiDoc-It®using
VisionWorksLS software.
Densitometric Analysis
Densitometric measurement of signal intensity was carried out using ImageJ software. To this end,
the different lanes were selected and the lane intensities were converted to a profile plot. This plot
shows a curve on which the background signal was eliminated by setting a threshold. The area de-
fined by the profile and the threshold was then measured resulting in a value which was reflecting the
amount of protein. Signal intensities of MIF were normalized to GAPDH.
3.4 Histology
3.4.1 Sample preparation
Cryotissue was used for the analysis of different organs of tumor bearing and naive mice. Tissues were
excised from the mouse as fast as possible and adjacent tissue was removed. Tissues were washed
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in PBS and embedded in Tissue-Tek®O.C.T.TM compound, which is a formulation of water soluble
glycols and resins, as fast and as dry as possible in Cryomold®containers. Afterwards, embedded tis-
sues were frozen on liquid nitrogen as fast as possible. Thereby, the embedding compound provides
structural support for freezing as well as sectioning later on. The resulting tissue blocks were stored
at -80◦C.
Frozen sections were prepared at a cryomicrotome at -25◦C after equilibrating block temperature.
Consecutive sections of 5 µm thickness were collected on SuperFrost®microscope slides in represen-
tative regions of the tissue. Sections were dried for one day and either stained directly or stored at
-80◦C until staining. Hematoxylin and eosin staining was always performed prior to further analysis
to verify tissue quality.
For the analysis of cultured or primary cells, adherent cell lines were grown on sterile cover slips in
24 well culture plates for 2 days until the desired confluence was reached. Cells on cover slips were
directly applied to the respective staining. Suspension cells were applied to the cytospin technology
for further processing. Therefore, a cytospin chamber was assembled and 50000 - 100000 cells were
given into the chamber in 100 µL FCS. The cells were then spun onto the microscope slide for 4 min-
utes at 40 g using the respective rotor. FCS was removed and the chamber was disassembled releasing
the microscope slide, which was dried prior to staining or storage at -80◦C.
3.4.2 Hematoxylin and eosin staining
The hematoxylin and eosin staining (HE stain) is probably the most common staining method in clas-
sical histology and often used for differentiation of tissue structures. The two staining components
result in blue colored basophilic structures (especially nuclei) by hematoxylin and red to pink appear-
ing acidophilic substances, which are most proteins and therefore results in pink cytoplasm, by eosin.
Cryosections were completely thawed prior to staining. The staining is carried out after rehydrating
the sections using decreasing alcohol concentrations. Staining in Shandon’s Instant Hematoxylin was
performed for up to 1 minute followed by blueing under running tap water. Next, eosinophilic stain-
ing was performed for 3 minutes in 0.5 % acidified aqueous eosin solution. Staining was followed by
a wash in desalted water and subsequent dehydration in increasing alcohol concentrations. Sections
were cleared in xylene, mounted using Roti®Histokitt and analyzed by light microscopy.
3.4.3 Pappenheim’s staining
The Pappenheim panoptic staining technique was used on blood smears or cytospins on microscopic
slides for the visualization of granulocytes and precursors. Slides were first stained with neutral May-
Grünwald solution, containing methylene blue and eosin in methyl ethanol, for 2 minutes and left in
water for the same time to develop staining. The second staining step was performed for 10 minutes
in diluted Giemsa solution followed by washing the same way. Specimens were dried and subse-
quently mounted using Roti®Histokitt.
3.4.4 Immunhistochemical staining
This technique was used to specifically stain selected antigens with a color reaction for subsequent
quantification. Antigens were detected by specific antibodies and peroxidase coupled secondary an-
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tibodies facilitated a peroxidase mediated conversion of soluble 3-amino-9-ethylcarbazole (AEC) to
a red precipitate.
Cryosections were thawed, dried and surrounded with wax (ImmEdge pen) to keep staining solu-
tions in place. All following steps were carried out in a humid chamber. Fixation was performed
using BD Cytofix / Cytoperm for 30 minutes. After washing with PBS, peroxidase block was applied
for 15 minutes to minimize background signal from endogenous peroxidases. Washing with PBS was
followed by incubation with primary antibody, diluted according to table 2.9 in PermWash buffer, at
4◦C over night. Antibody was removed by washing three times in PBS before the buffer was exchanged
for TBS. Tissues were incubated with two peroxidase conjugated secondary antibody consecutively
to enhance signals. Both secondary antibodies were diluted 1:50 in TBS 10 % FCS and 20 % mouse
serum, incubated for 30 minutes and followed by three washes with TBS. Visualization of bound an-
tibodies was performed by peroxidase mediated color reaction of the AEC substrate solution within
10 minutes. Residual substrate was removed by washing three times in TBS. Tissues were rinsed with
desalted water before counterstaining nuclei with Shandon Instant Hematoxylin for 10 seconds and
blueing-up with running tap water. After another rinse with distilled water, tissues were mounted
using Kaiser’s glycerol gelatine and analyzed by light microscopy.
3.4.5 Immunofluorescence staining
Cytospins, cover slips or thawed cryosections were stained for antigen expression using specific an-
tibodies. Cells were permeabilized using Cytofix / Cytoperm for 30 minutes and washed with PBS.
Primary antibodies were diluted in Perm Wash buffer and cells were stained for 60 minutes. After
washing 3 times with PBS, cells were incubated with fluorescently-coupled secondary antibodies in
PBS 5 % BSA for 30 minutes with addition of the nuclear staining reagents DAPI (1:36000) or 7AAD
(1:200). Cells were washed again and mounted using the aqueous mountant Fluoprep. Analysis was
carried out as fast as possible after solidification of mounting medium at 4◦C.
3.4.6 Apoptosis detection by TUNEL staining
Staining of apoptotic cells in cryotissues was performed by a TUNEL assay. TUNEL thereby refers
to Terminal deoxynucleotidyl transferase dUTP nick end labeling and detects DNA fragmentation
which is a process induced during apoptosis. To this end, a modification of the APO-DIRECTTM Kit
was applied. Buffers were provided by the kit.
Cryosections were thawed, dried and surrounded with wax (ImmEdge pen) to keep staining solutions
in place. All following steps were carried out in a humid chamber. Fixation was performed for 30
minutes in 3 % PFA and after washing with PBS further fixation was added using 70 % ethanol for
accessibility of the nuclear structures. After washing with WashBuffer, enzymatic labeling of DNA
double strand breaks was performed in the presence of 15 U TdT enzyme and 0.04 nM FITC-labeled
dUTPs in the provided reaction buffer for 1 hour at 37◦C. The reaction was stopped using Rinse Buffer
and nuclei were stained by DAPI diluted in RinseBuffer for 20 minutes. After washing in PBS, tissues
were mounted using Fluoprep.
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3.4.7 Image acquisition and quantification techniques
Microscopy was carried out using Axioskop 2 and AxioVision software. Fluorescence was excited us-
ing a 50W halogen lamp and detected using appropriate filters. Images were taken at 200× or 400×
magnification with an AxioCam MRc 5 camera for further quantification.
Immunohistochemical staining of cell subsets were counted by hand on 4 representative photomi-
crographs and represented as positive cells per region of interest (ROI). On some occasions, quantifi-
cation by ImageJ was performed. Therefore, colors were split by the Colour Deconvolution function
and after threshold adjustment, positively stained area was measured (as percentage of total area).
Fluorescence intensity was quantified on photomicrographs taken under exactly the same conditions
using ImageJ. If negative staining resulted in fluorescence signal, it was subtracted from the fluores-
cence intensity of the specific staining.
3.5 Molecular biology
3.5.1 Isolation of RNA and reverse transcription
Total RNA was isolated directly from PBS-washed and pelleted cells. RNeasy Mini or Micro Kits were
used depending on the number of cells, for more or less that 2 · 105 cells respectively. Isolation was
performed according to manufacturer’s instructions. In short the cells were lysed using RLT buffer
containing 1 %β-mercaptoethanol, homogenized using a QIAshredder spin column and equilibrated
for binding by 70 % ethanol. Purification of RNA was further conducted on a RNeasy spin column,
which is a silica membrane affinity column system, including several washing steps to remove DNA,
protein and salt contents. For removal of DNA, an additional DNase digestion was performed when
using the Micro Kit. RNA was eluted from the column using 30 or 14 µL RNase free water, respec-
tively for Mini or Micro isolation. This procedure provides an enrichment of mRNA because of the
membrane selectivity for RNA molecules >200 nucleotides. Determination of RNA concentration and
purity was carried out by photometric analysis using the Synergy II plate reader at 260 and 280 nm for
high sample volumes only.
200 ng RNA or the total eluate were directly set up in a reverse transcriptase (RT) reaction using
Table 3.5: Reverse transcriptase reaction.
Temperature Time
25◦C 10 minutes
42◦C 50 minutes
70◦C 15 minutes
the SuperScriptTM II RT kit. Primer anneal-
ing on RNA templates was performed using
20.833 ng / µL random primer and 0.833 mM
dNTP mix for 5 minutes at 65◦C. After incu-
bation with 1× first strand buffer and 0.011 M
DTT for 2 minutes at 25◦C, 10 units / µL re-
verse transcriptase were added and run ac-
cording to table 3.5. The resulting comple-
mentary DNA (cDNA) was stored at -20◦C.
3.5.2 Transcript Quantification by qRT-PCR
SYBR Green is an asymmetrical cyanine dye that binds to double stranded DNA. The DNA-dye com-
plex absorbs blue light at λmax = 494 nm and emits green light at λmax = 521 nm. By measuring the
fluorescence after every elongation phase, the dye can be used to visualize the amplification of DNA
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during the polymerase chain reaction (PCR), which is therefore called quantitative real time PCR. The
PCR cycle, at which a significant exponential increase in fluorescence is detected, is directly corre-
lated with the amount of DNA template that was present in the beginning of the reaction. This cycle
is called the Cycle Threshold (CT) and was used for further quantification.
qRT-PCR was performed on 10 ng target cDNA in MaximaTM SYBRTM Green mix using 0.5 µM of for-
ward and reverse primers for the gene of interest. The reaction was run and read in a LightCycler®-
capillary based system according to the program shown in table 3.6. Primer sequences and respective
annealing temperatures are listed in table 2.10. β-actin was analyzed as internal standard. Data ac-
quisition and analysis was performed using LightCycler 3 software.
Table 3.6: qRT-PCR program.
Purpose Temperature Time slope [◦C/sec] Data?
Initial denaturation
Denaturation 95◦C 10 min 20 None
Amplification 40 cycles
Denaturation 95◦C 15 sec 20 None
Annealing x◦C 30 sec 20 None
Extension 72◦C 30 sec 20 Single
Melting curve
Denaturation 95◦C 0 sec 20 None
Reannealing 57◦C 15 sec 20 None
Denaturation 98◦C 0 sec 0.1 Continuous
Cooling of the carousel
Cooling 40◦C 10 sec 20 None
3.5.3 Data analysis and hierarchical clustering
Differential expression was analyzed by the 2−∆∆CT method [120]. Expression was normalized to the in-
ternal standard and the difference between different treatments or cellular localization was assessed
depending on the aim of the experiment as shown in equation 10. Due to the exponential relation
of the DNA amount to the respective cycle, the normalized difference of mRNA which was present in
the original samples is described logarithmically. The resulting value represents the fold difference in
expression in the analyzed samples.
∆CT =CT (tar get )−CT (internalStandard) (9)
∆∆CT =∆CT (sample)−∆CT (re f erenceSample) (10)
relati veExpression = 2−∆∆CT (11)
Hierarchical clustering and heatmaps were generated using R software with the Euclidean distance
as distance metric and by applying complete linkage clustering.
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3.6 Statistics
Statistical analysis was carried out using GraphPad Prism software. Statistical significance was as-
sessed with either student’s t-test for comparison of two groups with equal variances or one way
ANOVA with Bonferroni post hoc testing for more than two groups. Results were considered signifi-
cant at p≤.05.
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4 Results
4.1 Role of HNC tumors in modulating neutrophil physiology
As the field of tumor immunology grew rapidly in the last decades, many studies concentrated on the
role of T regulatory cells (Treg) and macrophages[73, 2]. Currently, neutrophils (CD11b+Ly-6G+ cells)
have just started to emerge as important cell type in this context. Since then, different studies used
mouse models to further characterize CD11b+Ly-6G+ cell functions in spontaneous, induced or trans-
plantable tumor settings[14]. However, no head and neck cancer (HNC) model had been established
in this context so far. Recent studies from our group indicated tumor promoting functions of neu-
trophils in HNC patients which were inducible by tumor derived factors, such as the cytokines macro-
phage migration inhibitory factor (MIF) and CXCL8[39, 203]. Therefore, the first part of this work aimed
at the characterization of possible HNC mouse models to investigate functional implications of neu-
trophils in tumor bearing mice. One criterion for these models was to specifically resemble character-
istics of phenotypes that have been found with patient-derived or tumor factor-treated neutrophils
in the human system.
4.1.1 HNC cells interact with murine and human neutrophils via the MIF-chemokine
receptor axis
Neutrophil functions in immune cell-cancer interactions were highly debated in the literature be-
cause different studies could show both, pro- or antitumoral functions of these cells. When research
proceeded with looking for the respective mechanisms, it became clear that the microenvironment
is a key player for determining neutrophil functions. Data from our group suggested tumor derived
chemokines and cytokines as important inducers of a protumoral neutrophil phenotype in HNC pa-
tients and human neutrophil tumor interactions[39, 203]. For this reason, tumor derived MIF was cho-
sen to be analyzed in more detail in this section as well as the potential of murine CD11b+Ly-6G+ to
respond to this cytokine.
Human neutrophils migrate through endothelial cells in response to tumor derived MIF
We previously showed chemotactic properties of tumor derived MIF in a transwell assay[39]. This as-
say is in principle testing the general migratory potential that can be induced without the need of
integrin activation which is important for neutrophil extravasation. To assess whether MIF is capa-
ble of inducing infiltration of neutrophils into the tumor tissue, an assay was established to mimic
migration of immune cells through an endothelium. Additional activation of integrins is indispens-
able for the neutrophils to pass through this endothelial monolayer. First, tumor supernatants (SN)
were tested for their capacity to induce transendothelial migration (TEM). FaDu and UM22b cell lines
were used for the production of SN because their SN were shown to possess chemotactic properties
on neutrophils and contain notable amounts of MIF (1000 and 2000 pg / mL respectively). The TEM
assay was set up as described in section 3.1.7. Healthy donor neutrophils were seeded on a HMEC
monolayer (figure 4.1A) and were left to migrate towards different tumor SN for 4h. Both, FaDu and
UM22b SN, induced neutrophil migration through an endothelial monolayer (figure 4.1B), which was
dependent on the neutrophil donor and on the cell line used for SN production. To investigate the
impact of MIF in this process, SN were incubated with the chemical antagonist ISO-1[122] to inhibit
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Figure 4.1: Tumor-derived MIF induces neutrophil transendothelial migration. Human neutrophils
were isolated by density gradient and applied to an in vitro transendothelial migration assay (TEM) using a
HMEC monolayer grown on a 3 µm pore transwell insert. Tumor supernatant (SN) from different cell lines
was used as attractant. A HMEC monolayer was stained with hematoxylin and eosin directly on the transwell
membrane. A representative photomicrograph was taken at 630 × magnification (scale represents 50 µm). B
5 · 105 neutrophils were added to the upper well of a TEM setup and migrated towards either basic culture
medium or tumor SN for 4 h. Migrated cells were counted. Maximum migration was reflected by the cell count
of neutrophils in a well without transwell insert. C Tumor SN was pretreated with either DMSO or 50 µM of
the MIF inhibitor ISO-1 for 30 minutes. 5 · 105 neutrophils were added to the upper well of a TEM setup and
migrated towards either DMSO or ISO-1 SN reflected as MIFhigh and MIFlow, respectively. After 4 h, migrated
cells were counted. Bars represent mean±SEM of 5 (FaDu) and 3 (UM22b) independent experiments. Line
indicates p≤.05 by paired t-test.
MIF activity prior to the TEM assay. The induced migration was reduced to less than 70 % by inhibi-
tion of MIF in FaDu SN while the effect was much lower in UM22b SN. It was concluded that tumor
derived MIF is indeed capable of inducing transendothelial migration of human neutrophils which
might result in tumor infiltration by these cells.
Murine HNC cell lines express MIF in vitro and in vivo
As a next step, MIF expression was verified in murine cell lines as it is a potential modulator of
CD11b+Ly-6G+ cell numbers and activation in tumor bearing mice. Available murine HNC cell lines
were SCCVII, which derived from C3H mice, and BL6 derived MOPC cells, of which both subtypes,
HPV16 E6/E7 positive (MOPC+) and negative (MOPC-), were used. Additional cell lines from different
cancer entities, being B16F10 melanoma and EL4 T cell lymphoma, were used as a reference as they
were described to induce CD11b+Ly-6G+ cell modulation[222]. Expression of MIF was first determined
in cultured cells. Western Blot (WB) analysis of equal cell numbers showed varying expression of the
12 kDa protein in relation to GAPDH (figure 4.2A). SCCVII and MOPC- HNC cells expressed the high-
est detectable MIF amounts in conjunction with B16F10 cells. To confirm these results, SCCVII and
MOPC- cells were grown on cover slips, stained for MIF and analyzed by fluorescence microscopy
(immunofluorescence, IF). The IF analysis indicated a higher expression of MIF by MOPC- cells com-
pared to SCCVII, which was not observed by WB, suggesting that production and release of the cy-
tokine might also be dependent on cell confluence and stress during the experiment. Representative
photomicrographs are shown in figure 4.2B. Because of the variability of MIF expression, presence
of the cytokine was further verified in tumors derived from the respective cell lines. To this end, 5
· 105 HNC tumor cells were injected orthotopically into their respective hosts and grown for about 2
weeks. Resulting tumors were prepared as described in section 3.4.1 and analyzed for MIF expression
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Figure 4.2: MIF is expressed
by murine HNC cell lines. A
2 · 105 cells were lysed and ana-
lyzed by Western Blot. Membranes
were stained against MIF and GAPDH
and ImageJ densitometry was per-
formed. One representative of 3 ex-
periments is shown. Bars indicate
band intensity of MIF/GAPDH. Ab-
breviations: B16=B16F10, M-=MOPC-,
M+=MOPC+, S=SCCVII. B Cells were
grown on cover slips for 2 days and
stained for MIF in Cy3. Nuclei were
stained by DAPI. One representative
of 2 experiments is shown. Pictures
were taken at 200× magnification and
processed identically. The scale rep-
resents 50 µm. C Orthotopic tu-
mors from C3H (SCCVII) and BL6 mice
(MOPC-) were prepared for histology.
Cryosections were stained for MIF in
Alexa488. Pictures were taken as de-
scribed in B and are representative for
3 - 4 mice. D Mean fluorescence in-
tensity (MFI) of MIF was quantified
on stained tissue as shown in C. Tu-
mor tissue from MOPC- tumors was
compared to healthy mucosa from the
same animal. Line indicates signifi-
cance at p≤.05 as tested by paired t-
test.
by fluorescence microscopy. All murine HNC tumors expressed MIF without major differences (figure
4.2C). Expression was confirmed for B16F10 subcutaneous (SC) tumors as well (data not shown). To
evaluate the amounts of MIF, which were effectively produced by the tumor tissue, healthy mucosa
from MOPC- tumor bearing mice was collected and stained as well. Fluorescence intensities were
determined in healthy epithelial regions and in the tumor tissue of the respective mice (figure 4.2D).
MIF expression by tumor tissue was found to be higher than epithelial expression in 4 out of 5 tu-
mors. These results indicate that murine cancer cell lines, especially derived from the head and neck
region, share upregulated MIF expression with human tumors which might lead to a modulation and
attraction of CD11b+Ly-6G+ cells in tumor bearing mice which is consistent with our previous results
in HNC patients.
CXCR2 and CXCR4 are expressed on CD11b+Ly-6G+ cells in different compartments of
naive BL6 and C3H mice
Tumor derived chemokines such as CXCL1 and CXCL5 regulate both the migration and functional ac-
tivation of CD11b+Ly-6G+ cells[225, 138]. Furthermore, recruitment of CD11b+Ly-6G+ cells to the tumor
was described to be mainly CXCR2 and CXCR4 dependent, as these receptors share important roles
in inflammatory and homeostatic neutrophil trafficking[42, 171]. As MIF is another ligand for CXCR2,
CXCR4 and also CXCR7[199], the expression of these receptors was analyzed on CD11b+Ly-6G+ cells
in naive mice of the strains C3H and BL6. The cells were identified by flow cytometry as described in
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Figure 4.3: Chemokine receptor expression by CD11b+Ly-6G+ cells in naive mice. Cells were
isolated from bone marrow (BM), blood and spleen of naive BL6 (n=4) and C3H (n=3) mice and were analyzed
by flow cytometry. Representative results are shown in A for BL6 splenocytes indicating the gating strategy and
CXCR expression in histograms (filled curve=isotype stained cells, FMO; open curve=specific antibody signal).
Cells were analyzed for the expression of CXCR2 B, CXCR4 C, CXCR7 D and M-CSF-receptor E. ’nd’ indicates
that these cells have not been analyzed for the respective receptor (nd=not determined). Data are shown as
mean±SEM. Lines indicate significance as tested by one way ANOVA with p≤.05.
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figure 3.2 and 4.3A. CXCR2 expression was most abundant on the surface of CD11b+Ly-6G+ cells com-
pared to the other receptors especially when cells were derived from peripheral compartments (see
histogram for spleen derived cells in figure 4.3A). CXCR2 expression is regulated upon mobilization
of the cells from the bone marrow with increasing expression in spleen and blood in BL6 and in the
blood in C3H mice (figure 4.3B). In contrast, CXCR4 (figure 4.3C) and CXCR7 expression (figure 4.3D)
were not differentially regulated in the analyzed CD11b+Ly-6G+ cells of different tissue compartments
of naive mice. M-CSF-receptor, which is present on macrophages, monocytes and precursor cells as
well as myeloid derived suppressor cells (MDSC)[222], was analyzed in addition to the chemokine re-
ceptors and was hardly detectable on CD11b+Ly-6G+ cells from naive mice, as expected (figure 4.3E).
These results confirm the general capability of CD11b+Ly-6G+ cells to respond to HNC derived fac-
tors.
Chemokine receptors CXCR2 and CXCR4 are differentially expressed on CD11b+Ly-
6G+ cells in HNC tumor bearing mice
After having shown that CD11b+Ly-6G+ cells express receptors for HNC derived factors in naive mice,
receptor expression was determined in tumor bearing mice in different compartments including the
tumor itself. To this end, mice were inoculated with 5 · 105 HNC cells orthotopically (MOPC and
SCCVII in BL6 and C3H mice, respectively) and isolated cells were analyzed by flow cytometry after
two to three weeks of tumor growth. Comparable to naive mice, CXCR2 (figure 4.4A) was expressed
mainly in the periphery (blood and spleen) in tumor bearing BL6 mice. In tumor bearing C3H mice,
expression of CXCR2 was increased in the bone marrow compared to naive and did not differ between
bone marrow and spleen derived CD11b+Ly-6G+ cells. Low CXCR2 expression was found in tumor
infiltrating CD11b+Ly-6G+ cells in BL6 mice, which is consistent with high intratumoral CXCR2 ligand
availability and ligand-induced receptor downregulation[48, 220]. In contrast to CXCR2 expression,
CXCR4 and CXCR7 expression did not vary as much between the compartments (figure 4.4B+C). A
slight decrease of CXCR4 expression was observed in splenic CD11b+Ly-6G+ cells of tumor bearing
BL6 mice (figure 4.4B). CXCR4 and 7 expression was further unchanged in tumor infiltrating CD11b+-
Ly-6G+ cells. Despite overall low expression of M-CSF-R, slightly elevated levels were observed in
bone marrow and tumor derived CD11b+Ly-6G+ cells (figure 4.4), suggesting a MDSC like phenotype
of CD11b+Ly-6G+ cells in these tissues in the HNC model.
Collectively, these data characterize a chemokine-chemokine receptor axis which potentially results
in trafficking and accumulation of CD11b+Ly-6G+ cells in HNC bearing mice. These tumor models
therefore also resemble the relation of HNC tumors and neutrophils in HNC patients which is partially
mediated by homologous CXCR ligands.
4.1.2 Expansion of CD11b+Ly-6G+ cells correlates with tumor progression
Peripheral neutrophil counts are easily accessible in humans and in cancer patients, and increased
neutrophil numbers often associates with a poor overall survival[201]. In HNC patients, we previ-
ously described alterations in neutrophil function and the appearance of immunosuppressive sub-
sets[15, 204]. Comparable observations were also shown for several murine tumor models[222] but not
for HNC. After having demonstrated that potential ligands for CD11b+Ly-6G+ cells are expressed by
murine HNC tumors, accumulation of these cells was analyzed in the described tumor models. To
PhD Thesis - PMN in HNC mouse models Katrin Moses
Results 64
A FC gate:CD11b+Ly-6G+
BM blood spleen tumor
0
500
1000
1500
2000
MOPC- MOPC+ SCCVII
C
X
C
R
2 
e
xp
re
ss
io
n
[d
M
e
d
ia
n
]
B FC gate:CD11b+Ly-6G+
BM blood spleen tumor
0
200
400
600
MOPC- MOPC+ SCCVII
C
X
C
R
4 
e
xp
re
ss
io
n
[d
M
e
d
ia
n
]
C FC gate:CD11b+Ly-6G+
BM blood spleen tumor
0
50
100
150
MOPC- MOPC+ SCCVII
C
X
C
R
7 
e
xp
re
ss
io
n
[d
M
e
d
ia
n
]
D FC gate:CD11b+Ly-6G+
BM blood spleen tumor
0
50
100
150
MOPC- MOPC+
M
-C
SF
-R
 e
xp
re
ss
io
n
[d
M
e
d
ia
n
]
Figure 4.4: CD11b+Ly-6G+ cell expression of CXC receptors in tumor bearing mice. BL6 (n=5 per
tumor cell line) and C3H mice (n=4) have been injected with the indicated HNC cell lines orthotopically. Mice
were sacrificed after two to three weeks upon weight loss. Bone marrow, blood, spleen and tumor infiltrating
cells were isolated and analyzed by flow cytometry. CXCR2 A, CXCR4 B, CXCR7 C and M-CSF-R D expression
was evaluated on CD11b+Ly-6G+ cells. Data are shown as mean±SEM. Lines indicate significance as tested by
one way ANOVA among mice with the same tumor with p≤.05.
this end, orthotopic (ortho) as well as subcutaneous (SC) tumor locations were compared in their
capability of inducing changes in CD11b+Ly-6G+ cell abundance in different tissue compartments.
HNC tumors increase the frequency of CD11b+Ly-6G+ cells in the blood of tumor bear-
ing mice
In cancer patients, including our studies as described above, blood is frequently analyzed and many
changes were found in this compartment. To evaluate whether similar changes take place in the
murine models, blood was analyzed in this first characterization. For this purpose, BL6 and C3H
mice were injected with the respective HNC cell lines at orthotopic and subcutaneous locations as de-
scribed in section 3.2.2. EL4 tumors served as a reference cell line and were injected subcutaneously.
Accumulation of CD11b+Ly-6G+ cells in EL4 tumor bearing animals was previously described[222].
Blood was analyzed by flow cytometry after two to three weeks of tumor growth. Representative anal-
yses are shown in figure 4.5A for BL6 and figure 4.5B for C3H naive and tumor bearing mice indicating
an increase in numbers of analyzed cells. Detailed analysis in SC tumors revealed accumulation of
CD11b+Ly-6G+ cells in BL6 but not C3H mice (figure 4.5C). Furthermore, SC MOPC- tumors induced
slightly higher amounts of CD11b+Ly-6G+ cells than EL4 tumors. In contrast, frequencies of periph-
eral blood CD11b+Ly-6G+ cells consistently increased in both mouse strains independent of the in-
jected tumor cell line in orthotopic tumor bearing mice (figure 4.5D). To compare all experiments,
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Figure 4.5: CD11b+Ly-6G+ cells accumulate in blood of tumor bearing mice. BL6 and C3H mice
were injected with the indicated tumor cell lines at different locations. Tumor bearing and naive mice were
sacrificed after two to three weeks. Blood was taken from the abdominal aorta and was analyzed by flow cy-
tometry. A and B show representative contour plots for CD11b+Ly-6G+ cells from naive and tumor-bearing BL6
(A, tumor=MOPC- ortho) and C3H mice (B, tumor=SCCVII ortho). Frequency of CD11b+Ly-6G+ cells was ana-
lyzed in SC C and ortho D tumor-bearing mice. The relative accumulation to the mean of the respective naive
group (naive mean=1) is depicted in E. Data are shown as single measurements. Lines indicate significance as
tested by one way ANOVA within mouse strains with p≤.05 (only shown in E).
the relative induction of CD11b+Ly-6G+ cells was assessed by adjusting the mean of the naive mouse
groups to 1. While accumulation of CD11b+Ly-6G+ cells is most prominent in orthotopic tumor bear-
ing mice especially for MOPC- tumors, this difference between tumor locations is not statistically
significant. These results confirm modulatory effects of HNC tumors on peripheral blood CD11b+-
Ly-6G+ cells. Furthermore, on comparison to the well established EL4 cell line, it would imply that
modulation by HNC tumors represents a strong effect.
CD11b+Ly-6G+ cells expand in spleens of HNC tumor bearing mice
As a next step, accumulation of CD11b+Ly-6G+ cells in the spleen was assessed. The spleen has been
described as a major site of myelopoiesis in tumor bearing mice[223] and is therefore an important
reservoir of CD11b+Ly-6G+ cells. To analyze splenic composition in HNC bearing animals, BL6 and
C3H mice were injected with the respective cell lines as indicated in the figure at orthotopic and
subcutaneous administration sites. EL4 mice were used as a reference in BL6 mice with SC tumor
administration. After two to three weeks of tumor growth, splenocytes were isolated and frequency
of CD11b+Ly-6G+ cells was determined by flow cytometry. Representative FC plots already indicated
increased numbers of CD11b+Ly-6G+ cells in tumor bearing BL6 (figure 4.6A) and C3H mice (figure
4.6B). When analyzing SC tumors, an increased frequency was only apparent in EL4 tumor bearing
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Figure 4.6: CD11b+Ly-6G+ cells accumulate in the spleen of tumor bearing mice. BL6 and C3H
mice have been injected with the indicated tumor cell lines at different locations. Tumor bearing and naive
mice were sacrificed after two to three weeks and cells were isolated from the spleen. Analysis for CD11b+Ly-
6G+ cells was performed by flow cytometry as also indicated in A and B for naive and tumor-bearing BL6 (A,
tumor=MOPC- ortho) and C3H mice (B, tumor=SCCVII ortho). Frequency of CD11b+Ly-6G+ cells was analyzed
in SC C and ortho D tumor-bearing mice. The relative accumulation to the mean of the respective naive group
(naive mean=1) is depicted in E. Data are shown as single measurements. Lines indicate significance as tested
by one way ANOVA within mouse strains with p≤.05 (only shown in E).
animals compared to naive (figure 4.6C). In line with the data obtained from analysis of blood cells,
orthotopic tumors induced a more distinct increase in the frequency of CD11b+Ly-6G+ cells. To min-
imize inter experimental variances, data was adjusted to the mean frequency in the respective naive
group (figure 4.6E). Relative accumulation of CD11b+Ly-6G+ cells in the spleen was clearly induced
in tumor bearing mice with ortho tumors showing slightly higher induction than SC tumors. These
data demonstrate modulation of the splenic CD11b+Ly-6G+ reservoir in HNC tumor bearing mice
especially for orthotopic tumor locations.
HNC tumor progression correlates with the accumulation of CD11b+Ly-6G+ cells
The previous findings showed that CD11b+Ly-6G+ cell frequencies differ between naive and HNC tu-
mor bearing animals. Next, it was of major interest whether these changes depended on the general
intervention induced by tumor injection or on tumor size and time of tumor progression. To test
this, MOPC- and SCCVII cells were injected into BL6 and C3H mice, respectively. After two to three
weeks of tumor growth, CD11b+Ly-6G+ cell frequencies were assessed as described above and tumors
were explanted to determine tumor weight. In BL6 animals with MOPC- tumors, splenic CD11b+Ly-
6G+ frequencies correlated positively with tumor weight while peripheral blood cell numbers showed
a marginal positive correlation (figure 4.7A). Furthermore, splenic and peripheral blood CD11b+Ly-
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Figure 4.7: CD11b+Ly-6G+ cell accumulation is time and tumor size dependent. BL6 and C3H
mice have been injected with MOPC- or SCCVII cells, respectively, at different locations. A+B Tumor bearing
were sacrificed after two to three weeks and cells were isolated from the spleen and blood. Flow cytometry
data for CD11b+Ly-6G+ cells was correlated with the weight of the excised tumor for BL6 A and C3H mice B.
Lines indicate linear regression and dotted lines represent the respective 95 % confidence band of the best fit.
Significant correlation was observed for all data sets except BL6 blood with p≤.05 (indicated by *). C+D MOPC-
SC tumor-bearing mice were killed after the indicated periods. Frequency of CD11b+Ly-6G+ cells was analyzed
in blood C and spleen D of these mice. Data are shown as single measurements. Lines indicate significance as
tested by one way ANOVA with p≤.05.
6G+ cell frequencies were dependent on tumor weight in C3H mice with SCCVII tumors (figure 4.7B).
For identification of time dependent accumulation, BL6 mice were inoculated with SC MOPC- tumors
and frequencies of CD11b+Ly-6G+ cells were assessed after different periods of tumor growth. While
no changes were observed in the first week in blood (figure 4.7C), increased frequencies in the spleen
were already detectable after 8 days of tumor growth (figure 4.7D). With further tumor progression,
blood CD11b+Ly-6G+ cell counts also started to increase slightly after 18 days and accumulated sig-
nificantly 24 days after tumor cell injection (figure 4.7C).
Collectively, these data demonstrate tumor dependent accumulation of CD11b+Ly-6G+ cells in the
described mouse model. Time dependent increase in CD11b+Ly-6G+ cell frequencies has already
been described in other tumor models[223]. However, this is the first study to demonstrate that in a
murine HNC model this is also the case. It was demonstrated that tumor progression induced ac-
cumulation of CD11b+Ly-6G+ cells in the blood of tumor bearing animals, while the tumor affected
splenic neutrophils in a very early stage of tumor development. The low slope of the correlation
between splenic CD11b+Ly-6G+ numbers and tumor weight in advanced tumors further confirmed
that the splenic CD11b+Ly-6G+ cell reservoir is affected in earlier stages of tumor development and
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does not increase so much in the analyzed advanced stages. However, the peripheral blood CD11b+-
Ly-6G+ cell frequency was demonstrated to be highly dependent on tumor weight during advanced
tumor progression.
4.1.3 HNC tumors are infiltrated by Ly-6G+ cells
CD11b+Ly-6G+ cells can affect peripheral immune responses thereby influencing tumor progres-
sion[45, 137, 176]. Nevertheless, infiltration into the tumor is a critical step for inducing local effects
such as angiogenesis and tissue remodeling[91]. Furthermore, modulation by tumor derived factors is
most likely taking place at tumoral sites. It was therefore mandatory to assess the infiltration of tumor
tissue by CD11b+Ly-6G+ cells in the HNC models. To this end, mice were inoculated with the HNC
cell lines SCCVII, MOPC- and MOPC+ at SC and ortho administration sites. After two to three weeks
of tumor growth, tumors were isolated and applied to histological analysis or flow cytometry. EL4
tumor bearing mice were analyzed by flow cytometry as well. Histological characterization demon-
strated infiltration of polymorphnuclear Ly-6G+ cells in murine HNC tumor tissue (figure 4.8A+B). All
analyzed tumors were infiltrated with Ly-6G+ cells. While SCCVII cells attracted more Ly-6G+ cells
than MOPC- tumors at the SC tumor location (figure 4.8C), ortho tumors did not differ clearly in the
density of infiltrating cells (figure 4.8D). Flow cytometric analysis further confirmed increased infil-
tration in SCCVII SC tumors (figure 4.8E). Varied infiltration of all ortho tumors was also observed by
this technique (figure 4.8F). Compared to EL4 tumors, infiltration of HNC was remarkably high. Fur-
thermore, orthotopic tumors were consistently higher infiltrated than SC tumors within BL6 tumor
bearing mice. Surprisingly, when correlating tumor weight and Ly-6G+ cell infiltration as determined
by histology, SC infiltration was dependent on tumor weight (figure 4.8G) while ortho tumors were
constantly infiltrated independent of tumor progression (figure 4.8H).
Consistently, this data demonstrated HNC infiltration by Ly-6G+ cells. Infiltration was most pro-
nounced in orthotopically localized tumors which also induced higher peripheral accumulation of
CD11b+Ly-6G+ cells. Furthermore, density of infiltration was only found to correlate with tumor
weight in established SC tumors.
4.1.4 Assessing the infiltration of adaptive and innate immune cells in experimental
HNC tumors
As already indicated in the beginning of this chapter, tumors are not only primarily infiltrated by
CD11b+Ly-6G+ cells. The tumor immune crosstalk is rather characterized by strikingly heterogeneous
immune cell populations. These include T cells which can be roughly differentiated into CD4+ and
CD8+ cells but also comprise of T regulatory cells and Th17 cells[96]. The tumor immunoscore is fur-
ther complicated by additional infiltration by cells of the innate immune system such as NK cells and
monocytes giving rise to tumor associated macrophages[30]. To gain insight into the general immuno-
genicity of the described HNC mouse model, the tumoral infiltration of additional immune cells was
assessed in the following section.
Infiltration of T cells: CD4 in SC and CD8 cells in ortho HNC tumors
T cells are potential antitumor effector cells. Especially CD8 T cells can be directly cytotoxic on tu-
mor cells. Nevertheless, T cell infiltration is not necessarily associated with good clinical outcome
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Figure 4.8: Infiltration of Ly-6G cells in the tumor tissue. BL6 and C3H mice have been injected with
the respective tumor cells at different locations. Tumor-bearing were sacrificed after two to three weeks and
tumor tissue was analyzed. A Cryosections were stained for Ly-6G(FITC) and 7AAD. A representative example
is shown at 400× magnification. B Immunohistochemical staining for Ly-6G is presented at 200× magnifica-
tion (= 14 ROI). The scale represents 50 µm for all photomicrographs. Four of these regions of interest (ROIs)
per tumor were manually counted for the number of infiltrating cells as shown in C for SC and in D for ortho
tumors. E+F Flow cytometry for CD11b+Ly-6G+ cells was performed for different tumors of the SC E and ortho
F administration sites. Immunohistochemical results of BL6 animals as shown in C+D were applied to linear
regression analysis versus the weight of the respective explanted tumor (G for SC and H for ortho). Lines indi-
cate linear regression and dotted lines represent the respective 95 % confidence band of the best fit. Significant
correlation is indicated by * with p≤.05.
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Figure 4.9: Differential T cell infiltration in HNC tumors. BL6 and C3H mice were injected with MOPC-
or SCCVII cells at different locations. Tumor-bearing mice were sacrificed after two to three weeks and tumor
tissue was analyzed. A-C Flow cytometry was performed for CD4 and CD8 T cells as indicated in A. Frequencies
of CD4 B and CD8 cells C were analyzed. D-F Cryosections were stained for CD4 or CD8 by immunohistochem-
istry. Photomicrographs were taken at 200×magnification at four ROIs per tumor. Representative examples are
shown in D (scale represents 50 µm). Staining was analyzed by manual counting of tumor infiltrating CD4 E
and CD8 cells F. Single tumors are shown as data points and lines indicate means (horizontal) and significance
(vertical) as tested by one way ANOVA with p≤.05.
as also regulatory T cells are often found in tumor tissues. To characterize whether T cells infiltrate
experimental HNC tumors, BL6 and C3H mice were injected with the MOPC- or SCCVII tumor cells
at the SC or orthotopic site. After two to three weeks of tumor growth, tumors were excised and ei-
ther subjected to flow cytometry or immunohistochemistry for the analysis of infiltrating CD4 and
CD8+ cells (FC gating and representative photomicrographs are shown in figure 4.9A and D). By flow
cytometry, frequencies of CD4+ cells were highest in SCCVII SC bearing C3H mice (figure 4.9B). In
accordance with CD4 aided CD8 T cell infiltration[69], frequencies of CD8+ cells were also elevated in
SCCVII SC versus ortho tumors but did not differ significantly (figure 4.9C). Immunohistochemistry
confirmed highest infiltration of CD4+ cells in SCCVII SC tumor but differences were not as clear as in
flow cytometry (figure 4.9E). Contrary, CD8+ T cells were most abundant in SCCVII ortho tumors in
the histological analysis. In sum, T cells were found to infiltrate HNC tumors in the described mouse
model which was dependent on mouse strain and tumor location.
Infiltration of monocytes and NK cells is independent of HNC tumor location
Innate immune cells can differentially affect tumor progression. While NK cells are potential tumor
killers, macrophages can be alternatively activated to promote tumor progression and immature den-
dritic cells further induce immune tolerance[73, 63]. Tumor associated, M2 macrophages are derived
from peripheral blood monocytes or monocytic myeloid derived suppressor cells which can be iden-
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Figure 4.10: Innate immune cell infiltration in HNC tumors. BL6 and C3H mice were injected using
MOPC- or SCCVII cells at different locations. Tumor-bearing mice were sacrificed after two to three weeks and
tumor tissue was analyzed. Flow cytometry was performed for CD4 and CD8 negative (as shown in A) and
CD49b+ NK cells B. Frequencies of thereby identified NK cells were analyzed C. Monocyte frequencies were
assessed by CD11b and Ly-6C positivity D. Infiltration did not differ significantly.
tified by the markers CD11b and Ly-6C[222]. For the identification of additional innate immune cell
infiltration in HNC tissues, NK cells and monocytes were analyzed by flow cytometry in two to three-
week grown SCCVII and MOPC- tumors. NK cells were therefore identified by CD4 and CD8 negativity
and expression of CD49b[7] as shown in figure 4.10A and B. NK cell infiltration did not differ between
SC and ortho localization of either SCCVII nor MOPC- tumors with SCCVII tumors being generally
slightly higher infiltrated than MOPC- (figure 4.10C). For monocytic cells, this trend was reversed and
higher frequencies of CD11b+Ly-6C+ cells were present in BL6 tumor bearing mice without difference
in localization.
Taken together, the analysis of the composition of tumoral infiltration showed the highest immune
infiltrate in SCCVII SC tumors with high CD11b+Ly-6G+ as well as T and NK cell infiltration. T cell
infiltration further tended to depend on tumor localization while innate immune cells had consis-
tent tumor type specific infiltration patterns. Additional functional analysis would be necessary to
identify direct implications of these differential infiltration patterns.
4.1.5 Importance of CD11b+Ly-6G+ cell localization for regulatory functions
As CD11b+Ly-6G+ cells are modulated at different sites in the tumor bearing host, their functions
may differ depending on the tissue specific localization. One functional implication of CD11b+Ly-
6G+ cells is immunosuppression which can occur on several sites being the tumor tissue itself as
well as in the periphery including the secondary lymphoid organs[153]. Further functions seem to be
restricted to the tumor site like promotion of angiogenesis and tissue remodeling resulting in inva-
sion and metastasis[53]. Whether all cells of the population are capable of exerting these functions
or functional responses have to be induced by a local phenotypic shift was investigated by a seminal
study from Fridlender and colleagues. They presented differential gene expression patterns of naive
CD11b+Ly-6G+ cells compared to CD11b+Ly-6G+ cells from tumor bearing mice and between both
of them compared to tumor infiltrating Ly-6G+ cells demonstrating the significance of intratumoral
localization[55]. These data prompted us to investigate gene expression and functional properties of
CD11b+Ly-6G+ cells from different compartments of HNC bearing hosts.
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Bone marrow and spleen derived CD11b+Ly-6G+ cells have equal immunosuppressive
capabilities
It was suggested in the literature that immunosuppressive properties of CD11b+Ly-6G+ cells are de-
pendent on maturation and localization of these cells[60, 76] in tumor models. This study therefore
asked whether bone marrow derived and splenic CD11b+Ly-6G+ cells from HNC tumor bearing mice
differ in their capability of suppressing T cells. For this purpose, it was first tested whether splenic
immunosuppression might be a mechanism in this tumor model. To this end, spleen tissue from
naive and MOPC- tumor bearing BL6 mice was analyzed for the number of Ly-6G+ cells and prolif-
erating Ki67+ cells by immunohistochemistry. As already demonstrated by flow cytometry in section
4.1.2, this analysis confirmed accumulation of Ly-6G+ cells in tumor bearing mice (figure 4.11A and C,
black symbols). Coincidentally, a reduction of proliferating cells was observed suggesting a reduced
immune activation in HNC tumor bearing mice (figure 4.11B and C, grey symbols). As a next step,
direct suppressive activity of Ly-6G+ cells was assessed. Bone marrow derived Ly-6G cells were iso-
lated from MOPC- tumor bearing BL6 mice and were added to polyclonally activated and labeled T
cells. Proliferation of T cells and respective suppression by the added cells was assessed after three
days by flow cytometry. In a ratio of 1 to 10 Ly-6G+ cells to T cells, only minor suppressive activity
was observed, whereas up to 80 % of proliferation was suppressed when adding equal numbers of
Ly-6G+ to T cells (figure 4.11D). To compare different origins of Ly-6G+ cells, isolation was performed
from spleen as well. To this end, MOPC- tumor bearing CatchUp animals were used to facilitate pure
isolation of Ly-6G+ cells by sorting for tdTomato signal. T cell suppression assay was performed ac-
cording to the bone marrow suppression but different cell ratios were used. Splenic Ly-6G+ cells had
minor suppressive activity in a 1 to 20 (Ly-6G+ to T cell) mixture and showed ratio dependent increase
of T cell suppression (figure 4.11E). Even though both assays are not directly comparable because
different donor mouse strains were used, splenic Ly-6G+ cells seemed to be equally suppressive in
lower effector to target ratios than bone marrow derived Ly-6G+ cells. In an exemplary experiment,
this trend was not reproduced in a 1:5 ratio with cells derived from the same CatchUp animal (figure
4.11F). Collectively, suppressive activities were demonstrated to be equal for both spleen and bone
marrow derived Ly-6G+ cells from HNC tumor bearing animals.
Tumor infiltrating CD11b+Ly-6G+ cells upregulate protumoral modulators
As mentioned in the beginning of this chapter, intratumoral localization adds another level of ac-
tivation to CD11b+Ly-6G+ cells. HNC tumor derived factors furthermore proved to induce a pro-
tumoral phenotype in human neutrophils in in vitro studies[39, 203]. A protumoral activation was
therefore also hypothesized for intratumoral CD11b+Ly-6G+ cells in our HNC model. For an initial
study, splenic and intratumoral CD11b+Ly-6G+ cells were analyzed from MOPC- SC tumor bearing
BL6 mice by flow cytometry. In tumor infiltrating CD11b+Ly-6G+ cells, cell surface expression of
CD11b was increased, which may indicate local activation of these cells (figure 4.12A). Intracellular ef-
fector molecules showed no consistent regulation in this analysis. While iNOS was slightly increased
(figure 4.12B), Arginase1 protein expression was rather decreased in tumor infiltrating CD11b+Ly-
6G+ cells (figure 4.12C). As effector proteins could be released to the microenvironment prior to anal-
ysis, gene expression was to be assessed for further analysis of the activation status of tumor infiltrat-
ing CD11b+Ly-6G+ cells. To isolate Ly-6G+ cells as gentle as possible, CatchUp mice were used and
tdTomato+ cells were sorted without additional antibodies that might further activate the cells. For
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Figure 4.11: T cell suppression by splenic and bone marrow derived Ly-6G cells. A-C Spleen
cryosections from tumor-bearing and naive BL6 mice were stained for Ly-6G and Ki67. Representative pho-
tomicrographs for Ly-6G A and Ki67 B are shown at 200 × magnification with a scale representing 50 µm. C
Positive cells were counted in 4 ROIs and each symbol indicates the mean of a mouse. The line indicates sig-
nificance at p≤.05 as determined by student’s t-test. D-F Bone marrow derived Ly-6G+ cells were isolated from
tumor bearing BL6 mice by MACS technique. Ly-6G+ cells from spleen were isolated from CatchUp mice by
sorting of tdTomato+ cells. T cells were isolated from the respective animals by sorting for CD3 stained cells.
Proliferation dye 450-labeled T cells were stimulated by 50 U / mL IL2 and CD3/CD28 Beads and Ly-6G cells
were added in different ratios. Proliferation was assessed by flow cytometry after three days and suppression
by Ly-6G cells from bone marrow D and spleen E was calculated. Representative histograms for induction of
proliferation, suppression by bone marrow-derived Ly-6G cells and suppression by spleen-derived Ly-6G cells
are shown in F.
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Figure 4.12: Tumor infiltration results in activation of protumoral mediators. BL6 and CatchUp mice
were injected with MOPC- cells SC. A Spleen and tumor were isolated from BL6 animals after two weeks and
analyzed by flow cytometry. Cells were stained for CD11b and Ly-6G and median cell surface expression of
CD11b A as well as intracellular iNOS B and Arg1 C were analyzed on these cells. D+E Ly-6G+ cells were iso-
lated from tumors and spleens of five CatchUp animals by sorting for tdTomato signal. mRNA expression was
assessed by qPCR. Relative gene expression was calculated after normalization to β-actin comparing tumor
and spleen-derived cells in a hierarchical clustering analysis D. Selected increased genes are shown in E also
including iNOS and Arg1 which were only detectable in two animals.
five CatchUp animals, cells were isolated from spleen and tumor after three weeks of tumor growth.
Gene expression analysis was performed on a set of target genes which are differentially regulated
in pro versus antitumoral CD11b+Ly-6G+ cells as described by Fridlender et al.[54]. Differential gene
expression of tumor infiltrating and spleen derived CD11b+Ly-6G+ cells could be demonstrated in an
hierarchical cluster analysis (figure 4.12D). Antitumoral markers, such as ICAM-1 and TNFα, thereby
clustered in a group that is downregulated in tumor versus splenic Ly-6G+ cells. Furthermore, upreg-
ulation of the chemokines CCL2 and CCL3 was very pronounced in the tumor, which may result in
attraction of additional immune cells and thereby promoting tumor associated inflammation. Con-
sistently upregulated genes were summarized in figure 4.12E by the 2−∆∆CT analysis versus spleen.
Thereby it became apparent that also angiogenesis promoting VEGF is highly induced upon infil-
tration in the tumor. Only in two out of five animals, Arg1 and iNOS mRNA was detectable in both
groups. Nevertheless, upregulation was induced in tumor infiltrating CD11b+Ly-6G+ cells in the mice
with positive PCR results for Arg1 and iNOS. Thus, intratumoral activation of CD11b+Ly-6G+ cells is
crucial for inducing a protumoral phenotype shift.
Taken together, a HNC mouse model was established resembling tumor cell immune interactions
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which can also be found in HNC patients. CD11b+Ly-6G+ cells further accumulated in the periph-
ery of advanced HNC tumor bearing mice. Functionally, it was possible to show immunosuppressive
functions of CD11b+Ly-6G+ cells independent of localization in bone marrow or spleen of HNC tumor
bearing mice. Additionally, infiltration into the tumor tissue further activated Ly-6G+ cells as seen by
cell surface CD11b expression and induction of a protumoral gene expression pattern. Immunosup-
pressive activity of intratumoral CD11b+Ly-6G+ cells was implied by induction (gene expression) and
release (low protein content) of Arginase1 and induction of iNOS expression (mRNA and protein).
These data suggest several levels of suppression of antitumor responses by CD11b+Ly-6G+ cells in
HNC hosts and additional protumoral functions that become activated upon infiltration into the tu-
mor tissue. These HNC models with either SC or orthotopic localization are therefore well suited for
the analysis and further characterization of CD11b+Ly-6G+ cell protumoral activities.
4.2 Implication of Ly-6G+ cells in HNC tumor progression
It has been demonstrated that HNC tumors in murine models interact with CD11b+Ly-6G+ cells and
induce their accumulation in the periphery. A general status of T cell suppression may be mediated by
these cells in the HNC hosts. Furthermore, infiltration and activation in the tumor microenvironment
was described in the previous chapter. Nevertheless, additional immune cells were shown to infiltrate
these experimental tumors and these carry the potential of influencing tumor progression as well.
At least some of these cells might be attracted by CD11b+Ly-6G+ cell derived chemokines further
complicating the tumor-immune cell crosstalk. The next part of this study therefore aimed to analyze
the importance of CD11b+Ly-6G+ cells for tumor progression in this HNC model by either direct or
indirect effects. To this end, CD11b+Ly-6G+ cell depletion was utilized as a technique that is often
used to analyze granulocyte functions in different disease states such as infection, autoimmunity
and cancer[24, 32, 119]. αGr-1 (clone RB6-8C5) and αLy-6G (1A8) monoclonal antibodies (mAb) were
used to deplete CD11b+Ly-6G+ cells. For the analysis of longitudinal tumor growth, application of
antibodies was continued throughout the experiment in a three-days interval.
4.2.1 Effect of neutrophil depletion on establishment of tumors and progression of
advanced tumors
As tumor progression is characterized by different stages, it is therefore possible that neutrophils
could promote all or a number of these stages. While immune evasion and vascularization are crit-
ical during the establishment of a tumor, invasiveness and metastasis become more important in
advanced disease[206]. In experimental tumors, similar phases can be found. Upon tumor injection,
seeding to the organ takes place, which can be supported by structural remodeling and adjustment
of the microenvironment. Initial tumor growth can furthermore only occur upon induction of vas-
cularization. If immunosuppression is not mediated, experimental tumors can get rejected after one
week[101]. Supporting invasiveness further results in enhanced tumor growth. Therefore, implication
of CD11b+Ly-6G+ cells was assessed during tumor cell seeding as well as during late progression in
this HNC model.
Advanced tumors grow independent of CD11b+Ly-6G+ cells
A study by Mishalian and colleagues suggested that murine CD11b+Ly-6G+ cells are only implicated in
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Figure 4.13: Advanced tumor growth proceeds relatively independent of Ly-6G cells. Tumor-
bearing mice (n=4-5) were continuously treated with CD11b+Ly-6G+ cell-depleting antibodies as soon as a tu-
mor size of 3-5 mm was reached in one dimension. Tumor growth was assessed in BL6 (A+B, MOPC-) and C3H
mice (C+D, SCCVII) treated with either αGr-1 A+C or αLy-6G B+D. Data are presented as mean±SEM of the
relative volume to the tumor volume when starting treatment (tumor size at start of treatment was set to 1).
advanced tumor progression in a model using lung tumor or mesothelioma cells[133]. To investigate
whether a similar mechanism is present in the described HNC models, established tumor bearing
mice were depleted of CD11b+Ly-6G+ cells. To this end, the SC tumor model was chosen to enable
the determination of exact tumor volumes. MOPC- and SCCVII tumors were monitored daily under
continuous depletion of Ly-6G+ cells. In BL6 mice, tumor growth was slightly reduced after 5 days
of depletion using αGr-1 antibody (figure 4.13A). This tendency was confirmed when using αLy-6G
to more specifically address CD11b+Ly-6G+ cells (figure 4.13B). Nevertheless, these differences only
account for very small effects as no statistical significance was obtained. Contrary, this trend was
even smaller in SCCVII tumor bearing C3H mice when depleting with αGr-1 (figure 4.13C). Surpris-
ingly, a slight early reduction of tumor growth was observed when SCCVII tumors were depleted us-
ing the αLy-6G antibody but this is reverted into unchanged progression after day 2 (figure 4.14D). In
sum, only a minor influence on advanced tumor progression could be demonstrated for CD11b+Ly-
6G+ cells in the HNC tumor model.
CD11b+Ly-6G+ cells mediate tumor establishment
An effect of CD11b+Ly-6G+ cells on advanced tumor progression was not confirmed in this study.
Therefore, the mechanism indicated in the study by Mishalian did not seem to be shared by the herein
used HNC cell lines. They also indicated that early tumor growth can not be affected by depletion be-
cause CD11b+Ly-6G+ cells did not enter their tumors in early stages but were located in the tumor
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Figure 4.14: Ly-6G cells mediate tumor establishment. BL6 mice (n=4) were depleted of CD11b+Ly-
6G+ cells by injection of specific antibodies. After 2 days, MOPC- tumor cells were injected SC and tumor size
was determined under continuous antibody applications. Depletion was carried out using either Gr-1 A or
Ly-6G B specific antibodies. Relative tumor volume was calculated to day 3, which was the first day of tumor
measurement for Gr-1 depleted animals C. Data are presented as mean±SEM and lines indicate significant
differences calculated by student’s t-test with p≤.05. Final tumor volume and weight of tumor explants from
Gr-1 treated animals was assessed at days 18-22 D.
periphery[133]. Contrary, immunohistochemistry indicated considerable infiltration of CD11b+Ly-
6G+ cells within the first days in the HNC model (data not shown). As a consequence, the impact
of this early presence of CD11b+Ly-6G+ cells in HNC tumor bearing mice was analyzed. For this anal-
ysis, BL6 mice were depleted of CD11b+Ly-6G+ cells and MOPC- tumor cells were injected SC into the
CD11b+Ly-6G+ cell free mice 2 days after start of treatment. Tumor growth was monitored to evaluate
an influence of CD11b+Ly-6G+ cells on this stage of tumor progression and treatment was contin-
ued during the whole experiment. First, both isotype and αGr-1 treated animals developed small
tumors within three days. After one week, a reduced tumor size became apparent in the depleted
group (figure 4.14A). To confirm that this effect was mediated by the absence of Ly-6G and not Ly-6C
cells, the experiment was repeated using αLy-6G antibody. Again, tumors appeared simultaneously
but depleted animals consistently develop slow growing tumors (figure 4.14B). The reduced tumor
growth was even more pronounced when analyzing the relative tumor volume to day 3, which indi-
cates the speed of tumor progression (figure 4.14C). Accordingly, final tumor volumes and weights, as
measured between day 18 and 22 when the experiment was finished, were reduced in αGr-1 treated
animals compared to respective isotype treated controls (figure 4.14D).
Collectively, this data provides strong evidence for an implication of CD11b+Ly-6G+cells in early tu-
mor formation and seeding in the HNC model. Furthermore, late tumor progression is less affected
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Figure 4.15: Enhanced T cell infiltration in depleted tumors. BL6 mice were depleted of CD11b+Ly-
6G+ cells using αGr-1 mAB. After 2 days, MOPC- tumor cells were injected SC and antibody application was
continued. Tumors were isolated 5-7 days after tumor cell injection and analyzed by immunohistochemistry
(T cells) and fluorescence microscopy (NK cells). Tumor infiltrating CD8 A and CD4 B T cells as well as asialo+
NK cells C were assessed by manual counting of 4 ROIs per tumor at 200×magnification.
by the presence or absence of CD11b+Ly-6G+ cells.
4.2.2 T cell dependent delay of early tumor growth
The presence of CD11b+Ly-6G+ cells enhanced HNC tumor growth especially in the early phase of
tumor progression. Nevertheless, differences in tumor volumes were rather manifested with some
delay while formation of the first visible small tumor nest was not affected. It is therefore likely that an
antitumoral adaptive immune response is hosted in neutropenic tumor bearing mice. As a next step,
it was obvious to analyze the role of anti tumor effector cells in growth delay by CD11b+Ly-6G+ cell
depletion.
Early tumor infiltration and immune cell distribution is changed upon depletion
Potential antitumor effector cells are T as well as NK cells which can attack tumor cells directly via per-
forin and granzyme and by Fas ligation[180]. To investigate whether CD11b+Ly-6G+ cells in the HNC
model suppress these antitumor effectors thereby facilitating especially early tumor progression, tu-
mor tissues were analyzed in the early establishment phase. For this purpose, MOPC- cells were in-
jected into CD11b+Ly-6G+ cell depleted and undepleted BL6 mice. Tumors were isolated between
day 5 and 7 of tumor progression and analyzed by immunohistochemistry. Early tumors were found
to be consistently higher infiltrated with T cells when mice were treated with αGr-1 antibody (figure
4.15). This trend was most clearly observed for CD8+ cells (figure 4.15A) but also CD4+ cell density
increased slightly (figure 4.15B). NK cell infiltration was assessed by fluorescence microscopy on the
same tumors but for these cells, no differential infiltration was found (figure 4.15C). Thus, enhanced
T cell infiltration in Gr-1 depleted mice indicated a T cell suppressive function for CD11b+Ly-6G+ cells
in the HNC model.
T cells partially mediate delayed tumor growth
After having shown that T cells can enter CD11b+Ly-6G+ cell depleted tumors more easily than in
neutrophil competent mice, the impact of this infiltration had to be determined. Do T cells in neu-
tropenic mice mediate delayed tumor progression? To answer this question, a combination of Gr-1
and CD8 depletion was performed. BL6 mice were continuously depleted using antibodies against
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Figure 4.16: Depletion of CD8 T cells does not necessarily diminish Gr-1 depletion effects. A BL6
mice (n=4) were depleted of either CD11b+Ly-6G+ cells alone usingαGr-1 mAB or CD11b+Ly-6G+ cells and CD8
T cells by additional application of the mAB 2.43. After 2 days, MOPC- tumor cells were injected SC and tumor
size was determined under continuous antibody applications. Data are presented as mean±SEM for the Gr-1
group and single growth curves are shown for Gr-1 + CD8 depletion. B Athymic nude mice were injected with
MOPC- tumor cells with or without depletion by Gr-1 mAB and tumor growth was monitored. Single growth
curves are shown.
CD11b+Ly-6G+ cells or both cell types and MOPC- cells were injected SC to monitor tumor progres-
sion. Again, Gr-1 depletion reduced tumor growth, but additional CD8 depletion did not ultimately
result in abolishment of this effect (figure 4.16A). Only in two out of four double depleted animals,
tumor growth was enhanced compared to the Gr-1 depleted group. To exclude additional effects by
CD4 T cells, a tumor growth analysis was carried out in athymic nu/nu mice. These mice lack mature
T cells of both types and are therefore unable to mount an antitumor T cell response. nu/nu mice
were depleted of CD11b+Ly-6G+ cells using αGr-1 antibody and MOPC- tumor cells were injected to
monitor tumor growth. Two out of three depleted and one out of four undepleted tumors grew slowly
in nu/nu mice but one of the depleted tumors also grew nearly as fast as the fastest undepleted tumor
(figure 4.16B). Therefore, Gr-1 cells do not seem to influence tumor growth in nu/nu mice as they do
in BL6 mice.
This data indicate that T cells are implicated in reduction of tumor growth by CD11b+Ly-6G+ cell de-
pletion. T cells infiltrated depleted tumors to a higher extent than CD11b+Ly-6G+ cell competent tu-
mors. Nevertheless, depletion of CD8+ cells alone was not capable of restoring normal tumor growth
in all mice. Equal tumor growth in nu/nu mice independent of the presence of Ly-6G+ cells suggests
that both CD8 and CD4 T cells might be involved in the observed growth delay.
4.2.3 CD11b+Ly-6G+ cells facilitate tumor establishment by structural remodeling of
host tissue
Early tumor growth was slowed in Gr-1 and Ly-6G depleted animals. At least in BL6 animals, not only
CD8 T cells were responsible for reduction of tumor growth. To investigate additional mechanisms
by which CD11b+Ly-6G+ cells could mediate tumor progression, tumor vascularization was assessed.
Induction of VEGF expression in tumor infiltrating neutrophils as shown in section 4.1.5 already in-
dicated an influence of CD11b+Ly-6G+ cells on tumor angiogenesis. This was furthermore shown
by studies in other tumor models where depletion was used as well[90]. Furthermore, vessel density
was reduced in depleted orthotopic MOPC- tumors but not in SC tumors when analyzed after one to
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Figure 4.17: Ly-6G cells provide structural support for the tumor. Intratumoral vessel density was
assessed by immunohistochemical staining A (scale represents 50 µm). Vessel density was analyzed in MOPC-
tumors isolated at day 3 from mice which were depleted by αGr-1 or treated with isotype mAB. To this end,
the number of CD31+ vessels was counted manually in 4 ROIs per tumor at 200×magnification B. Significance
was tested by student’s t-test. BL6 mice were depleted using αGr-1 and injected with tumor cells in a PBS
MatrigelTM mixture. Tumor growth was followed for 20 days C.
two weeks (data not shown). To assess a very early effect on tumor vascularization, BL6 mice were
depleted of neutrophils using αGr-1 antibody and MOPC- cells were injected into either depleted or
isotype treated mice. Tumor vascularization was assessed as soon as a small tumor mass was visible at
day 3 after tumor cell injection. Analysis was carried out by immunohistochemical staining of CD31
identifying endothelial cells (figure 4.17A). Microvessel density, as reflected by the number of CD31+
cells per region of interest, was remarkably reduced in CD11b+Ly-6G+ cell depleted tumors (figure
4.17B). To demonstrate that support by induction of angiogenesis and tissue remodeling is induc-
ing neutrophil enhanced tumor seeding, this support was mimicked by coinjection with MatrigelTM.
MatrigelTM MOPC- mixtures were injected SC into Gr-1 depleted or isotype treated BL6 mice and tu-
mor growth was monitored. Notably, MatrigelTM tumors grew faster than in the normal SC model
even though only one fifth of the normal cell number was injected. Tumor growth was unaffected by
depletion of CD11b+Ly-6G+ cells in this growth factor rich tumor model (figure 4.17C). Accordingly,
direct tumor support by growth factors, vascularization and tissue remodeling is involved in CD11b+-
Ly-6G+ cell mediated tumor establishment.
Taken together, the presented data indicate a crucial role of CD11b+Ly-6G+ cells in establishment of
HNC tumors rather than promoting advanced tumor progression. The underlying mechanism was
identified by a lack of Ly-6G+ cell mediated T cell suppression as well as missing structural and an-
giogenesis inducing support for tumor cell seeding by CD11b+Ly-6G+ cells. Furthermore, it is unique
that both mechanisms could be described in one study thereby implicating that tumor associated
CD11b+Ly-6G+ cells mediate diverse protumoral functions simultaneously.
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4.3 Detailed characterization of neutrophil depletion in tumor bearing mice
Tissue specific functional activity of Ly-6G+ cells is only starting to emerge[55] and beside ex vivo anal-
ysis of isolated cells, in vivodepletion is often used to assess functional implications of these cells. The
data presented in this study also convincingly demonstrated how antibody mediated depletion can
reveal mechanisms of CD11b+Ly-6G+ cells in tumor bearing hosts. Nevertheless, it was also indicated
in chapter 4.1.2 that CD11b+Ly-6G+ cell dynamics are affected by tumor burden in this HNC model in
accordance with studies in other tumor models[222]. As tumor derived factors inducing myeloid cell
expansion might interfere with the applied technique of antibody mediated depletion, this part of the
study aimed to investigate the efficacy of CD11b+Ly-6G+ cell depletion in HNC tumor bearing mice.
4.3.1 The phases of CD11b+Ly-6G+ cell depletion in the peripheral blood
As peripheral blood is easily available in small amounts, the efficacy and duration of antibody medi-
ated in vivo depletion is usually only monitored in blood by most of the studies. This study therefore
started to assess depletion efficacy in the peripheral blood in HNC bearing mice as well.
Complete peripheral blood depletion
The presence of a tumor was shown to induce peripheral blood expansion of CD11b+Ly-6G+ cells
(chapter 4.1.2). To assess whether this expansion can be overcome by antibody mediated depletion
and to investigate the efficacy of the treatment, MOPC- tumor bearing mice were depleted usingαGr-
1 or αLy-6G antibodies starting at a tumor size of 5 mm. Depletion was continued by antibody ap-
plication on every third day and Ly-6G+ cell frequencies were monitored in tail vein blood by flow cy-
tometry daily. In accordance with many other studies which analyze treated animals after 24 hours,
Ly-6G+ cells were drastically reduced after one day and also remained completely depleted for sev-
eral days for both αGr-1 (figure 4.18A) and αLy-6G (figure 4.18B) treatment. A comparable efficacy
was demonstrated in SCCVII bearing C3H animals (not shown). To further verify flow cytometry re-
sults, blood smears from identically treated BL6 animals were analyzed microscopically using Pap-
penheim’s staining. No segmented or banded neutrophil granulocytes were observed by this tech-
nique for the same period of observation while Ly-6G negative eosinophils remained present (not
shown). Thus, HNC tumor burden does not interfere with the onset of antibody mediated depletion.
Rebound of CD11b+Ly-6G+ cells upon continued depletion pressure
Many cancer studies, including this one, monitor and treat tumor bearing mice for longer than one
week with CD11b+Ly-6G+cell depleting antibodies. In a majority of studies, the treatment approached
or exceeded three weeks[197, 4, 54, 67, 92, 113, 139, 150] with depletion efficacy being often only mentioned
in the methods section but not directly demonstrated. This study therefore analyzed peripheral blood
depletion for a longer period in mice carrying HNC MOPC- tumors. Depletion was achieved by αGr-
1 injection in 5 mm tumor bearing mice and was repeated every third day. Starting with normal
Ly-6G+ cell numbers (figure 4.19A), complete depletion was induced rapidly and was stable for at
least 5 days in the peripheral blood (figure 4.19B). Nevertheless, after some additional time on day
10, Ly-6G+ cells started to be detectable (figure 4.19C) and two weeks after start of treatment, nor-
mal Ly-6G+ cell frequencies were present in the blood of continuously treated tumor bearing animals
(figure 4.19D). Thus, complete depletion was found to be very transient in the peripheral blood of
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Figure 4.18: Ly-6G cells are depleted from the peripheral blood for several days. MOPC- tumor-
bearing mice were continuously depleted using either αGr-1 A or αLy-6G mAB B starting at a tumor size of 3-5
mm. Frequencies of peripheral blood Ly-6G+ cells were determined daily in tail vein blood by flow cytometry.
tumor bearing animals. Ly-6G+ cells started to reappear to detectable numbers after approximately
one week under continued antibody applications and reached normal levels after some additional
days which was consistent over several experiments as summarized in figure 4.19E. Using αLy-6G
antibody to deplete neutrophils resulted in similar kinetics of CD11b+Ly-6G+ cell rebound as well as
when depleting in tumor bearing C3H mice (not shown).
These data demonstrate for the first time that CD11b+Ly-6G+ cells rebound upon antibody mediated
depletion within two weeks under continued antibody application. Treatment with Ly-6G+ cell de-
pleting antibodies thereby is divided into two phases: the complete peripheral blood depletion phase
and the phase of CD11b+Ly-6G+ cell rebound. Notably, it was not possible to prolong the complete
peripheral depletion phase neither by increasing antibody application frequencies nor by switching
epitope specificity of the applied antibody between Gr-1 and Ly-6G (not shown).
4.3.2 Total peripheral blood depletion phase - the resistant neutrophil reservoir
As already indicated above, depletion is most often monitored in the peripheral blood but tissue spe-
cific functions of CD11b+Ly-6G+ cells are critical for several effector functions. Furthermore, recent
studies revealed depletion resistance of bone marrow cells in naive mice[163] as well as inefficient
depletion in the liver in experimental tumor models[123]. Based on these observations, depletion ef-
ficacy was monitored in different tissue compartments of HNC tumor bearing mice in the present
study.
Undepleted bone marrow cells are covered with depletion antibody
When analyzing the function of cells by depleting the respective cell type, it is critically important
that the targeted cells are removed from the organs in which they exert these functions. Given the
above stated studies, different organs were analyzed during the complete peripheral blood depletion
phase. To this end, MOPC- tumor bearing mice were depleted of neutrophils using αGr-1 or αLy-6G
antibodies. The organs of interest were isolated after several days of treatment and analyzed by flow
cytometry for CD11b and Ly-6G positive cells. By αGr-1 antibody treatment, significant reduction of
the frequency of CD11b+Ly-6G+ cells was observed in all organs except for liver (figure 4.20A). The
same holds true for bone marrow and spleen from mice treated with αLy-6G antibody (figure 4.20B).
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Figure 4.19: Ly-6G cell reappear under deple-
tion pressure. MOPC- tumor-bearing mice were
continuously depleted using αGr-1 mAB. Frequen-
cies of peripheral blood Ly-6G+ cells were deter-
mined in tail vein blood by flow cytometry. A-D
show representative flow cytometry plots at differ-
ent stages of depletion being day 0 (A, before anti-
body injection) as well as day 5 B, day 10 C, show-
ing the first reappearing cells, and day 15 D, indi-
cating increased numbers of Ly-6G+ cells. E shows
means±SEM of 6 experiments with 36 mice in total,
which have been measured on different days.
Surprisingly, a prominent reduction of stained cells was also observed in the bone marrow. Detailed
analysis of the progression of depletion in the bone marrow revealed normal CD11b+Ly-6G+ cell fre-
quencies already at day 10 preceding peripheral blood reappearance and an increase by 50 % at day
16 (figure 4.20C). When analyzing day 4-5 flow cytometry results in more detail, unchanged numbers
of CD11b positive cells become apparent in Gr-1 depleted animals during complete peripheral blood
depletion (figure 4.20D). This indicated limitations in conventional flow cytometry for the detection
of these cells in antibody treated animals. Overestimation of Ly-6G+ cell depletion in the bone mar-
row was further validated by directly staining isolated cells with anti-rat secondary antibody which
was able to bind to the in vivo antibody coated bone marrow derived Ly-6G+ cells (figure 4.20E). As
these results were alarming for the estimation of depletion efficiency in other organs as well, a sim-
ilar analysis was carried out in spleen derived cells. CD11b+Ly-6G+ cell frequencies are much lower
in this organ under normal conditions and the described analysis was not able to confirm any anti-
body coverage on CD11b+Ly-6G+ cells from splenocytes of depletion antibody treated animals (figure
4.20F and G). These results reveal that depletion is rather inefficient and classical flow cytometry for
Ly-6G+ cell counts is not reliable in bone marrow due to epitope masking by the depletion antibody
while similar antibody coating was not observed in other organs during peripheral blood depletion.
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Figure 4.20: Bone marrow cells are not depleted but covered with antibody. MOPC- tumor-bearing
mice were continuously depleted using αGR-1 or αLy-6G mAB as indicated. CD11b+Ly-6G+ cells were ana-
lyzed by flow cytometry in different organs. A Gr-1 treated animals were analyzed for frequencies of CD11b+-
Ly-6G+ cells in bone marrow, spleen, blood, liver and lymph nodes (LN) on day 4-5 after depletion. B Bone
marrow and spleen from Ly-6G treated animals was measured on day 5 after tumor injection. C Time depen-
dent changes in bone marrow of Gr-1 treated animals were assessed on day 5, 10 and 16. Flow cytometry plots
of bone marrow cells indicate an increase in Ly-6G negative cells in D, which stain positive for anti-rat FITC
secondary antibody E on day 5 after start of treatment. Similar analysis in spleen derived cells did not show the
same result (F and G.
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Viable cells reside in tumor tissue and spleen
This study demonstrated that conventional flow cytometry for surface markers is not the ideal meth-
od for detection of Ly-6G+ cells under depletion pressure at least in the bone marrow. As a conse-
quence, validation of tissue specific depletion was to be achieved by immunohistochemistry of cry-
otissues. For this purpose, MOPC- tumor bearing mice were depleted using Gr-1 antibody and anal-
ysis was carried out during the complete peripheral blood depletion phase. Microscopic analysis
revealed the presence of residual Ly-6G+ cells in spleens and tumor tissue of treated animals (figure
4.21A). Quantification of splenic Ly-6G+ cell density revealed significant reduction to 10-50 % of nor-
mal levels in αGr-1 treated mice (figure 4.21B) and to 25-55 % by αLy-6G treatment (figure 4.21C).
Nevertheless, considerable numbers of Ly-6G+ cells were present under treatment and were not de-
tected before. Notably, depletion efficacy seemed to be much higher when analyzing flow cytome-
try data (see figure 4.20B and the previous paragraph). Still, antibody coverage was not observed in
spleen derived cells. Therefore, another mechanism seems to lead to limited Ly-6G+ cell detection in
the spleen by flow cytometry. In addition, reduction of Ly-6G+ cells in the tumor tissue was even less
efficient and did not even reach statistical significance. In order to analyze viability of intratumoral
Ly-6G+ cells, we took advantage of the novel CatchUpIVM-red model[75]. In these mice, neutrophils
are detectable by Ly-6G specific Cre-mediated activation of tdTomato reporter gene expression and
can therefore be visualized for intravital microscopy. For this purpose, eGFP expressing MOPC- cells
were generated as described in section 3.1.2 to identify tumor tissue. MOPC-eGFP cells were injected
into the cutis of the ear resulting in growth of a solid tumor within one week. In this setting, it was
possible to noninvasively follow neutrophils in the tumor of living mice under treatment with αGr-1.
Additional intraveneous (IV) injection of fluorescently labeled nanocrystals facilitated visualization
of vascular structures. As shown in a series of images over a time of 17.5 minutes in figure 4.21D, this
technology confirmed the presence of residual tumor infiltrating Ly-6G+ cells and further demon-
strated that these cells were viable and migratory.
Taken together, different tissues were shown to host viable depletion resistant Ly-6G+ cells during the
phase of complete peripheral blood depletion in the HNC model. As these organs, such as spleen and
the tumor itself, are also sites of protumoral functions by neutrophils, these results suggest careful
interpretation of studies in which efficacy and duration of depletion are not monitored and docu-
mented in detail. Furthermore, incomplete depletion in these organs might constitute to accelerated
CD11b+Ly-6G+ cell rebound.
4.3.3 Counteracting depletion - enhanced granulopoiesis and CD11b+Ly-6G+cell
survival
Even though many studies, including this one, report antitumoral effects of CD11b+Ly-6G+ cell de-
pletion by long term application of antibodies, this study clearly demonstrated limited efficacy of this
treatment with peripheral blood CD11b+Ly-6G+ cells reappearing after several days. This raises the
question for the source and mechanism of depletion rebound in HNC tumor bearing mice.
Systemic effects of depletion are found in the serum
Systemic changes in the serum proteome can be induced by HNC tumors[203]. As these factors may
affect CD11b+Ly-6G+ cells and granulopoiesis in untreated as well as in depleted mice, serum cy-
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Figure 4.21: Viable Ly-6G+ cells are present in tumor tissue and spleen. BL6 or CatchUp mice bearing
MOPC- tumors were depleted of CD11b+Ly-6G+ cells. A-C Immunohistochemical staining of cryosections from
spleens and tumors of BL6 mice were analyzed for Ly-6G+ cells manually on 200×magnified photomicrographs
(representative see A, scale represents 50 µm) at day 4-7 after depletion. Four ROIs were analyzed per tumor
for αGr-1 B or αLy-6G C treated animals. The mean value of the respective isotype group was set to 1. Lines
indicate significant decreases as calculated by student’s t-test withp≤.05. D CatchUpIVM-redanimals bearing ear
tumors were depleted using αGr-1. Intravital imaging was carried out on day 2 after depletion. Blood vessels
were visualized by IV injection of Qtracker 655. Maximum intensity projection of a 30 µm stack is shown for 8
different points in time spread over 17 minutes and 30 seconds as indicated.
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Figure 4.22: Granulopoiesis inducing cytokines increase upon depletion of Gr-1+ cells. MOPC-
tumor bearing BL6 mice were continuously depleted of Ly-6G+ cells by αGr-1 treatment. Mice were sacrificed
at different intervals of treatment and blood was taken for analysis of serum parameters. Serum concentrations
of G-CSF A, KC B, IL6 C and IFNγ D were determined by ELISA. Lines indicate significance as calculated by one
way ANOVA with p≤.05.
tokine content was analyzed by ELISA at different stages of depletion in MOPC- tumor bearing BL6
mice. G-CSF was not detectable in naive or small tumor bearing mice but upon depletion with αGr-1
antibody, this granulopoiesis driving factor was dramatically increased (figure 4.22A). Highest G-CSF
levels were present during complete peripheral blood depletion and decreased rapidly in accordance
with CD11b+Ly-6G+ cell repopulation of the host. In addition, serum levels of KC, which only slightly
increased upon tumor progression, were highly increased at the same time as G-CSF probably in-
ducing CD11b+Ly-6G+ cell mobilization (figure 4.22B). KC serum concentration decreased upon de-
pletion rebound as well. Given the natural function of CD11b+Ly-6G+ cells in antimicrobial defense,
depleted mice could easily suffer from infections which could also result in the increase of the de-
scribed cytokines. Notably, no generalized signs of infections were observed in the treated animals.
Nevertheless, serum concentrations of additional infection associated cytokines were analyzed in de-
pleted animals to exclude an underlying inflammation. IL-6 was not elevated in either control nor de-
pleted mice in any phase of depletion (figure 4.22C). In accordance, IFNγ was not detectable in any
sample (figure 4.22D) therefore excluding general infections in depleted mice. Thus, granulopoiesis
modulating cytokines are highly induced upon depletion while infections are not present.
Depletion induces granulopoiesis in the spleen
CD11b+Ly-6G+ cells reappear after several days of complete depletion in the peripheral blood which
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Figure 4.23: Depletion en-
hances extramedullary gran-
ulopoiesis. MOPC- tumor bear-
ing BL6 mice were continuously
depleted of Ly-6G+ cells. A Spleens
were analyzed for apoptotic cells
by TUNEL staining on cryosections
of day 5-7 after start of treatment.
B Proliferation in bone marrow and
spleen was assessed by BrdU in-
jection 2 hours prior to analysis
in mice at day 4-8 after start of
treatment. Analysis was carried
out by flow cytometry. C-F Bone
marrow cells and B220 depleted
splenocytes from mice at day 4-8
after start of treatment were iso-
lated and cultured for 5 days in the
presence of 100 ng / mL G-CSF.
Frequency of CD11b+Ly-6G+ cells
was assessed by flow cytometry C.
Survival was assessed in the same
cultures by analysis of viability dye
staining within the population of
CD11b+Ly-6G+ cells D. Represen-
tative FC plots are shown for bone
marrow E and spleen F. Signifi-
cance was assessed by student’s t-
test with p≤.05.
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is associated with increased granulopoiesis inducing cytokines in the periphery. Bone marrow and
spleen are major sites of granulopoiesis[177, 30]. Given the relative inefficacy of depletion at these sites
compared to blood, these organs were analyzed during complete peripheral blood depletion as po-
tential sources of Ly-6G+ cell development and maturation. As a first step, cellular turnover in the
spleen of CD11b+Ly-6G+ cell depleted MOPC- tumor bearing mice was assessed. To this end, cry-
otissue was collected at day 5-7 after start of continuous treatment and apoptosis was analyzed by
TUNEL assay. Apoptotic cells were not elevated in spleens of either αGr-1 nor αLy-6G treated mice
but rather trended towards reduced numbers as shown in figure 4.23A. Therefore, increased cellular
turnover in the spleen of depleted mice was excluded. To further identify the source of Ly-6G+ cell
production in tumor bearing depleted mice, BrdU was incorporated in vivo for two hours before ana-
lyzing different organs by flow cytometry. Despite a great variability among αGr-1 treated animals, a
clear and very substantial increase in the percentage of BrdU+ among Ly-6G+ cells was noted in bone
marrow and spleen (figure 4.23B). It is noteworthy that this increase was more pronounced in spleen
than bone marrow. The potential of both organs to produce CD11b+Ly-6G+ cells during complete pe-
ripheral blood depletion was further assessed by in vitro culture in the presence of G-CSF for 5 days.
Bone marrow produced constant amounts of CD11b+Ly-6G+ cells independent of treatment as de-
termined by flow cytometry (figure 4.23C and E). Remarkably, splenocyte cultures of isotype treated
tumor bearing mice produced only minor amounts of CD11b+Ly-6G+ cells while splenocytes demon-
strated enhanced granulopoietic capacities uponαGr-1 treatment (figure 4.23C and F). When analyz-
ing survival in these cultures, bone marrow CD11b+Ly-6G+ cells were constantly viable and survival
of splenic CD11b+Ly-6G+ cells was prolonged in cultures from αGr-1 treated mice (figure 4.23D).
Collectively, this data provides strong evidence for preferential induction of extramedullary rather
than bone marrow granulopoiesis in tumor bearing mice under αGr-1 depletion pressure. This pro-
cess is potentially driven by high systemic levels of G-CSF and KC.
4.3.4 Immature regulatory Ly-6G+ cells drive the CD11b+Ly-6G+ cell rebound phase
Long term antibody mediated depletion of CD11b+Ly-6G+ cells is often performed in murine cancer
studies including this study in chapter 4.2. Simultaneously, tumor driven modulation of neutrophil
differentiation and biology has been described[30, 223] and is also present in the HNC model (chapter
4.1). This study further aims to identify the role of the tumor during CD11b+Ly-6G+ cell rebound and
the fate of the arising Ly-6G+ cells as they appear during the rebound phase in long term experiments.
Accelerated CD11b+Ly-6G+ cell rebound in tumor bearing animals
As mentioned above, an influence of tumor derived factors on the outcome of depletion is not un-
likely. In serum samples, induction of KC was also more pronounced in tumor bearing mice com-
pared to naive mice when depleting with αGr-1 (not shown). To evaluate the influence of tumor
burden on the dynamics of depletion and rebound, MOPC- tumor bearing and naive mice were sub-
jected to αGr-1 depletion and peripheral blood was monitored by flow cytometry. Between day 9 and
11 after onset of depletion, Ly-6G+ cell frequencies already started to increase rapidly in tumor bear-
ing mice in contrast to naive mice (figure 4.24A). Only a small number of naive mice (2/10) started to
enter CD11b+Ly-6G+ cell rebound as defined by Ly-6G+ cell frequencies >2 %. In contrast, as many
as 7 out of 11 tumor bearing mice displayed complete CD11b+Ly-6G+ cell rebound at the given time
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Figure 4.24: CD11b+-
Ly-6G+ cell rebound is
enhanced by the tumor.
Naive and MOPC- tumor bear-
ing BL6 or CatchUp mice were
continuously depleted using
αGr-1. Frequencies of Ly-
6G+ cells were assessed in tail
vein blood by flow cytometry
on day 9-11 in BL6 animals A.
The number of depleted mice
versus mice in the rebound
phase was analyzed using 2 %
as cut off value and was tested
by Chi2 test B. For CatchUp
mice, a similar trend is shown
on day 7-9 for tdTomato+
cells in tail vein blood C and
the progression of depletion
and rebound is indicated by
relative tdTomato numbers to
isotype D. Significance was
assessed by student’s t-test
with p≤.05 between naive and
tumor bearing animals and is
indicated by a vertical line.
(figure 4.24B). To exclude detection limitations in flow cytometry in this critical phase, a similar exper-
iment was performed using CatchUp mice. Thus, Ly-6G+ cells could be monitored in the flow cytome-
ter without external antibody dependent detection but by tdTomato signal. Differential CD11b+Ly-
6G+ cell rebound was confirmed in these mice with an earlier onset of 2 days at day 7 to 9 after start of
treatment (figure 4.24C). When analyzing tdTomato+ cells relative to simultaneously treated isotype
controls, fast CD11b+Ly-6G+ cell rebound became apparent in MOPC- tumor bearing animals while
naive mice entered CD11b+Ly-6G+ cell rebound more slowly (figure 4.24D). These data indicate that
reappearance of Ly-6G+ cells is accelerated by the presence of an HNC tumor in two different mouse
strains and using two different flow cytometric detection methods.
Prolonged survival of reappearing immature cells in the spleen
Reappearing cells are present during an experiment as soon as depletion is carried out for longer
than one week in tumor bearing mice. As indicated in section 4.3.3, increased survival was present in
CD11b+Ly-6G+ cells generated ex vivo from spleens of depleted animals during complete peripheral
blood depletion. Increased survival is also associated with lower maturation stages and these were
further linked to suppressive activities[153]. Survival and maturation was therefore analyzed in Ly-
6G+ cells from mice with CD11b+Ly-6G+ cell rebound under constant antibody applications. Splenic
Ly-6G+ cells were isolated from BL6 MOPC- tumor bearing mice in the rebound phase by MACS tech-
nique and cultured ex vivo for 24 hours. Survival, as determined by flow cytometry for AnnexinV
and 7AAD double negative cells, was increased in cells from animals in the rebound phase compared
to the respective isotype control mice (figure 4.25A). For additional morphological analysis, MOPC-
tumor bearing CatchUp mice were depleted using αGr-1 until CD11b+Ly-6G+ cells rebound and Ly-
6G+ cells were isolated by FACS from spleen and bone marrow. Anti-apoptotic mechanisms were
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Figure 4.25: Depletion is followed by expansion of long-lived Ly-6G cells. MOPC- tumor bearing BL6
or CatchUp mice were continuously depleted using αGr-1. A Ly-6G cells were isolated by MACS from spleen of
BL6 mice after CD11b+Ly-6G+ cell rebound and cultured for 24 hours before survival was assessed by Annex-
inV 7AAD flow cytometry. B-E tdTomato+ cells were isolated by FACS from bone marrow, blood and spleen of
CatchUp animals in the rebound phase. Cells were analyzed by cytospin. MCL-1 was stained (representative
photomicrograph at 1000× magnification B) and analyzed on 4 ROIs at 400× magnification for fluorescence
intensity by ImageJ. Spleen Ly-6G cell MCL-1 expression is indicated relative to a bone marrow specimen of
the same batch C. Pappenheim staining of cytospin indicate nuclear morphology at 1000× magnification for
isotype treated animals D and those which rebound from depletion E. The scale represents 50 µm for all pho-
tomicrographs. 1 = myelocyte, 2 = metamyelocyte, 3 = banded, 4 = segmented
investigated as survival was enhanced despite continuous antibody treatment, because depletion an-
tibodies were discussed to act via inducing apoptosis[1, 163]. To this end, cytospin preparations were
stained for the Bcl-2 family member MCL-1 and expression was analyzed by quantification of fluores-
cence intensity. Notably, Ly-6Ghigh as well as Ly-6Gint tdTomato+ cells expressed MCL-1 (figure 4.25B).
Mean fluorescence intensity was normalized to a simultaneously processed bone marrow sample.
MCL-1 expression analysis thereby indicated that splenic and bone marrow derived Ly-6G+ cells ex-
press similar levels of the anti-apoptotic protein in tumor bearing untreated mice. More importantly,
expression was enhanced in spleen derived Ly-6G+ cells after CD11b+Ly-6G+ cell rebound in tumor
bearing mice while bone marrow expression remained constant (figure 4.25C). Cytospin preparations
of spleen derived cells were also analyzed for morphological differences by Pappenheim stain. Cells
isolated from isotype treated animals mainly composed of mature neutrophils with characteristically
segmented nuclei (>90 %, figure 4.25D). In contrast, a high proportion of immature cells was identi-
fied among preparations from rebound phase animals (figure 4.25E). According to the nuclear mor-
phology, tdTomato+ cells from spleens in the rebound phase contained some mature segmented cells
and a mixture of myelocytes, metamyelocytes and banded neutrophils. In summary, these results
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Figure 4.26: Reappearing
cells show activated surface
marker expression. MOPC-
tumor bearing BL6 mice in the
rebound phase of Gr-1 depletion
were analyzed by flow cytometry.
Representative histograms for
CXCR2 expression on blood A and
spleen derived CD11b+Ly-6G+ cells
B are presented. CD11b+Ly-
6G+ cells were analyzed for CXCR2
C, CD62L D, CXCR4 E and CXCR7
F expression. Means±SEM of three
mice are shown.
demonstrate for the first time that tumor induced factors counteract Gr-1 depletion and strengthen
anti-apoptotic signals in the rebound phase under constant depletion pressure possibly resulting in
faster complete CD11b+Ly-6G+ cell rebound.
Activated phenotype by surface marker expression
This study indicated earlier that reappearing cells are characterized by prolonged survival and imma-
ture phenotype. In addition to the maturation status, activation can also induce survival and mod-
ulate functional properties. Both maturation and activation are associated with differential cell sur-
face expression of CXC chemokine receptors[165, 42]. To identify the phenotype of reappearing cells
in HNC bearing mice, cell surface expression of CXCRs as well as L-selectin, which is downregulated
upon activation[93], was analyzed by flow cytometry in blood as well as in spleen. CXCR2 was promi-
nently regulated on rebound CD11b+Ly-6G+ cells with decreased cell surface levels of the receptor in
blood and spleen of αGr-1 treated animals (figure 4.26A-C). Contrary, L-selectin was unchanged in
blood but low in spleen derived CD11b+Ly-6G+ cells in the depletion rebound phase (figure 4.26D)
suggesting an activated phenotype in spleen but not blood. Additionally, CXCR4 was highly variable
in isotype treated animals but constantly low on CD11b+Ly-6G+ cells that rebound from depletion in-
dicating decreased shuttling to the bone marrow (figure 4.26E). Finally, CXCR7 was unchanged by the
treatment (figure 4.26F). Collectively, cell surface expression of different markers indicate a mixture of
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Figure 4.27: Reappearing Ly-
6G cells express inflammatory
modulators. MOPC- tumor bear-
ing BL6 mice in the rebound phase
of Gr-1 depletion were sacrificed
and Ly-6G+ cells were isolated from
the spleen by MACS technique. In-
tracellular Arginase1 (Arg1) A and
reactive oxygen species (ROS) B
content was assessed by flow cy-
tometry. Significance was calcu-
lated by paired student’s t-text with
p≤.05. C mRNA expression of
different genes was analyzed by
qPCR from 2 exemplary pairs of
mice. Data was normalized to β-
actin and relative differences be-
tween rebound and isotype treated
Ly-6G+ cells were visualized in a
heatmap after hierarchical cluster-
ing of genes using R software.
activated and immature CD11b+Ly-6G+ cell phenotypes as already shown partially by morphological
analysis.
Regulatory molecules are differentially expressed in rebound CD11b+Ly-6G+ cells
Reappearing CD11b+Ly-6G+ cells were demonstrated to share immature and activated phenotypes.
Both can be associated with immunomodulatory and protumoral functions. It was therefore crucial
to analyze functional mediators in these cells which are coming up during long term depletion ex-
periments. To this end, MOPC- tumor bearing BL6 mice were continuously depleted using αGr-1
and Ly-6G+ cells were isolated from the spleen during CD11b+Ly-6G+ cell rebound. Flow cytometric
analysis of the intracellular effector molecules arginase1 and reactive oxygen species (ROS) displayed
expected interexperimental variability, but levels were consistently induced in αGr-1 treated animals
in the rebound phase compared to controls (figure 4.27A and B). Finally, using a panel of candidate
marker genes for tumor associated neutrophil polarization[54], gene expression was measured in two
pairs of cells from rebound and isotype treated animals by qPCR. Data were visualized by hierarchical
clustering suggesting changed regulatory properties of CD11b+Ly-6G+ cells in the rebound phase (fig-
ure 4.27C). The most prominent and consistent changes were observed in CCL17 upregulation and
reduced TNFα expression. Both indicate a polarization towards a protumoral phenotype as TNFα
was described in conjunction with an antitumoral phenotype and CCL17 mediated regulatory T cell
recruitment by neutrophils in another study[54, 132].
In summary, the presented data provides evidence for a limited applicability of long term depletion
in tumor bearing mice. Tissue specific depletion was shown to be incomplete and granulopoiesis
was rapidly induced in the spleen resulting in CD11b+Ly-6G+ cell rebound. Furthermore, the results
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of the final experiments suggest that Ly-6G+ cells, which reappear under depletion pressure, have an
immature and immunoregulatory phenotype. The presence of residual, depletion resistant, migra-
tory intratumoral Ly-6G+ cells, enhanced extramedullary granulopoiesis and the rapid reappearance
of immature regulatory cells should therefore be considered when using αGr-1 treatment to analyze
in vivo functions of neutrophils and MDSC in tumor bearing mice.
4.4 Role of Ly-6G in tumor-neutrophil interactions
Neutrophil specific expression of Ly-6G has been used for identification and depletion of these cells
in mice for a long time. Although identified as a key neutrophil marker, surprisingly, the function
of this molecule was unknown until recently. In 2012, Wang et al. published a study suggesting
that ligation of Ly-6G with nondepleting antibody doses results in reduced migratory properties of
CD11b+Ly-6G+ cells[208]. They identified an association of Ly-6G and β2-integrins which was cru-
cial for β2-integrin dependent migration. This is in line with a study indicating that the structurally
related molecule CD177 on human neutrophils can interact with PECAM and transendothelial migra-
tion can be diminished by blocking CD177[169]. However a recent study poignantly demonstrated that
Ly-6G knockout neutrophils are functionally normal and do not lack migratory properties using the
CatchUp model[75]. This suggests an antibody dependent effect in the earlier studies and leaves Ly-
6G without function again. To assess potential functions of Ly-6G in neutrophil-tumor interactions,
CatchUp animals have been used in this study for comparison of heterozygous Ly-6G competent and
homozygous Ly-6G knockout mice.
4.4.1 Differential tumor growth in Ly-6G KO animals
As CD11b+Ly-6G+ cells have been demonstrated in the earlier chapter to be involved in progression
of the HNC tumor model, tumor progression was analyzed in hetero and homozygous CatchUp an-
imals. To this end, MOPC- cells were injected SC into the respective hosts and tumor volume was
monitored over time. Differential tumor growth became apparent during the course of disease while
initial tumor formation was not affected in both female (figure 4.28A) and male (figure 4.28B) mice.
Surprisingly, Ly-6G knockout resulted in accelerated tumor growth suggesting an antitumoral func-
tion of the molecule. Furthermore, tumor growth between male and female mice also differed sub-
stantially.
Collectively, a tumor promoting environment was suggested by the presented results in homozygous
CatchUp animals with Ly-6G knockout.
4.4.2 Ly-6G is dispensable for infiltration into tumor tissue but affects gene expression
This study indicated differential tumor growth in Ly-6G knockout and competent mice. Possible
mechanisms could be mediated by migratory deficiencies upon lack of Ly-6G as indicated in an ear-
lier study[208] as well as a modulation of neutrophil effector functions. This study therefore assessed
tumor infiltration as well as several effector genes to elucidate the mechanism of differential tumor
growth.
Ly-6G KO neutrophils infiltrate into MOPC tumors
As indicated above, Ly-6G could be involved in migratory properties of neutrophils. To address mi-
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Figure 4.28: Ly-6G knockout affects growth of HNC tumors. Homozygous (Ly-6G-/-) and heterozygous
(Ly-6G+/-) CatchUp mice were injected with MOPC- tumors SC and tumor growth was evaluated in female A
and male mice B. Data are presented as mean±SEM of 4-5 mice. Statistical significance is indicated by vertical
lines and was assessed by student’s t-test with p≤.05
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Figure 4.29: Ly-6G knockout cells infiltrate tumor tissue normally. Tumors were excised from MOPC-
bearing CatchUp animals. Flow cytometry was performed for identification of tdTomato+ cells in homozygous
(Ly-6G-/-) mice A. Number of CD11b+ cells was assessed in the tumor by immunohistochemistry on cryosec-
tions. 4 ROIs of 200× magnification (as shown in B, scale represents 50 µm) were analyzed manually in het-
erozygous (Ly-6G+/-) and Ly-6G knockout (Ly-6G-/-) mice C.
gration into the tumor tissue in the HNC model, MOPC- cells were injected SC into Ly-6G compe-
tent as well as knockout CatchUp animals and tumor tissue was analyzed after three weeks of tumor
growth. Using flow cytometry, tdTomato+ cells were detectable in the tumor mass of Ly-6G-/- mice
(figure 4.29A). As intratumoral localization is mandatory for CD11b+Ly-6G+ cell functions in this con-
text, verification of the exact localization in this tumor mass was crucial. To this end, cryotissue from
MOPC- tumors grown in the respective mice was analyzed. As Ly-6G was not available for identifica-
tion of neutrophils in Ly-6G-/- mice, CD11b was stained in the available tissues. Examination of the
immunohistochemical staining revealed that CD11b stained exclusively granulocytic cells in MOPC-
tumors (figure 4.29B). CD11b and thereby granulocytic infiltration in MOPC- tumors did not differ
between Ly-6G competent and knockout mice (figure 4.29C). Infiltrating cells were evenly distributed
throughout the tumor tissue in all groups. Thus, Ly-6G deficient neutrophils are capable of migrating
into HNC tissues normally.
CD11b+Ly-6G+ cells from Ly-6G KO mice exert differential gene expression
After demonstrating that intratumoral migration is not affected in Ly-6G deficient mice, a phenotypic
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Figure 4.30: Differential gene ex-
pression in Ly-6G deficient versus
competent CatchUp neutrophils.
Ly-6G cells were isolated from spleen
and tumor of 4 MOPC- tumor bearing
CatchUp animals (2 pairs of homo and
heterozygous animals). Gene expression
was analyzed by qPCR and processed
via normalization to β-actin and rela-
tion of Ly-6G-/- to Ly-6G+/- gene expres-
sion. Heatmaps and hierarchical cluster-
ing for spleen derived A and tumor in-
filtrating B Ly-6G cells are shown indi-
cating the differential gene expression in
homo vs heterozygous cells.
difference between neutrophils from Ly-6G competent and deficient mice was likely. To address this
hypothesis, gene expression of N1 and N2 polarization markers[54] was assessed in neutrophils iso-
lated from MOPC- tumor bearing mice with both genotypes. Isolated cells derived from tumor tissue
and spleen of two pairs of mice. qPCR was performed to assess gene expression and visualization
was operated by a heatmap and hierarchical clustering analysis. In the spleen, most markers were
detectable and pronounced differential gene expression was found for the cytokine IL-10 and the
chemokine CCL17 which are highly downregulated in neutrophils from Ly-6G deficient mice (figure
4.30A). The other markers were not consistently regulated in both mouse pairs and arginase1 was
upregulated in one but not detectable in the other set of samples. Unfortunately, expression of many
genes was also not detectable in one set of tumor infiltrating neutrophil samples, which was probably
due to low cell numbers resulting in low RNA concentrations. The most remarkable changes in tumor
infiltrating neutrophils were observed for CCL17 expression, again, but in the tumor it was upregu-
lated in one out of two Ly-6G deficient neutrophil samples while it was not detectable in the other set
(figure4.30B). This is of interest as CCL17 could mediate Treg recruitment[132]. Furthermore, antitu-
moral TNFα was downregulated in one pair of mice but unchanged in the second data set. Therefore
a lower antitumoral N1 phenotype was not supported by this data. Upregulation, even though not to
the same extent as for CCL17, was observed for the chemokines CCL2 and CCL3 and for VEGF.
Collectively, the mechanism of enhanced tumor growth in Ly-6G deficient animals was not mediated
by affecting migratory properties of neutrophils in line with previous observations in the CatchUp
model[75]. Gene expression analysis revealed reduced protumoral CCL17 and IL-10 expression in the
spleen of Ly-6G deficient mice which is not in accordance with enhanced tumor growth. Furthermore,
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enhanced CCL17 as well as CCL2, CCL3 and VEGF expression was demonstrated in tumor infiltrat-
ing neutrophils suggesting modulation of tumor associated inflammation and angiogenesis in Ly-6G
deficient mice.
4.4.3 Differences in T cells from Ly-6G deficient mice
T cells can mediate antitumoral responses but are also regulated and suppressed by CD11b+Ly-6G+-
cells in tumor bearing mice. Furthermore, differential influence of Ly-6G deficient neutrophils on T
cells was indicated by gene expression analysis. Functional interaction between both cell types was
therefore addressed in the next part of this study.
Ly-6G does not mediate T cell suppression
Decreased IL-10 and increased Arg1 expression by Ly-6G deficient neutrophils in the spleen of tumor
bearing mice suggested an altered interaction between these cells and T cells. Furthermore, a differ-
ential capability for the regulation of T cells might be a mechanism by which Ly-6G competent and
knockout neutrophils could influence tumor progression. To test this hypothesis, tdTomato+ cells
were isolated from spleens of MOPC- tumor bearing hetero and homozygous CatchUp mice. Prolifer-
ation dye labeled CD3+ cells from heterozygous mice were stimulated using αCD3/αCD28 beads in
the presence of 50 U / mL IL-2 and Ly-6G cells were added in different ratios. Proliferation of T cells
was analyzed after 3 days of culture by flow cytometry (figure 4.31A). Ly-6G knockout neutrophils did
not result in differential suppression of T cell proliferation in either a 1:20 (figure 4.31B), 1:5 (figure
4.31C) nor in a 1:2.5 neutrophil to T cell ratio (figure 4.31D). Thus, Ly-6G knockout neutrophils exerted
normal T cell suppressive capabilities in an ex vivo polyclonal proliferation assay.
Tregs are not enhanced in the tumor tissue
T cell activation was not differentially affected by Ly-6G competent and knockout neutrophils. Nev-
ertheless, enhanced CCL17 expression in one tumor of Ly-6G deficient animals suggested possible
effects on T regulatory cells resulting in enhanced infiltration. To analyze the abundance of Tregs in
the tumors, cryotissue of MOPC- SC tumors from the respective mice was analyzed by immunohis-
tochemistry. CD4+ T cells were found to equally infiltrate tumors from both genotypes (figure 4.32A
and B). A high cell number was also found to express the Treg associated transcription factor FoxP3
in the nucleus (figure 4.32C). Treg infiltration into MOPC- tumors was slightly decreased in Ly-6G
deficient females compared to Ly-6G competent mice from the same gender (figure 4.32D). Remark-
ably high numbers were observed when calculating the abundance of Tregs among tumor infiltrating
CD4+ cells in Ly-6G competent but not in knockout female mice (figure 4.32E). In heterozygous mice,
between 66 and 100 % of infiltrating CD4+ cells were made up of FoxP3+ cells while in knockout mice
this abundance ranged between 20 and 57 % and was therefore significantly reduced. Surprisingly,
this was not apparent in the smaller group of male mice.
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Figure 4.31: Equal T cell suppression by hetero and homozygous CatchUp Ly-6G cells. Ly-6G
cells and CD3 T cells were isolated from the spleen of MOPC+ tumor bearing CatchUp animals and subjected
to a T cell proliferation (stimulation of proliferation with 50 U / mL IL2 and CD3/CD28 Beads) and suppression
assay using different Ly-6G to T cell ratios. Suppression of polyclonal proliferation is indicated in representative
histograms for hetero A-C and homo D-F animals using 1:20 A+D, 1:5 B+E and 1:1 C+F Ly-6G:T cells. Analysis
of homo and hetero animals processed on the same day are shown for the ratio of 1:20 G, 1:5 H and 1:1 I Ly-6G:T
cells
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Figure 4.32: Treg tumor infiltration differs in homozygous CatchUp animals. Tumors were excised
from MOPC- bearing CatchUp animals and analyzed by immunohistochemistry. Number of CD4+ cells was
assessed in the tumor on 4 ROIs of 200× magnification (as shown in A, scale represents 50 µm) and analyzed
manually B. FoxP3+ cells were analyzed the same way. A representative staining is shown in C. FoxP3+ nuclei
were counted manually D and the ratio of CD4 T cells and FoxP3+ nuclei was calculated for each tumor E.
Vertical line indicates statistical significance as determined by student’s t-test with p≤.05.
Consequently, this study promoted evidence for differential tumor promoting environments in Ly-6G
competent and knockout mice. While neutrophils of both genotypes readily infiltrated HNC tumor
tissue, gene expression suggested a modulation of tumor associated inflammation and angiogenesis
in Ly-6G deficient mice. Interaction with T cells was further analyzed but suppressive capacities of
neutrophils were not affected by presence or absence of Ly-6G. Surprisingly, reduced abundance of
tumor infiltrating regulatory T cells was demonstrated in Ly-6G deficient mice which is not in line
with enhanced tumor progression. Collectively, Ly-6G mediated modulation of tumor growth and
defective T regulatory cell accumulation in Ly-6G knockout homozygous CatchUp animals would re-
quire further investigation. It is therefore rather likely that enhanced tumor progression is induced by
affecting different tumor promoting cell types such as macrophages or by regulation of angiogenesis
in these mice.
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5 Discussion
This thesis investigated the role of neutrophils in the immunological tumor-host interaction in a
mouse model of head and neck cancer. In the different parts of the study, the following questions
and topics were addressed.
1. Are CD11b+Ly-6G+ cells affected by HNC tumors in mice? Yes, they are. A mouse model
for HNC-CD11b+Ly-6G+ cell interaction was established. In this model, CD11b+Ly-6G+ cells
were influenced by tumoral factors via the chemokine/CXCR2 axis. CD11b+Ly-6G+ cells rapidly
accumulated in spleen and peripheral blood and cell frequencies increased with tumor pro-
gression. Furthermore, it was demonstrated that bone marrow and spleen derived CD11b+Ly-
6G+ cells from HNC bearing mice have T cell suppressive capacities. Infiltration into the tumor
tissue induced local activation of protumorigenic properties of CD11b+Ly-6G+ cells.
2. Do CD11b+Ly-6G+ cells affect HNC tumor progression? As indicated above, intratumoral
CD11b+Ly-6G+ cells were characterized by a protumor phenotype. Further experiments sug-
gested a distinct role of CD11b+Ly-6G+ cells especially in tumor establishment and adjustment
of the tumor niche rather than in advanced tumor progression. Both inhibition of T cell func-
tion and potential effects on tumor angiogenesis as well as structural remodeling were sug-
gested by the data presented in this study.
3. Is experimental depletion of CD11b+Ly-6G+ cells affected by the presence of a tumor? In ad-
dition to inducing changes in CD11b+Ly-6G+ cell development and biology, HNC also limited
antibody mediated depletion of these cells. This study described a phase of complete deple-
tion of CD11b+Ly-6G+ cells in the peripheral blood, which is followed by the reappearance of
the cells despite continuous antibody application. During the complete peripheral blood de-
pletion phase, detailed analysis revealed a reservoir of resistant CD11b+Ly-6G+ cells not only in
the bone marrow but also in spleen and tumor. Furthermore, extramedullary granulopoiesis
was highly induced in depleted animals, which showed remarkable high G-CSF and KC serum
levels. These processes resulted in the CD11b+Ly-6G+ cell rebound during continuous deple-
tion, which was found to be faster in HNC tumor bearing animals than in naive mice. It was also
shown for the first time that reappearing CD11b+Ly-6G+ cells display a pronounced regulatory
phenotype which might interfere with long term experiments.
4. Does Ly-6G play a role in CD11b+Ly-6G+ cell-tumor interactions? In a pilot study, this ques-
tion was addressed in CatchUp mice. The Ly-6G knockout genotype resulted in accelerated
tumor growth in a subcutaneous HNC model. While CD11b+ cells equally infiltrated tumor
tissue in both genotypes, gene expression revealed changes in T cell regulating cytokines. Sur-
prisingly and not in accordance with accelerated tumor growth, regulatory T cell infiltration
was decreased in tumors from Ly-6G-/- mice. Therefore, the function of Ly-6G was not fully
elucidated in this initial study and requires more detailed analysis in the future.
Some of the main findings and controversies of this study will be discussed in the following sections.
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5.1 Interaction of neutrophils and HNC
As described in section 1.3, many scenarios have been identified in which murine CD11b+Ly-6G+ cells
and human neutrophils are affected by the tumor and may in turn affect tumor progression. The later
include suppression of antitumor immunity as well as the direct or indirect promotion of angiogen-
esis, invasiveness and metastasis of tumor cells. Notably, these functions were usually described in-
dependent of each other in distinct models or tumor entities. In HNC patients, recent data suggested
similar protumoral mechanisms of neutrophils[203] but a murine model for HNC-neutrophil interac-
tion was not described so far. This thesis presented such a model and the central advances achieved
in this model will be discussed in the next sections.
5.1.1 Effects of the tumor on CD11b+Ly-6G+ cell frequencies and functions
Recently, many tumor cell lines were described to induce CD11b+Ly-6G+ cell accumulation in tu-
mor bearing mice. One study by Youn et al. compared several cell lines in their capacity of inducing
CD11b+Ly-6G+ cell accumulation[222]. They presented that highest induction of CD11b+Ly-6G+ cells
in BL6 mice is achieved by the EL4 lymphoma cell line. As human HNC was also associated with accu-
mulation of neutrophils and immunosuppressive subsets[15, 203], a comparable HNC mouse models
would represent a tool for detailed analysis of neutrophil-tumor interactions and possible interven-
tions. Nevertheless, described HNC mouse models using tumor cell lines and chemical cancer in-
duction were not shown to be associated with CD11b+Ly-6G+ cell modulation so far. The HNC model
presented in this study was characterized to induce CD11b+Ly-6G+ cell accumulation in spleen and
blood in relation to tumor progression (section 4.1.2). For comparability to other studies. this study
used the EL4 cell line, which was characterized by Youn et al.[222], as a reference. Surprisingly, the
reported CD11b+Ly-6G+ cell frequencies of 30 % of all splenocytes were not induced in this study
by neither EL4 nor any of the tested HNC cell lines. Regardless of this difference, a significant in-
duction of splenic CD11b+Ly-6G+ cell frequencies was demonstrated by the reference cell line in the
presented study. This is also in line with a study from another group demonstrating a two-fold in-
crease of splenic CD11b+Ly-6G+ cells upon EL4 tumor burden[123]. It was therefore concluded, that
the difference to the Youn study was not due to differential activity of the reference tumor cell line.
Potential explanations for the difference in detected cell numbers might include the mice themselves,
which might have been obtained from different breeders, or diverging protocols for splenocyte isola-
tion and flow cytometry procedures subsequently resulting in the detection of remarkably different
cell numbers. Consequently, the herein presented changes in CD11b+Ly-6G+ cell distribution upon
tumor burden were highly relevant and compared to well established tumor cell lines, the HNC tu-
mors induced high amounts of these cells. This finding implicated a pronounced role of neutrophils
in the course of HNC progression.
When demonstrating that CD11b+Ly-6G+ cells accumulate in a tumor model, the consequence of
such a process gains interest. In the past, many studies concentrated on functional analysis of spleen
and blood derived CD11b+Ly-6G+ cells. Especially when investigating myeloid derived suppressor
cells (MDSC), these sources were chosen because of the robust accumulation in the respective or-
gans in the course of tumor progression. As implicated by the terminology, immunosuppression is
a central process of spleen derived MDSC function in these studies (summarized in reference [14]).
Further data provided evidence for an impact of the tumor on bone marrow derived neutrophils,
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which is in accordance with deregulated granulopoiesis[25]. This process could result in the release
of immature cells from the bone marrow to the circulation where they were shown to be highly
immunosuppressive[18, 60]. Thus, the induction of a higher number of immature CD11b+Ly-6G+ cells
would further contribute to the general state of immunosuppression in tumor bearing mice. Never-
theless, it is unclear whether the immunosuppressive capacity is an intrinsic feature of CD11b+Ly-
6G+ cells or whether it requires local activation. Regarding this question, a study in a prostate tumor
model suggested that peripheral CD11b+Ly-6G+ cells from liver or spleen indeed require activation
of iNOS by IFN-γ to gain T cell suppressive capacities[76]. To clarify intrinsic suppressive activity of
CD11b+Ly-6G+ cells in the HNC model, spleen and bone marrow derived cells from tumor bearing
mice were analyzed ex vivo in the presented study. Suppression of polyclonal T cell proliferation
by splenic as well as bone marrow derived neutrophils was thereby confirmed (figure 4.11). In this
experimental setup, production of IFN-γ by T cells is also induced (not shown) and could induce
suppressive activities in both cell types. Nevertheless, in Ly-6G to T cell ratios of 1:2.5 or 1:1 only a
few T cells were actually activated and the amount of IFN-γ production was therefore negligible. An
intrinsic immunosuppressive capacity of CD11b+Ly-6G+ cells independent of organ specific localiza-
tion was therefore indicated by the presented data in HNC bearing mice.
How are these neutrophil modulating processes induced? Tumor derived factors seem to be critical
for the induction of neutrophil accumulation and functions[40]. As the microenvironment of each tu-
mor entity differs, differential activation and subsequent functions of neutrophils arise. In line with
this hypothesis, TGF-β was identified as a key factor driving a protumoral CD11b+Ly-6G+ cell pheno-
type. TGF-β blockade resulted in a phenotypic shift towards an antitumoral phenotype of CD11b+-
Ly-6G+ cells in a mesothelioma and lung tumor model[54]. Additionally, TGF-βwas recently indicated
to promote a shift towards a neutrophil subset with immunosuppressive properties and low density
among blood CD11b+Ly-6G+ cells[170] suggesting further peripheral effects of tumor derived factors.
Additional cytokines are likely to promote comparable activations. For example, a recent study in-
dicated that the role of neutrophils in HNC patients was induced by a tumor cell-neutrophil cross
talk which was at least partly dependent on tumor derived macrophage migration inhibitory factor
(MIF)[39]. In the present study, overexpression of MIF in murine HNC cell lines was demonstrated in
comparison to healthy tissue (figure 4.2), which further strengthens the potential role of this molecule
in HNC. Additionally, MIF might be one factor for induction of accumulation of CXCR2 and CXCR4
responsive cells like neutrophils (figures 4.4 and 4.7). KC, a more potent ligand for CXCR2, was also
produced by the HNC cell lines (not shown). Both cytokines could result in the attraction of CD11b+-
Ly-6G+ cells to the tumor tissue, which is likely to be induced by CXCR2 ligands. This assumption is
based on receptor downregulation in the tumor tissue (figure 4.4), which was described to be induced
by prolonged ligand exposure[48, 220]. It was therefore suggested, that in the HNC model the tumor in-
duced a CXCR-ligand dependent modulation of neutrophils which could result in an activation of
protumoral functions.
Despite the described peripheral functions of CD11b+Ly-6G+ cells, a local activation at the tumor site
becomes more and more apparent as indicated in the previous paragraph. This is in line with stud-
ies demonstrating that not only peripheral neutrophil numbers but especially the amount of tumor
infiltrating cells are clinically associated with poor outcome for example in HNC[207, 203]. Accord-
ingly, a recent study suggested that immunosuppressive capacities of CD11b+Ly-6G+ cells are limited
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to the site of ongoing inflammation in a prostate tumor model[76]. In detail, the authors showed T
cell suppression by splenic CD11b+Ly-6G+ cells as well but tumor infiltrating cells were much more
suppressive because they did not depend on T cell derived IFN-γ. Functionally, CD11b+Ly-6G+ cell
infiltration into the tumor was shown to be required for the induction of a metastatic phenotype of
fibrosarcoma cells in another study[200]. Furthermore, transcriptomic analysis offered the possibil-
ity of analyzing detailed phenotypic differences from small cell populations. A detailed comparison
of naive neutrophils, peripheral neutrophils from tumor bearing mice and tumor infiltrating neu-
trophils was provided by Fridlender et al. in Balb/C mice[55]. The results demonstrated downregula-
tion of structural genes and cytotoxicity in tumor infiltrating CD11b+Ly-6G+ cells and further charac-
terized upregulation of immunoregulatory genes as a key mechanism induced in tumor bearing mice
with peripheral CD11b+Ly-6G+ cells showing lower upregulation than tumor infiltrating CD11b+Ly-
6G+ cells. Further upregulation of 13 chemokines was also presented by this group in tumor infil-
trating cells compared to CD11b+Ly-6G+ cells from naive mice. This data demonstrated the broad
character of intratumoral activation in the Balb/C mouse model. The present study also analyzed
CD11b+Ly-6G+ cells from different localizations in HNC bearing BL6 and CatchUp mice on the BL6
background to evaluate similar intratumoral activations. Tumor infiltrating CD11b+Ly-6G+ cells were
more activated than splenic CD11b+Ly-6G+ cells as determined by cell surface CD11b expression (fig-
ure 4.12A). Notably, CD11b upregulation is a general characteristic of tissue resident neutrophils as
it is upregulated upon extravasation to enhance migration into the tissue[104]. Nevertheless, extrava-
sation is generally also associated with activation but the fate of this activation in turn depends on
the local factors[40]. In the HNC tumor, CD11b+Ly-6G+ cells furthermore exerted higher expression
and release of Arg1 and higher protein content of iNOS compared to spleen derived cells (see figure
4.12), which suggested that increased immunosuppression is likely to be a feature of tumor infil-
trating CD11b+Ly-6G+ cells in this model. Notably, iNOS was classified as part of a “N1” antitumor
phenotype of CD11b+Ly-6G+ cells[54, 133] because of its proinflammatory function. Regardless of this
classification, both iNOS and Arg1 were shown to be key mediators of CD11b+Ly-6G+ cell dependent
T cell suppression and tumor promotion[36]. Therefore, iNOS was considered a tumor promoting fac-
tor in this model. Furthermore, intratumoral localization also affected mRNA expression of proan-
giogenic VEGF, suggesting that promotion of angiogenesis is not intrinsic to CD11b+Ly-6G+ cells but
specifically induced at the tumor site. MMP9 would further support this function in the tumor but
was not found to increase in comparison to spleen derived CD11b+Ly-6G+ cells. Adding even more
complexity, the chemokines CCL2 and CCL3 were also highly expressed on mRNA levels in tumor
infiltrating neutrophils in HNC tumors. By the production of these chemokines, recruitment of addi-
tional immune cells is mediated. CCL2 was implicated in a number of studies to recruit monocytic
cells further promoting tumor progression[121, 134, 156]. Additional expression of CCL3 could recruit
regulatory T cells and other CCR5 expressing leukocytes[172]. Furthermore, this chemokine was as-
sociated with enhanced angiogenesis in a lung tumor model by induction of MMP9 expression by
macrophages, which in turn also promoted metastasis formation[216]. Collectively, these data suggest
a profound activation of protumoral functions of CD11b+Ly-6G+ cells in the HNC tissue being sup-
pression of antitumor responses, attraction of additional tumor promoting immune cells and direct
as well as indirect promotion of angiogenesis. These complex activations demonstrated that CD11b+-
Ly-6G+ cell effects on tumor progression might occur directly as well as indirectly via additional cell
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lines further shaping the tumor microenvironment
The presented data indicated that HNC tumors affect neutrophils at different tissue compartments of
the tumor bearing host. An intrinsic capacity of CD11b+Ly-6G+ cells in suppressing T cell activation
was demonstrated. On top of that, accumulation in the periphery as well as migration towards the
tumor tissue was induced by tumoral factors which locally activated versatile tumor promoting func-
tions. Thereby, neutrophils are promoted to not only interfere with activation of immune responses
but also mediate attraction of additional immune cells. The tumor tissue therefore becomes a ma-
jor site of direct protumoral CD11b+Ly-6G+ cell activation while peripheral CD11b+Ly-6G+ cells from
tumor bearing mice directly promote tumor growth via intrinsic immunosuppressive functions.
5.1.2 Impact of CD11b+Ly-6G+ cells on tumor progression
As mentioned before, neutrophils did not only accumulate during tumor progression but exerted
specific tumor promoting functions as well. The detailed knowledge of neutrophil functions is cen-
tral for understanding disease progression and for the development of potential therapeutic strate-
gies. This does not only address the nature of the function itself as the timing of neutrophil activity
is even more important. Next to their central role in acute inflammation, neutrophils were shown
to substantially contribute to chronic inflammatory diseases by sensing danger associated molecu-
lar patterns (DAMPs) and releasing further immunogenic products[22]. Thereby, they could also be
conductive to the establishment of malignant lesions as many cancer entities may result from in-
flammatory processes[44]. In transplantable experimental models, this process is of course lacking.
Nonetheless, these experimental tumors proceed in different stages as well. In line, they need to
establish first, evade recognition by the immune system and require stromal support and nutrient
supply during the growth phase. Earlier studies already indicated that the tumor promoting activ-
ity of CD11b+Ly-6G+ cells might be limited to different stages of tumor progression in experimental
models as well. Accordingly, Mishalian et al. presented that only late tumor progression is affected
by Ly-6G+ cell depletion because early tumors of the tested lung and mesothelioma cell lines neither
attracted nor interacted with CD11b+Ly-6G+ cells[133]. To further analyze the contribution of CD11b+-
Ly-6G+ cells to HNC progression in the models presented herein, antibody dependent depletion was
applied in this study as well and was carried out during both phases, HNC establishment and seed-
ing as well as advanced tumor progression (see section 4.2.1). Presence of CD11b+Ly-6G+ cells had
only a slight effect on advanced HNC tumor progression in BL6 and hardly any effect in C3H mice
(figure 4.13). In contrast, early tumor establishment and onset of progression was dependent on the
presence of neutrophils especially in the BL6 HNC model (figure 4.14). These findings were contra-
dictory to the results in the Mishalian study[133], which might be due to the different tumor models
in both studies. A key difference between the HNC model and the lung and mesothelioma models
of the Fridlender group is the onset of infiltration of Ly-6G+ cells into the tumor tissue. Transplanted
HNC tumors were infiltrated immediately after induction of tumor progression within a few days
(data not shown) while in the other models, the authors stated that infiltration started at the stage
of advanced tumor volumes. For this reason, CD11b+Ly-6G+ cells can take over important tumor
promoting functions in the presented HNC models which was not possible in the Mishalian study.
Furthermore, additional data from different tumor models indicated that early promotion of tumor
formation by neutrophils in transplantable tumor models is not limited to tumors derived from HNC
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cell lines[67, 90, 113, 139, 197, 200, 150]. For this reason, neutrophil induced tumor establishment was iden-
tified as a key process in experimental HNC tumors as these cells were attracted early on.
If an immune response is raised against transplanted tumor cells, this would result in the eradication
of the tumor within a few weeks. Therefore, a central task during establishment of an experimen-
tal tumor is made up by the suppression of an immune activation or the blockade of the access of
antitumor effector cells to the site of tumor formation. Immunosuppressive functions of CD11b+Ly-
6G+ cells were demonstrated in a number of tumor models which also resulted in the name granulo-
cytic myeloid derived suppressor cells (MDSC) for CD11b+Ly-6G+ cell in tumor bearing hosts[18, 183].
Detailed mechanisms of neutrophil induced suppression of antitumor immunity were summarized
in section 1.3.2. In line with these mechanisms, Grizzle et al. showed that TS/A tumors get rejected in
young mice which do not mount a neutrophil response while the tumor induces CD11b+Ly-6G+ cell
accumulation in older mice resulting in the ability of tumor formation[67]. Another group also indi-
cated that adoptive immunotherapy against the HER-2/neu antigen can only be effective in a trans-
genic breast tumor model if a combination with CD11b+Ly-6G+ cell depletion is performed[139]. Fur-
thermore, anti-PD1 therapy, which should result in enhanced activation of antitumor T cells, was
only effective in a model of rhabdomyosarcoma if CD11b+Ly-6G+ cell infiltration into the tumor was
blocked as well[79]. These studies demonstrated the potential role of neutrophils in tumor associ-
ated immunosuppression not only for tumor formation but also for immune targeting therapies. The
presented study indicated an early implication of CD11b+Ly-6G+ cells in the formation of experimen-
tal HNC (figure 4.14) and immunosuppression was therefore assessed as a potential mechanism of
the observed growth delay. In histological analysis, antitumor effector cell infiltration was affected
in the first days of tumor progression under CD11b+Ly-6G+ cell depletion (figure 4.15). T cell sup-
pressive activity of CD11b+Ly-6G+ cells from HNC tumor bearing animals was further confirmed in
vitro (figure 4.11) but simultaneous depletion of CD11b+Ly-6G+ and CD8 T cells did not resolve delay
of tumor progression in all mice (tumor progression was benefited in 50 % of the double depleted
mice as shown in figure 4.16). Furthermore, in nude mice, which are unable to mount a directed T
cell response, Gr-1 depletion did only result in slightly but not significantly reduced tumor growth of
BL6 derived MOPC- cells. Therefore, T cells seemed to be affected by CD11b+Ly-6G+ cells in the HNC
model but they did probably not represent the only mechanism of CD11b+Ly-6G+ cell mediated HNC
progression. Additional immune cells might also be affected by neutrophils in this model and should
be analyzed in future studies in more detail. Based on an accumulation in the draining lymph node of
HNC tumor bearing GR-1 depleted animals (data not shown), NK cells were a promising candidate for
further analysis and have not been addressed in detail in this study. NK cells were shown to be manip-
ulated by CD11b+Ly-6G+ cells via NKG2D downregulation[113, 45] resulting in reduced cytotoxicity by
diminished perforin production[187, 117]. These antitumor effector cells were likely to be involved in
reduced tumor progression upon CD11b+Ly-6G+ cell depletion in the HNC model. Even though their
presence in the tumor upon depletion did not change very much, NK cells could be more cytotoxic
in the absence of CD11b+Ly-6G+ cells. Conclusively, suppression of T cell responses presented as a
potential mechanism of CD11b+Ly-6G+ cell mediated establishment of HNC tumors but additional
mechanisms seem to be present in this model.
Another event of key importance to tumor formation is angiogenesis as a tumor mass is not able to
exceed a volume of 2 mm3 without vascular supply[141]. Angiogenesis is often taking place in accor-
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dance with further changes in the local tissue structure including matrix remodeling, which enables
the generation of a tumor niche. CD11b+Ly-6G+ cells were able to substantially take part in these
processes by release of proteases and growth factors[218, 103] (for more details see section 1.3.2). In
histological analysis, the presented study indicated that angiogenesis was affected in the first days
of tumor progression under CD11b+Ly-6G+ cell depletion (figure 4.17B). Further Gr-1 depletion ex-
periments using the matrix providing component MatrigelTM indicated that the component sub-
stituted for a function of the neutrophils because depletion had no effect on these tumors (figure
4.17C). MatrigelTM provides ECM structure as well as diverse growth factors to the tumor and pro-
motes angiogenesis[149, 43], which ablated the effects observed by CD11b+Ly-6G+ cells depletion in
the presented experiments. Therefore, an additional function of CD11b+Ly-6G+ cells was suggested
by these experiments. CD11b+Ly-6G+ cell presence resulted in stromal support to HNC tumor cells,
probably by matrix remodeling protease activities, during seeding and establishment of the tumor
and further induced early angiogenesis.
While many studies concentrated on distinct functions of CD11b+Ly-6G+ cells in tumor progression
(as described in section 1.3.2 and 1.3.3 in more detail), a simultaneous exertion of a combination of
those functions was rarely addressed. Only one study by Srivastava et al. reported about two simul-
taneous functions of CD11b+Ly-6G+ cells in tumor bearing mice[187]. In a SC lung tumor model, they
demonstrated neutrophil mediated T and NK cell suppression as well as promotion of angiogene-
sis, which was diminished after depletion of these cells. As the majority of studies presented data
about one explicit function of CD11b+Ly-6G+ cells in the context of a tumor burden, it would be likely
that several neutrophil phenotypes exist which are either proangiogenic, metastasis-promoting or
immunosuppressive. The way of activation of these potential phenotypes is not clarified in detail.
In contrast, gene expression of HNC infiltrating CD11b+Ly-6G+ cells suggested activation of diverse
functions (figure 4.12), which made this study consider immunosuppression as well as angiogenesis
and structural (stromal) support as possible causes of CD11b+Ly-6G+ cell mediated tumor progres-
sion in the HNC models. The experiments presented in sections 4.2.2 and 4.2.3 supported this hy-
pothesis. It was presented that the absence of T cells as well as additional matrix reverse the delay
of tumor formation and onset of progression by CD11b+Ly-6G+ cell depletion. This study therefore
provided evidence for simultaneous proangiogenic and immunosuppressive functions of CD11b+Ly-
6G+ cells in the establishment phase of HNC progression.
5.1.3 Potential role of the neutrophil molecule Ly-6G
In a pilot study, the importance of the neutrophil specific murine protein Ly-6G was furthermore ad-
dressed in the context of HNC progression. A role for Ly-6G in CD11b+Ly-6G+ cell integrin-mediated
migration was suggested by a study of Wang et al. in 2012[208] but was not confirmed in a Ly-6G knock-
out model[75]. In line with these previous results in the CatchUp animals used herein, migration into
HNC tumors was unaffected by the absence of Ly-6G (figure 4.29). It was therefore concluded that
Ly-6G is dispensable for the migration of CD11b+Ly-6G+ cells. As Wang et al. used antibodies in their
study to block Ly-6G function, antibody mediated activation or unspecific effects are most likely to be
the underlying mechanism of their observation. Even though enhanced tumor growth was presented
in Ly-6G knockout animals (see figure 4.28), this study lacks a comprehensive mechanism for this ef-
fect due to the small size of the studied groups. Further research would be necessary to identify the
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exact implication of CD11b+Ly-6G+ cells in tumor growth differences between Ly-6G-/+ and Ly-6G-/-
mice. Unexpectedly, Tregs were reduced in tumors from Ly-6G-/- mice even though higher induction
of CCL17 expression by a tumor infiltrating neutrophil could have been associated with higher Treg
infiltration (as also described in reference [132], see figures 4.32 and 4.30). This result rather sug-
gested a generalized defect of Treg cells in Ly-6G-/- CatchUp mice which could be further investigated
but is not probable to be implicated in tumor progression. An antitumor role of Treg cells was so
far only demonstrated in inflammation induced cancers such as colorectal cancer[47]. A comparable
mechanism is rather unlikely in the presented transplantable SC tumor model. Increased expres-
sion of VEGF in tumor infiltrating CD11b+Ly-6G+ cells of two Ly-6G-/- versus Ly-6G-/+ pairs suggested
that further analysis should concentrate on tumor angiogenesis, which is likely to result in enhanced
tumor growth. Nevertheless, the mechanism of a potential suppression or regulation of VEGF expres-
sion by Ly-6G remained elusive and further investigations would be required to draw comprehensive
conclusions from the presented implication.
5.2 Limitations of experimental antibody mediated neutrophil depletion
Experimental elimination of neutrophils by depletion antibodies is a well established method, which
is used to decipher the function of these cells in murine models of inflammation, infectious diseases
and cancer. Nevertheless, a longitudinal analysis of treatment efficacy in different tissue compart-
ments was not provided so far. The presented study revealed a number of limitations of the technique
in a HNC tumor model by performing these analysis, which will be discussed in the following section.
5.2.1 Incomplete depletion in different tissues of tumor bearing mice
Application of Ly-6G depleting antibodies results in fast elimination of peripheral blood neutrophils
within one day[23, 32] and blood is the most frequently tested organ when assessing depletion effi-
cacy. If the thereby determined efficacy would be correct, the depletion would be the perfect tool
for the analysis of CD11b+Ly-6G+ cell functions in murine models. However, first limitations of this
techniques arose from the identification of undepleted CD11b+Ly-6G+ cell reservoirs in bone mar-
row of naive mice[163] and local CD11b+Ly-6G+ cells in the liver of tumor bearing animals[123]. These
cells were detected as soon as 24 hours after antibody injection. Nevertheless, many studies carry
out long term depletion especially in the field of oncology to assess tumor growth without assessing
further tissue specific efficacy. In addition to CD11b+Ly-6G+ cells residing in bone marrow and liver,
the presented study identified depletion resistant cells in spleen and tumor within 4 days of deple-
tion using αGr-1 antibody4 while peripheral blood cells were completely eradicated (see figure 4.18
and 4.21). Intratumoral cells were further characterized directly in vivo by noninvasive multipho-
ton microscopy and their viability and migratory capacity was demonstrated (figure 4.21). Of note,
these cells from CatchUp animals with Ly-6G promoter dependent tdTomato expression had lower
fluorescence intensity than intratumoral cells from undepleted mice (n=1, data not shown). This
observation suggested a low Ly-6G promoter activity, which would be in line with a rather imma-
ture phenotype[78]. Therefore, insufficient intratumoral depletion might be due to a combination of
limited antibody penetration in the tissue and low abundance of Ly-6G surface expression in a sub-
set of immature tumor infiltrating CD11b+Ly-6G+ cells. Inefficient depletion was further confirmed
4Depletion was always carried out continuously with antibody injection every three days after start of treatment.
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in HNC tumor bearing mice after αLy-6G mediated depletion, which was demonstrating a general
functional disadvantage of the technique. Notably, CD8 depletion was found to be complete in the
tumor tissue even after three weeks of antibody treatment (data not shown). Therefore, resistance
to depletion might be an intrinsic feature of neutrophils probably due to their fast cellular turnover.
Given the pronounced importance of intratumoral CD11b+Ly-6G+ cells as described in the previous
section, inefficient depletion in the tumor should not be ignored. It is rather likely that these cells
interfere with the desired study outcome as they might still be able to exert their protumoral func-
tion. Furthermore, immature cells were often described to be potentially more immunosuppressive
than mature neutrophils[19, 60]. Nevertheless, many studies identified tumor promoting mechanisms
of CD11b+Ly-6G+ cells using this technology. Several potential reasons for this controversy exist. De-
pletion could be more efficient in other tumor models for example because of a different tumor ar-
chitecture and microenvironment which might not support the survival of CD11b+Ly-6G+ cells in the
tumor during depletion. Another reason could be that the mechanisms described in these studies are
the central reason for the progression of the described tumors. This would mean that having a high
number of depleted neutrophils resulted in the break down of the tumor promoting mechanisms of
these models, which can not be compensated by a small number of remaining CD11b+Ly-6G+ cells.
Furthermore, residual CD11b+Ly-6G+ cells could also be functionally impaired. Such a scenario has
been described by Ribechini et al. They reported the loss of suppressive activity of depletion resistant,
antibody coated CD11b+Ly-6G+ cells in the bone marrow[163]. A similar response could be induced
in CD11b+Ly-6G+ cells in other tissues if they were coated with the depletion antibody. Whether this
is a possible mechanism and whether it also holds true for functions like promotion of angiogenesis
remains to be determined by future studies. Incomplete depletion in a number of tissues as shown
in this thesis anyway requests for more detailed analysis of depletion efficacy in upcoming cancer
studies.
Detection of murine neutrophils can be easily performed by flow cytometry using the surface markers
CD11b and Ly-6G. Therefore, flow cytometry is also frequently used in depletion studies to determine
depletion efficacy. Although limited detection of depletion antibody-coated neutrophils was already
demonstrated in bone marrow neutrophils[163], flow cytometry did not loose importance for this pur-
pose. The use of secondary antibodies enabled for the detection of depletion antibody-coated cells
as well. Surprisingly, the presence of resistant cells was not apparent in flow cytometry in the pre-
sented study. Spleen resident resistant cells were not detectable by neither CD11b and Ly-6G flow
cytometry nor by using secondary antibodies (figure 4.20) but immunohistochemistry (IHC) revealed
remarkable resistance to depletion by neutrophils in the very same organ (figure 4.21). These results
indicated further limitations of flow cytometry for the sake of testing for depletion efficacy. Nev-
ertheless, the reasons for these dramatic differences in both techniques remain elusive. A possible
explanation could be the loss of these resistant Ly-6G+ cells during the isolation procedure while they
can not disappear from the intact organ that is analyzed by IHC. Furthermore, IHC could be more
sensitive in detecting Ly-6Glow neutrophils which would be missed by a flow cytometry strategy that
is looking for classical Ly-6Ghigh mature cells. A low expression of Ly-6G by residual neutrophils was
also suggested by intravital microscopy as discussed above. Nevertheless, limitations of flow cytom-
etry are alarming because virtually all studies either do not check or report depletion efficiency at
all[202, 113, 155], check depletion efficacy only in the peripheral blood[54, 90, 139, 150, 189], analyze addi-
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tional organs only by flow cytometry[84, 197, 161, 116, 181] or directly state that CD11b+Ly-6G+ cell num-
bers are only reduced[59, 92, 116, 139, 182, 187, 140]. These facts highlight the importance of the data pre-
sented in this study and suggest careful monitoring as well as choice of monitoring techniques when
considering depletion of neutrophils.
5.2.2 Mechanisms of CD11b+Ly-6G+ cell rebound
As neutrophils are the key cell type of immediate immune responses against invading pathogens,
their life cycle is closely regulated (see also section 1.1.1). Keeping in mind that these cells possess
a remarkably short life span, fast mechanisms are likely to exist to regulate neutrophil numbers in
case of acute infection or loss of cell numbers. This mechanism is called “emergency granulopoiesis”
and is characterized by accelerated hematopoietic stem and progenitor cell (HSPC) proliferation[114].
Cain et al. indicated in their study on emergency granulopoiesis that this proliferative response is
a consequence of the inflammation and G-CSF driven exhaustion of the bone marrow neutrophil
pool[23]. They further demonstrated that the number of bone marrow neutrophils inversely corre-
lated with HSPC proliferation 48 hours after a single dose injection of different amounts of αGr-1
antibody. This response resulted in a reconstitution of bone marrow neutrophil numbers within 4
days after single dose αGr-1 treatment5 and was preceded by a G-CSF response, which peaked be-
tween day 1 and 2 after antibody injection. In the presented study, a remarkable increase in serum
G-CSF was detected on day 5 after start of continuous αGr-1 treatment even though bone marrow
repopulation was already induced (see figures 4.22 and 4.20). This result indicated that upon contin-
uous antibody presence and tumor burden, additional regulatory mechanisms take place to adjust
neutrophil numbers. In line, the cytokine KC was also increased in the treated animals. As a conse-
quence of high levels of CD11b+Ly-6G+ cell stimulating factors, an increased level of granulopoiesis
was observed in spleen derived cells from tumor bearing, depleted animals (see figure 4.23). This
is in line with data showing tumor- as well as G-CSF-induced mobilization of progenitor cells to the
spleen and the resulting enhancement of this organ as a site of extramedullary granulopoiesis[25, 30].
As CD11b+Ly-6G+ cell modulation is also a key characteristic of tumor progression in the HNC model
and many other studies, potential interference of tumor burden with antibody mediated depletion
was tested in the presented study. The emergency-like granulopoiesis in response to neutrophil de-
pletion was observed in both naive and tumor bearing mice in this study. Of note, the presence of a
tumor accelerated this process and resulted in earlier rebound of neutrophils in the peripheral blood
(figure 4.24). These findings suggested that cancer related inflammation potentiates the depletion
induced granulopoiesis albeit the mechanisms responsible for this effect still need to be elucidated.
Even though granulopoiesis is enhanced under depletion pressure, the resulting CD11b+Ly-6G+ cells
would still be depleted by the applied antibodies. Based on this assumption, long term studies were
designed and carried out. A depletion period of three weeks can be found in a number of studies in the
field of tumor immunology[150, 84, 4, 197, 113, 54, 139, 67, 92, 117]. Nevertheless, data presented in this study
reliably demonstrated a profound CD11b+Ly-6G+ cell rebound during long term depletion, which is
taking place after about ten days (figures 4.19 and 4.24). This fact raises the question of the mecha-
nism of rebound under depletion pressure. To assess this question, the mode of action of antibody
induced depletion is of importance, which is a topic of vivid debate. Most likely, antibody binding and
5αGr-1 was dosed at 100 µg per mouse IP. Detection was carried out including a secondary antibody.
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ligation of Ly-6G results in activation and apoptosis of the affected cell[163], which is probably at least
partly involving complement factors[1] leading to the final elimination of sequestered, dying cells by
phagocytes especially in spleen, liver and bone marrow[20]. For bone marrow compensation of deple-
tion, an antiapoptotic mechanism has been suggested by Ribechini et al. involving enhanced expres-
sion of the Bcl-2 family member MCL-1 in bone marrow resident CD11b+Ly-6G+ cells[163]. In section
4.3.4, it was shown that upon rebound during continuous depletion, MCL-1 is especially increased in
spleen derived CD11b+Ly-6G+ cells while its expression in bone marrow resident CD11b+Ly-6G+ cells
was comparable to the control group. Furthermore, survival of spleen derived CD11b+Ly-6G+ cells
was also increased (figure 4.25) suggesting a similar antiapoptotic mechanism taking place in the re-
bound phase. The described compensatory mechanisms ultimately resulted in the reappearance of
neutrophils with an immature phenotype. It is rather likely that these cells could also get depleted
by the antibody when they undergo maturation. But their immature status in combination with their
high numbers enabled the process of CD11b+Ly-6G+ cell rebound during long term depletion.
The presence of high numbers of immature neutrophils during the rebound phase of long term de-
pletion challenges the applicability of these experimental settings. The function and phenotype of
these cells is central to the interpretation of all studies with depletion periods of more than one week.
Immature myeloid cells including CD11b+Ly-6G+ cells exert immunosuppressive activity in infec-
tious diseases[65] as well as in cancer[5, 60]. Furthermore, key effector mediators of immature myeloid
suppressive cells are Arginase1[143] and reactive oxygen species (ROS)[105]. Both mediators were also
found to be constitutively increased in the immature cells resulting from rebound during long term
depletion in the present study (figure 4.27). Furthermore, reduced non-specific, αCD3 and αCD28-
induced T cell proliferation was observed in mixed splenocyte cultures from mice in the rebound
phase (data not shown) indicating an increased state of peripheral T cell suppression in these ani-
mals. Finally, the reappearing CD11b+Ly-6G+ cells were tested for expression of anti- and protumoral
phenotypic markers. This set of markers originally derived from a study by Fridlender et al. who ob-
served an antitumoral phenotypic shift of tumor infiltrating neutrophils6 upon TGF-β inhibition[54].
In the present study, the most remarkable changes between isotype-treated and depletion-resolved
spleen-derived CD11b+Ly-6G+ cells were an upregulation of CCL17 and a simultaneous downregu-
lation of TNF-α expression, which are representatives from the protumor “N2” and the antitumor
“N1” group, respectively. It was therefore concluded, that a phenotypically protumoral N2 shift is
taking place in peripheral CD11b+Ly-6G+ cells from tumor bearing mice after long term depletion
is resolved. These changes could further result in increased Treg expansion as CCL17 was recently
shown to be a key mediator in CD11b+Ly-6G+ cell-Treg crosstalk[132]. These results are of central
importance for long term depletion experiments, as they demonstrate the presence of immature im-
munomodulatory neutrophils which are capable of interfering with the study outcome.
5.2.3 Consequences for data interpretation
In conclusion, it is not advisable to carry out long term depletion using neutrophil specific antibodies
especially under CD11b+Ly-6G+ cell modulating conditions such as HNC and other tumor models.
Even though many studies found detailed mechanisms of CD11b+Ly-6G+ cell mediated tumor pro-
gression using this technique, they very likely worked in a tumor model with very strong neutrophil
6In the respective study termed tumor associated neutrophils (TAN)
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mediated effects. Nevertheless, in many models as well as in human disease, a majority of functions
could be shared between related cell types. In line with this, other cells like monocytes could take over
for neutrophil mediated functions like immunosuppression and promotion of angiogenesis[82, 137],
which would not be affected by single cell type depletion. Therefore, the complex crosstalk between
the various cell types that are implicated in tumor progression is hard to be dissected experimentally.
For this reason and with the knowledge of the limitations presented in this study, one conclusion is
central: Especially studies which show no effect of neutrophil depletion on tumor progression (and
probably also in the context of other disease models) might have been affected by the phenomena
of incomplete depletion and CD11b+Ly-6G+ cell rebound. This key conclusion is not only applicable
for published data but is of particular interest for the first part of the presented study. It was demon-
strated that the presence of CD11b+Ly-6G+ cells is more important for tumor establishment and for-
mation than for advanced and established tumor progression in a transplantable HNC model (figures
4.13 and 4.14). As incomplete depletion and CD11b+Ly-6G+ cell reappearance was demonstrated in
the same model, the role of CD11b+Ly-6G+ cells in advanced tumor progression is very likely under-
estimated by the presented data. The growth curves in section 4.2.1 were recorded during a period
between one to two weeks after induction of CD11b+Ly-6G+ cell depletion and compensatory cell ex-
pansion was therefore not present for the longest part of observation as rebound started around day
ten. Nevertheless, resistant undepleted cells were present throughout the experiment. As the activity
and fate of these cells is not clarified yet, their capacity of compensating for the loss of many CD11b+-
Ly-6G+ cells is hard to be estimated. It is still very likely, that resistant cells are capable of exerting
similar functions as immature reappearing cells, thereby interfering with the outcome of the study
by immunosuppression and promotion of tumor growth. A higher impact of CD11b+Ly-6G+ cells in
advanced tumor progression in the HNC model is therefore likely.
Taken together, the presented study provided evidence for limited applicability of long term antibody
mediated neutrophil depletion especially in murine tumor models. Furthermore, depletion has to be
monitored critically in more organs than peripheral blood and with more methods than flow cytom-
etry to ensure the best possible quality of data interpretation.
5.3 Therapeutic implications
An association between high peripheral neutrophil counts and tumor progression as well as poor
survival has been found for a variety of malignant diseases[201]. Further functional alterations of neu-
trophils in respective patients included neutrophil survival, ROS and cytokine production and further
mediators like VEGF and MMP9 which directly affect tumor progression (see section 1.2.2). On the
other hand, chemotherapeutic agents were shown to rapidly induce neutropenia, which might cause
severe side effects and delays in therapy[31]. Given the important antimicrobial roles of neutrophils,
infections could arise from severe neutropenia resulting in longer hospitalization and increased treat-
ment costs. As a compensatory treatment for such side effects, G-CSF arose as a tool for limiting
neutropenia especially in phases of high dose treatment as for example in adjuvant breast cancer
therapies[46]. A similar study in HNC resulted in an unexpected improvement of survival[192]. Never-
theless, G-CSF is known to drive mobilization of HSPCs in humans as well and this treatment could
also result in the accumulation of immunoregulatory cells in line with the data from the depletion
experiments in the presented study. This effect might further interfere with treatment outcome and
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could even result in accelerated tumor progression. Remarkably, Di Maio et al. showed in an analysis
of three randomized trails in advanced non-small cell lung cancer that mild therapy-induced neu-
tropenia was actually associated with longer survival in comparison to patients who did not develop
neutropenia[34]. Thus, regulation and manipulation of neutrophil numbers in cancer patients under
treatment resembles a balance act between risk of infections and interference with treatment out-
come.
As manipulation of neutrophil cell numbers proved difficult for the reasons discussed above, other
modes of neutrophil manipulation might be more promising. Earlier studies and the first part of this
study implicated CXCR2 ligands as key mediators of neutrophil attraction to the tumor. Given the
intratumoral activation of neutrophils, which was discussed earlier, this infiltration process might
be a promising target for future therapies. Promising results were achieved in murine tumor studies
using antagonists to CXCR2[79, 92] and safety of CXCR2 inhibition was already demonstrated in two
studies dealing with respiratory diseases for treatment periods of 4 weeks[142] as well as 6 month[162].
Besides migratory blockade, which might also interfere with migration towards infection sites, neu-
trophil phenotypic shift could be a potential starting point for further treatment. In this way, the an-
titumoral potential of neutrophils would be efficiently used to strike back cancer progression. Such
strategies could include interference with response modifiers such as TGF-β and IFN-β[54, 90] or ac-
tivation of neutrophil cytotoxic and immune activating functions via microbial compounds[94, 193].
Further translational research will be needed to define potential treatment regimens aimed at mod-
ulating neutrophil numbers, migration, localization or function. Effectiveness of such treatments
would have to be determined for the respective tumor entity as the distinct microenvironment in the
tumor mass also affects treatment outcome. To this end, tumor models as presented in this study are
key tools for preclinical evaluation of possible interventions.
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5.4 Conclusions
In this study, a murine HNC model was developed to investigate interactions between CD11b+Ly-
6G+ cells and the tumor. This model was characterized by expansion of CD11b+Ly-6G+ cells in blood
and spleen of tumor bearing animals, which was not demonstrated before in HNC. Central experi-
ments presented local activation of CD11b+Ly-6G+ cells in the tumor tissue. Thus, this model rep-
resents major characteristics of neutrophil-HNC interactions in human cancer patients as reported
in former studies[38, 39, 203, 204]. In these HNC models, this study further strengthened the hypothe-
sis, that neutrophil mediated effects in the tumor bearing host were not limited to one direction but
that these cells rather exert a number of functions. Among these, immunosuppression as well as
promotion of angiogenesis were suggested as mechanisms in HNC. Importantly, this study was able
to provide evidence that protumorigenic CD11b+Ly-6G+ cells are not necessarily entrained by the tu-
mor during tumor progression to become protumorigenic as it was put forward by earlier studies[133].
Instead, CD11b+Ly-6G+ cells have intrinsic capacities to quickly promote early processes such as es-
tablishment and formation of tumor cell accumulations at least in transplantable tumor models.
Finally, the presented thesis contains unprecedented longitudinal analyses of the efficacy of antibody
mediated Ly-6G+ cell depletion in different tissue compartments of tumor bearing mice. Incomplete
depletion of neutrophils was thereby indicated in spleen and tumor in experimental tumor mod-
els and was further followed by rapid expansion of immunoregulatory immature granulocytic cells.
Therefore, future long term studies on modulation and function of CD11b+Ly-6G+ cells require Ly-
6G+ depletion techniques which are more sophisticated and effective than antibodies. With the de-
velopment of Ly-6G-Cre mice[75], genetically driven specific depletion of Ly-6G+ cells may become
available in future studies.
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Summary
In contrast to other cells of the immune system, the role of neutrophils in cancer has only started to
emerge in the last decades. Previous studies of our group showed that high infiltration of neutrophil
granulocytes in head and neck cancer (HNC) tissues correlated with poor survival of patients with ad-
vanced disease. Further in vitro studies indicated that human neutrophils are manipulated by tumor
cells to acquire a protumoral phenotype. Neutrophil manipulation by experimental tumors was also
described for a variety of tumor types in murine models but HNC models were not yet tested in this
respect. Therefore, at first, this study addressed the effect of murine experimental HNC on CD11b+-
Ly-6G+ cells in the tumor bearing host and, secondly, the role of these cells in HNC progression. A
central method for these analyses was the antibody mediated depletion of Ly-6G+ cells. In this regard
the efficacy of depletion in different organs of the host and the impact of tumor burden on depletion
efficacy were analyzed. Finally, a pilot study in the last part concentrated on a potential role of the
murine neutrophil specific molecule Ly-6G for CD11b+Ly-6G+ cell function during neutrophil-tumor
interaction.
In the transplantable HNC models presented herein, tumors induced accumulation of CD11b+Ly-
6G+ cells in the periphery (blood and spleen). Tumors transplanted to an orthotopic site were supe-
rior to subcutaneous tumors in this respect. This accumulation correlated with tumor progression
in line with observations in HNC patients. Infiltration into the tumor tissue further activated Ly-
6G+ cells and induced a protumoral gene expression pattern including increased expression of im-
munosuppressive Arg1 and iNOS, proangiogenic VEGF and a cytokine pattern that was distinct from
splenic Ly-6G+ cells.
Using antibody mediated depletion, CD11b+Ly-6G+ cells were found to be mainly implicated in HNC
cell seeding and establishment of a tumor while the presence of neutrophils did not further promote
advanced tumor progression. The experiments suggested that neutrophils promoted tumor estab-
lishment by different mechanisms involving the regulation of T cell functions as well as by providing
structural support and inducing angiogenesis.
A detailed characterization of antibody mediated neutrophil depletion (usingαGr-1 as well asαLy-6G
antibodies) revealed that the depletion in the peripheral blood could be divided into an initial one-
week complete depletion phase, which was followed by the reappearance of Ly-6G+ cells (rebound
phase) despite continued antibody treatment. A depletion resistant pool of viable neutrophils resided
in the tumor tissue, spleen and bone marrow during complete peripheral blood depletion. Reap-
pearance of neutrophils during the rebound phase was accompanied by enhanced extramedullary
granulopoiesis and occurred faster in tumor bearing mice than in naive mice. Reappearing CD11b+-
Ly-6G+ cells displayed an immature phenotype and strongly expressed immunoregulatory molecules.
In the last part, comparison of neutrophils from Ly-6G+/- and Ly-6G-/- mice suggested that the mole-
cule Ly-6G is not involved in neutrophil-to-tumor migration. Nevertheless, enhanced HNC progres-
sion was observed in Ly-6G-/- mice. The underlying mechanism remains to be determined in future
studies.
In summary, the presented HNC models were shown to possess characteristics of the human disease
in terms of tumor-neutrophil interactions. Therefore, further functional analysis as well as thera-
peutic interventions involving neutrophil functions could be carried out in these models. Depletion
experiments showed that CD11b+Ly-6G+ cells strongly promote early phases of tumor growth in this
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model, most likely by influencing antitumor activity of T cells and by modulation of the recipient tis-
sue niche. During tumor progression, Ly-6G+ cells expand in the blood, spleen, bone marrow and
tumor and display tissue specific alterations in function and gene expression. Analysis of Ly-6G+ cells
in later phases of tumor growth is limited by the rapid re-appearance of these cells despite continuous
treatment with depleting antibodies which is mediated by enhanced extramedullary granulopoiesis
and by the presence of viable, migratory, depletion resistant cells in bone-marrow, spleen and tu-
mor. This transient, short-term nature of Ly-6G+ cell depletion in the periphery and the continuous
presence of tissue resident depletion resistant cells emphasize the need for careful monitoring and
cautious interpretation of negative results in murine models of tumor-neutrophil or tumor-myeloid
derived suppressor cell interaction.
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Zusammenfassung
Die Rolle von Neutrophilen im Zusammenhang mit Krebserkrankungen fand in der Tumorimmuno-
logie lange Zeit wenig Beachtung und wird erst seit einigen Jahren intensiv bearbeitet. In Kopf-Hals-
Tumor (KHT)-Patienten mit fortgeschrittenem Tumorstadium konnten vorherige Studien in unserer
Gruppe zeigen, dass eine starke Infiltration des Tumorgewebes mit einer schlechten Überlebensrate
assoziiert ist. Daraufhin wurden in vitroUntersuchungen durchgeführt, welche zeigten, dass humane
Neutrophile in Anwesenheit von tumoralen Faktoren einen tumorfördernden Phänotyp annehmen.
Weiterhin sind in der Literatur einige experimentelle Tumorsysteme beschrieben, welche eine tumor-
fördernde Veränderung von Neutrophilen beschreiben. Untersuchungen zur Rolle von Neutrophilen
in murinen KHT Modellen liegen bisher nicht vor. Aus diesem Grund war es ein Hauptziel des ersten
Teils der vorliegenden Arbeit, Neutrophile (CD11b+Ly-6G+) in murinen KHT Modellen zu charakter-
isieren und deren Rolle in Bezug auf die Progression des experimentellen Tumors zu identifizieren.
Als zentrale Methode diente hierfür die antiköpervermittelte Depletion von Ly-6G+ Zellen, welche
im weiteren Verlauf der Arbeit näher auf ihre Effektivität in unterschiedlichen Geweben untersucht
wurde. Weiterhin wurde der Einfluss der Tumorpräsenz auf die Effektivität der antikörpervermittel-
ten Depletion analysiert. In einer abschließenden Pilotstudie sollte außerdem eine potentielle Funk-
tion des neutrophilenspezifischen Proteins Ly-6G, das nur in der Maus vorkommt, im Kontext der
Funktion von Neutrophilen in der Interaktion mit Tumoren untersucht werden.
Initiale Untersuchungen der vorliegenden Arbeit deuten auf eine Interaktion von Tumorzellen und
Neutrophilen hin, welche zu einer tumorprogressionsabhängigen Expansion von CD11b+Ly-6G+ Zel-
len in der Peripherie (Blut und Milz) führte. Orthotop transplantierte Tumoren lösten in diesem
Zusammenhang eine stärkere Expansion als subkutane Tumoren aus. Diese Beobachtungen deck-
ten sich mit Daten aus vorherigen Studien in KHT Patienten. Weiterhin konnte demonstriert werden,
dass die Lokalisation im Tumor zu einer weiteren Aktivierung der CD11b+Ly-6G+ Zellen führte und
dass dies die Expression eines tumorfördernden Genexpressionsprofils zur Folge hatte. Dieses war
charakterisiert durch immunsuppressive Gene wie Arg1 und iNOS und Gefäßversorgung förderndes
VEGF und beinhaltete außerdem verschiedene Cytokine, die weitere Immunzellen anlocken können.
Im weiteren Verlauf konnte durch antikörpervermittelte Depletion der Neutrophilen eine zentrale
Funktion in der Entstehungsphase der transplantierten Tumoren festgestellt werden, während bereits
etablierte Tumoren weniger stark von der Unterstützung durch CD11b+Ly-6G+ Zellen abhingen. Auf
funktioneller Ebene wurden durch die gezeigten Experimente verschiedene Mechanismen zur neu-
trophilenvermittelten Tumorentstehung nahegelegt, wobei sowohl die Regulation von T Zellen als
auch eine eher strukturelle Unterstützung des Gewebeumbaus und der Gefäßversorgung eine Rolle
spielten.
Im nächsten Schritt wurde die antikörpervermittelte Depletion von Ly-6G+ Zellen in einem der KHT
Modelle näher betrachtet. Hierbei konnte die Depletion im peripheren Blut in verschiedene Sta-
dien eingeteilt werden. Eine vollständige Depletion wurde während der ersten Behandlungswoche
beobachtet und obwohl die Antikörperdosierung fortlaufend aufrechterhalten wurde, kam es nach
circa zehn Tagen zu einem Wiederauftreten von Ly-6G+ Zellen. Während der vollständigen Deple-
tion im Blut wurde außerdem eine depletionsresistente Population von lebendigen Ly-6G+ Zellen im
Tumorgewebe sowie in der Milz und im Knochenmark identifiziert. Weiterhin wurde die vollständige
Depletionsphase durch die Gegenwart eines Tumors weiter verkürzt. In diesem Zusammenhang kon-
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nte eine verstärkte extramedulläre Granulopoese festgestellt werden, die zu einer Ansammlung von
Neutrophilen führte, welche einen unreifen Phänotyp aufwiesen und weiterhin durch eine hohe Ex-
pression von immunmodulierenden Molekülen charakterisiert waren.
Im letzten Teil wurde gezeigt, dass die Migration von CD11b+Ly-6G+ Zellen in das Tumorgewebe
nicht von der Expression des Moleküls Ly-6G auf der Zelloberfläche abhängt. Trotzdem konnte ein
gesteigertes Tumorwachstum in Ly-6G-/- Tieren beobachtet werden. Im Rahmen dieser Studie war es
nicht möglich einen zugrundeliegenden Mechanismus zu identifizieren.
Zusammenfassend konnte in der vorliegenden Arbeit erstmalig gezeigt werden, dass eine Auswahl
von murinen KHT Modellen Charakteristika der humanen Erkrankung im Hinblick auf eine Interak-
tion von Tumor und Neutrophilen widerspiegelt. Das beschriebene Modell kann für weiterführende
funktionelle Analysen tumorassoziierter Neutrophiler sowie zur Testung möglicher therapeutischer
Interventionen genutzt werden. Depletionsexperimente deuteten darauf hin, dass besonders die
frühe Tumorprogression in diesen Modellen stark durch CD11b+Ly-6G+ Zellen beeinflusst wird in-
dem diese die antitumorale Funktion von T Zellen einschränken und außerdem zur Etablierung einer
lokalen Nische für die Tumoretablierung beitragen. Während der anschließenden Tumorprogres-
sion expandieren Ly-6G+ Zellen in Blut, Milz und im Tumorgewebe und weisen dabei gewebespez-
ifisch veränderte Funktionen auf, welche mit distinkten Genexpressionsmustern einhergehen. Eine
Analyse der CD11b+Ly-6G+ Zell Funktionen in diesen späteren Phasen der Tumorprogression ist mit-
tels Antikörperbehandlung durch deren Widererscheinen unter Depletionsdruck, welches durch de-
pletionsresistente Zellen und verstärkte extramedulläre Granulopoese induziert wird, nur limitiert
möglich. Diese Charakteristika des Depletionsverlaufes unterstreichen die zwingende Notwendigkeit
einer peniblen Überwachung der Depletion und implizieren, dass negative Ergebnisse in murinen
Krebsmodellen zur funktionellen Rolle von Neutrophilen oder MDSCs7 besonders vorsichtig inter-
pretiert werden müssen.
7suppressive Zellen der myeloiden Linie, aus dem Englischen: Myeloid derived suppressor cells
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Appendix
This sections lists supplementary figures and additional information in relation to the presented
study.
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Figure A.1: Sorting strategy for Ly-6G+ cell isolation from CatchUp animals. Cells were isolated from differ-
ent organs of CatchUp animals and applied to FACS sorting. Representative density plots for blood (A), bone
marrow (B), splenocytes (C) and tumor (D) are shown. tdTomato+ cells were identified by gating on singlets
(first panel), leukocytes (second panel), tdTomato+ cells with high and intermediate SSC (panel 3) and by ad-
ditionally excluding autofluorescent cells using the FITC channel (panel 4). For tumor infiltrating cells, gating
on living cells (D panel 2) was added.
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Figure A.2: Sorting strategy for CD3+ T cell isolation. Cells were isolated from spleens of CatchUp animals,
stained using anti-CD3²-FITC and applied to FACS sorting. Representative density plots are shown. FITC+ cells
were identified by gating on singlets (first panel), living (second panel) leukocytes (panel 3) with high FITC
fluorescence (panel 4).
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